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REGULATORY T CELL CONTROL OF ANTI-TUMOUR RESPONSES 
 
By Timothy Malcolm 
 
One of the main obstacles to immunotherapy of cancer in humans is the 
immunosuppressive environment that surrounds the tumour mass, preventing any 
effective immune response from halting or reversing the threat of the tumour. Thus the 
observations in Balb/c mice that CD25+ regulatory T cells (T regs) mediate suppression 
of antigen specific responses to CT26 and a number of tumours of distinct histological 
origin, was deemed worthy of investigation. The aim of this project was to examine in 
greater detail the immunosuppressive response generated by CT26, by using the 
irradiated tumour which we expected would represent an equivalent tumour challenge. 
 
Overall the work described here indicates that, despite being essentially an equivalent 
antigen exposure, the response induced in the irradiated CT26 model is different to the 
live CT26 model. In the live CT26 model T reg depletion is critical to the survival of the 
tumour challenge, as well as the generation of the cross-protective response. In the 
irradiated CT26 model, the cross-protective response is not dependent on the T reg 
depletion, but the absence of T regs does boost the anti-CT26 response.  
 
My second project sought to study tumour immunity in the context of the TAZ10 
transgenic model of autoimmunity. The main conclusion from this project was that 
endogenous processing of the autoantigen TPO is dependent on the signal peptide, and at 
some point in the intracellular transport of TPO the pathway diverges into the pathway 
that allows the processing of TPO and the association of MHC class II molecules with 
TPO peptides, for recognition by CD4+ MHC class II restricted T cells.   iii 
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Chapter 1. Introduction 
 
1.1 The immune system overview 
 
The world is full of microorganisms, many of them pathogens that are capable of killing 
other organisms. To deal with this threat all eukaryotes have developed anti-pathogen 
devices, the first line being the innate immune defences. The innate immune system 
recognises microorganisms via germline-encoded pattern-recognition receptors (PRRs), 
which recognise pathogen-associated molecular patterns (PAMPs). These PAMPs are 
found on microbial components that are evolutionary conserved, because they are 
essential to the survival of the microorganism and therefore not likely to be altered. These 
include bacterial products such as LPS, flagellin, LTA, PG and CpG DNA; and viral 
products such as dsRNA and ssRNA. (Akira, Uematsu et al. 2006). 
In addition to these innate defences, jawed vertebrates have evolved an adaptive immune 
system mediated by lymphocytes. All jawed vertebrates, beginning with cartilaginous 
fish, have rearrangeable immunoglobulin (Ig) V, D, and J gene segments, which allow 
the generation of a diverse lymphocyte receptor repertoire, expressed by T and B 
lymphocytes, capable of recognising a nearly infinite antigenic world. Antigen-mediated 
triggering of T and B cells initiates specific cell-mediated and humoral immune responses 
(Cooper and Alder 2006). The birth of the adaptive immune system is thought to have 
occurred when a transposable element containing RAG1 and RAG2 invaded the Ig gene, 
allowing greatly increased receptor diversity (Flajnik and Du Pasquier 2004). RAG1 and 
RAG2 are recombination activation genes, which catalyse the process of TCR gene 
rearrangement when the V, D and J segments are brought together in a continuous V-J or 
V-D-J coding block, forming complete V domain exons that are responsible for antigen 
recognition by the TCR (see section 1.4). (Oettinger, Schatz et al. 1990) 
 
This development of a complicated „anticipatory immunity‟ must have given enormous 
fitness value on the early vertebrates that acquired it. This point of view is strengthened 
by the fact that the immunoglobulin (Ig) system of lymphocyte-based recombination is 
not the only such system present in vertebrates. In fact the only surviving jaw-less   2 
vertebrates, the lamprey and hagfish, assemble receptors known as variable lymphocyte 
receptors (VLRs). Instead of immunoglobulin genes, the lymphocytes of these jaw-less 
fish rearrange modular leucine-rich repeat (LRR) cassettes to create functional mature 
VLR genes. A VLR of unique sequence is expressed by each lymphocte, the lymphocytes 
appear to undergo clonal amplification in response to stimuli, and can release their 
receptors into the plasma showing the potential for humoral immunity (Pancer, Amemiya 
et al. 2004).  
 
The fact that two such similar systems arose, estimated to be approximately 500 million 
years ago (during the Cambrian period), suggest that the benefits may have been beyond 
simply recognising antigen. Fossil records do not indicate a massive eradication of 
species during the Cambrian period that would imply that a devastating new pathogen 
emerged that favoured a revolution in immunity (Cooper and Alder 2006). 
It is now thought that the immediate selective pressure may instead have been facilitation 
of the developmental and morphological plasticity of the vertebrates. This plasticity 
allowed an explosion (known as the „Cambrian explosion‟) of innovation in vertebrate 
development, morphology and function that led to the breadth and variety of vertebrate 
species we now witness. The development of the anticipatory immunity had the 
advantage that self-reactive lymphocytes were deleted before maturing to full immune 
status, which would have conferred a massive benefit to the organisms that first 
developed it. The removal of the risk of lethal autoimmunity freed them to diversify in 
morphology, creating anatomical structures that previously would have been targeted by 
the „old‟ immune system. The wholly innate immune system of the early vertebrate and 
invertebrate ancestors had immune cells expressing a vast arsenal of LRR-containing 
receptors, engendering enormous binding versatility despite the receptors being germline-
encoded. This system was at least in part used in order to allow many symbiotic 
relationships between host and microorganisms (Noverr and Huffnagle 2004). However, 
a system with such a vast array of receptors would have had the drawback of containing 
some self-reactive receptor variants that would have engaged in autoimmune type 
interactions with the newly evolving molecular determinants of early vertebrates. This 
interference may have been the crucial obstacle to the explosion of vertebrate   3 
diversification seen during the Cambrian period, and one of the major factors why two 
forms of lymphocyte-based recombination immunity emerged more or less around the 
same time (Cooper and Alder 2006). 
 
These ideas are by no means an interesting but irrelevant historical detail, as with such a 
perspective the way in which the innate and adaptive immune systems are arranged and 
regulated, and how the two spheres interact, are better understood. 
This perspective lends a new insight on central tolerance, where the randomly generated 
receptors are assessed, with the self-reactive clones being deleted while potentially useful 
clones are spared (see section 1.5). The ability to select non-autoreactive clones becomes 
more central to the reason why the whole adaptive system exists, as the ability to delete 
self-reactive variants would have solved the problems arising from the arsenal-approach 
in vertebrate ancestors.   
Furthermore, a possible vestige of this transition from an immunity that is entirely innate 
– the arsenal approach; to an immunity that has an adaptive component – the lymphocyte 
based receptor recombination approach; is that „adaptive‟ lymphocytes retained „innate‟ 
immune functionality.  
For example Toll-like receptors (TLRs), which are LRR containing innate receptors that 
recognise specific PAMPs, and are present on innate cells like macrophages, are also 
present on B cells and some types of T cell (Akira, Uematsu et al. 2006). Plasmacytoid 
dendritic cells, derived from a common lymphoid progenitor, express TLR7 and TLR9 
(Lund, Sato et al. 2003).  
It also lends some perspective to the thought that the adaptive immune system was not 
simply grafted on to the innate system, when the ties between the two systems are more 
entwined than that. For example the cytotoxic killing mechanisms used by Natural killer 
(NK) cells and cytotoxic T cells (CTLs) are similar despite one cell coming from the 
innate arm, and the other from the adaptive (Flajnik and Du Pasquier 2004).  On a similar 
theme, both NK cells and T cells produce IFN-  (Hoebe, Janssen et al. 2004). 
  
The innate system is defined by the germline-encoded, non-clonal, and constitutive 
pattern-recogntion receptors (PRRs), which serve as the early recognition receptors for   4 
pathogen invaders. These receptors are expressed by antigen presenting cells (APCs), like 
macrophages and dendritic cells (DCs), and their triggering lead to phagocytosis of 
foreign-bodies or engagement of the complement-cascades that can eliminate the 
pathogens without necessarily needing to activate the adaptive immune response (Akira, 
Uematsu et al. 2006).   
The adaptive system is defined by the clonal receptors expressed by its two main 
components B and T lymphocytes. These receptors form a diverse repertoire, capable of 
recognising and responding to a massive array of foreign peptides presented by APCs. 
Once activated, they release antibody and cytokines, and mediate cellular cytotoxicity in 
order to eliminate pathogens.  
The bridge between the innate and adaptive immune components is the DC. Triggering of 
their PRRs by pathogen-associated molecules modulates their activation status, which in 
turn affects their induction of T lymphocytes that recognise the antigens that they present 
(Hoebe, Janssen et al. 2004).  
These aspects will be described in detail in the following sections.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   5 
1.2 The innate immune system 
 
Early recognition of microbes by components of the innate immune system is essential to 
the successful removal of pathogens. It serves as both a first line of defence in its own 
right, and secondly as a means of enlisting dendritic cells, and T and/or B cells into the 
overall response (Hoebe, Janssen et al. 2004). 
The innate system has a number of means to recognise microbial pathogens. These means 
reside under the umbrella term of pattern-recognition receptors (PRRs), which recognise 
evolutionary conserved molecular patterns of microbial and viral origin, known as 
pathogen associated molecular patterns (PAMPs). PRRs possess other common 
characteristics: they are expressed constitutively in the host, are germline encoded, 
nonclonal, expressed on all cells of a particular type, and independent of immunological 
memory (Akira, Uematsu et al. 2006).  
 
Much work of late has been focused of a family of PRRs that belong to the Toll-like 
receptors (TLRs), which were described just over ten years ago (Medzhitov, Preston-
Hurlburt et al. 1997). TLRs are type I integral membrane glycoproteins characterised by 
the extracellular domains containing varying numbers of leucine-rich-repeat (LRR) 
motifs. The cytoplasmic signalling domain is homologous to the IL-1R, and is termed the 
Toll/IL-1R homology (TIR) domain (Bowie and O'Neill 2000).  
The TLR receptors, of which there are 12 types in the mammalian genome, can be 
roughly divided into those that recognise viruses (TLR3, 7, 8, and 9) and those that 
recognise bacteria or protozoans (TLR1, 2, 4, 5, 6 and 11) (Lee and Iwasaki 2007). To 
serve such purposes those TLRs that seek to identify extracellular pathogens such as 
bacteria are located on the cell surface and generally recognise lipids, while those that 
seek to detect viruses are expressed in intracellular vesicles and generally recognise 
nucleic acids (Akira, Uematsu et al. 2006).  
Signalling through TLRs activates the same signalling molecules used for IL-1 signalling, 
and thus it leads to the production of pro-inflammatory cytokines and chemokines (Akira 
and Takeda 2004). Cells that prominently express TLRs are APCs like macrophages and   6 
DCs, and thus the production of such secreted mediators is important for the 
establishment of an adaptive response.   
 
Although TLRs are receiving much recent attention, they are not the only receptors that 
are influential. Some receptors that have been known for some time include: C-type 
lectins, mannose receptors, scavenger receptors that enable the recognition, phagocytosis, 
and thus eventual elimination of foreign bodies (Lee and Iwasaki 2007). This is also the 
case with the complement system, which comprises a group of more than 30 plasma 
proteins. This system is often closely associated with an antibody response (the classic 
pathway) to facilitate the uptake of microbes by phagocytotic cells, but can also recognise 
and eliminate microbes independent of antibody (via the lectin pathway or the alternative 
pathway) (Hoebe, Janssen et al. 2004). 
 
Another extremely significant part of the innate immune system is the natural killer (NK) 
cell. NK cells mediate cellular cytoxicity and produce chemokines and inflammatory 
cytokines such as IFNγ, and tumour necrosis factor (TNF) (Trinchieri 1989). They are 
important in attacking pathogen-infected cells, especially early in the immune response, 
and they also target tumour cells and are thought to be involved in tumour surveillance. 
They are also affected by, and can themselves regulate, the adaptive immune response, 
especially via interaction with dendritic cells (Raulet 2004).  
To recognise their targets NK cells use a multiple receptor strategy, whereby an 
individual NK cell can be triggered through various receptors independently or in 
combination, depending on the ligands presented by the target cell (Raulet, Vance et al. 
2001). Although most of these receptors were first discovered in NK cells, and thus are 
called NK receptors (e.g NKG2D), many of them are also expressed on other cell types 
(like T cells) (Raulet 2004). 
NK cells use three main recognition strategies. They can recognise pathogen-encoded 
molecules, the upregulation of self-protein in transformed and infected cells (induced 
self), or the absence of self-protein that is normally expressed but has been down-
regulated by infected or transformed cells (missing-self) (Raulet, 2004).   7 
An important NK receptor that recognises pathogen-encoded molecules is Ly49H, a 
stimulatory receptor on mouse NK cells which recognises a product of m157 of mouse 
cytomegalovirus (MCMV) (Arase, Mocarski et al. 2002). This receptor enables NK cells 
to limit early stage MCMV infections. Other examples of NK receptors specific for 
pathogens are NKp46 and NKp44 receptors which recognise influenza virus 
haemaglutinin (Mandelboim, Lieberman et al. 2001). Another strategy used by NK cells 
are receptors that recognise induced-self. An important one is the NKG2D receptor that 
recognises self-proteins that are upregulated on the surface of most tumours and many 
infected cells. Ligands for this receptor in humans include MHC class I chain-related A 
chain (MICA), MICB (Bauer, Groh et al. 1999), UL16-binding protein (ULBP), and Rae-
1 (Cosman, Mullberg et al. 2001). Other receptors that have been linked to NK-mediated 
lysis of tumour cells are NKp46, NKp44 and NKp30 (Raulet 2004). 
The other strategy that NK cells use, and actually was the first strategy that was 
discovered, is the recognition of missing-self (figure 1.1). The principle is that NK cells 
have receptors that send inhibitory signals when they bind their ligands, which are 
expressed on normal cells, but the loss of these ligands unleashes the NK cell to attack 
the target cell (Ljunggren and Karre 1990). This principle was first suggested when it was 
found that tumour cells lacking the MHC-class I molecule was the most sensitive to NK 
cell attack (Ljunggren and Karre 1985). Inhibitory recognition of classical MHC class I 
molecules (class Ia) is mediated mainly by Killer immunoglobulin-like receptors (KIR) in 
humans and Ly49 receptors in mice (Valiante, Lienert et al. 1997).  
 
 
 
 
 
 
 
 
 
 Target
NK
Target
+
-
NK +
Activation receptor
Inhibitory receptor
MHC class I
Activation receptor
ligand
Granule release (Cytotoxicity)
Cytokine
production
Figure 1.1. The control of NK cell activation. NK cell activation is controlled by 
the integration of signals from activation and inhibitory receptors. (a) Inhibitory NK 
cell receptors recognise self MHC class I and restrain NK cell activation. (b) When 
unimpeded by the inhibitory receptors, binding of NK cell activation receptors to 
their ligands on target cells results in NK cell stimulation. This stimulation results in 
cytokine production and granule release leading to cytoxicity.
(a)
(b)  9 
Although they are different in structure, KIRs and Ly49 receptors are very similar in their 
pattern of expression and function. Each family consists of approximately 10 genes that 
bind different subsets of MHC class I molecules (although not all of these are inhibitory). 
These receptors are expressed in a „variegated‟ manner, meaning that each receptor is 
expressed on a subset of NK cells, and multiple receptors are expressed on each NK cell, 
so that a partially overlapping repertoire of NK specificities is generated (figure 1.2). 
This has the effect of allowing individual NK cells to discriminate among cells 
expressing different class I molecules. For example, a host cell that downregulates only 
one MHC class I molecule will elicit a response by the subset of NK cells whose only 
self-specific inhibitory receptor recognises that particular molecule. Cells that have 
completely lost class I expression will be even more sensitive to attack by most NK cells 
(Raulet, Vance et al. 2001).  
      
When you examine the MHC-specific receptor system it begins to resemble adaptive 
immune receptor systems in some respects. Although there are many fewer NK receptors 
compared to T cell receptors, their repertoire is still relatively complex because of the 
random co-expression of many possible combinations of NK receptors. Unlike T cell 
receptors many of the NK cell receptors are inhibitory, although some are stimulatory. 
But like T cell receptors there is a possibility that the combination of NK cell receptors 
would make an autoreactive „clone‟. In the case of NK cells this may be because the cell 
expresses a stimulatory receptor for a self MHC molecule and/or lacks an inhibitory 
receptor for a self MHC molecule. In such a case these autoreactive „clones‟ can be 
silenced, resembling the negative selection of T cell receptors (figure 1.2). As far as we 
know there is no positive selection of NK cells as there is for T cells (Raulet, Vance et al. 
2001). 
NK cells also show some clonal expansion in response to viral infections (Dokun, Kim et 
al. 2001), although this is considerably less than the 1,000-fold clonal expansion that can 
be seen by naïve T cells in response to viral antigen (Raulet 2004).     
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Figure 1.2. Generation of the NK cell repertoire. Many of the NK cell receptors are 
inhibitory (red), although some are stimulatory (green). Random expression of receptors can 
lead to the appearance of potentially autoreactive clones. This may occur because a clone 
expresses a stimulatory receptor specific for a self cells and/or because the clone lacks 
inhibitory receptors specific for self cells. Such potentially autoreactive clones are silenced.  11 
1.3 The adaptive immune response 
 
For the first five to six decades of the 20
th century immunological research concentrated 
on examining the „transferable‟ immunity represented by antibody. But by the 1960s it 
was becoming accepted that there was also „cellular antibody‟, i.e. lymphocytes, and by 
the 1970s it was clear that thymus derived lymphocytes (T cells) were distinct from 
antibody-producing lymphocytes (B cells) (Masopust, Vezys et al. 2007). Further 
developments indicated that these T cells were cytotoxic, and expressed cloned receptors 
on their surfaces. This was demonstrated by experiments where lymphocytes were 
incubated on monolayers of allogeneic targets, resulting in their destruction. When non-
absorbed cells were gently removed, they showed little specific cytotoxicity. However, 
when absorbed cells were eluted from the monolayer of target cells, these lymphocytes 
were both cytotoxic and specific (Golstein, Erik et al. 1971). In 1975 it was discovered 
that depletion of Ly-2 (CD8ʱ) and Ly-3 (CD8β) bearing lymphocytes abolished the cell 
mediated cytotoxicity (Kisielow, Hirst et al. 1975). Thus the distinction between CD8 
and CD4 T cells was established. 
 
1.3a CD8+ T cells 
 
It was in two papers in the mid 1970s by Zinkernagel and Doherty that established the 
MHC restriction of CD8 T cells (Zinkernagel and Doherty 1974). This was demonstrated 
by observing that T cells that were derived from a LCMV-infected mouse would only 
lyse targets that shared at least one set of H-2 molecules. They put forward two possible 
hypotheses to explain this observation. The first was called the intimacy (or two receptor) 
hypothesis, which suggested that MHC recognition occurred separately and in addition to 
viral protein recognition. The second was called the altered self hypothesis, which 
suggested that the infection induced a complex between the viral and H-2 antigens. 
Further experiments by the pair led to the rejection of the former hypothesis in favour of 
the latter (Zinkernagel and Doherty 1974). Concerns about this hypothesis, in particular 
questions as to how would the single MHC molecule structurally be able to bind the vast 
array of viral proteins, persisted for many years. But the altered self hypothesis gained   12 
more support when, in the early 1980s, studies suggested that the MHC bound linear 
proteins rather than whole 3-dimensional proteins, which resolved many of these 
concerns (Townsend, Rothbard et al. 1986). Things became even clearer when the 
Bjorkman et al produced the crystal structure of MHC class I in 1987.  
But before that discovery immunologists in the early 1980s were still concerning 
themselves with defining the putative T cell receptor (TCR). By this point the B cell 
receptor had been fully characterised, and the diversity of the receptor explained by the 
new and exciting idea of gene rearrangement (Masopust, Vezys et al. 2007). The T cell 
receptor was harder to define because it did not bind free antigen, it was not produced in 
high quantities, nor secreted. But by the early 1980s clonotypic antibodies, generated 
against T cell hybridomas, allowed immunologists to define the TCR as a heterodimeric 
receptor with variable and constant regions, quite like immunoglobulin (Samelson, 
Germain et al. 1983).   
So by the mid 1980s the TCR had been defined and it seemed that MHC bound short 
peptides. But a lot of questions remained about how this TCR would see the „altered self‟ 
MHC. These questions were answered when the crystal structure of class I MHC was 
shown in 1987 (Bjorkman, Saper et al. 1987). At the same time they interpreted this 
image as showing that the TCR engages peptide-binding groove of MHC along with the 
bound peptide (Bjorkman, Saper et al. 1987). Suddenly this previously clouded subject 
became clear. It was seen that most MHC-polymorphisms were situated at points that 
could contact peptide or TCR (so called functional positions), and also that allotypic 
differences affecting T cell reactivity were concentrated in the peptide-binding groove. 
Consequently this work simultaneously provided the mechanism for MHC restriction and 
allele specificity.  
At the end of the 1980s the final connection between CD8 T cells and MHC class I was 
made when it was proposed that CD8 was not just a marker, but that it increases the 
avidity of T cells for their targets by directly binding to class I MHC. A range of 
experimental approaches confirmed this proposition, including co-immunoprecipitation 
studies, cell-cell binding assays, and the use of artificial vesicles expressing purified CD8 
or HLA molecules (Rosenstein, Ratnofsky et al. 1989). 
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While the base understanding of CD8 T cells was now in place there were still several 
important discoveries to be made. In the early 1990s, work by Rammensee and 
colleagues sought to better characterise class I MHC-bound peptides. They found that the 
preferred length of bound peptides was shorter than was previously thought, at 8-10 
amino acids, and also that each class I MHC had a preference for specific amino acids at 
specific „anchor‟ positions (Falk, Rotzschke et al. 1991). This last observation allowed 
the characterisation of the binding motifs for different class I MHC molecules. Over the 
next decade and a half, incremental discoveries allowed the field to build up a much 
better picture of the „life‟ of a CD8 T cell. In particular how a naïve T cell differentiates 
into effector T cells and then how effector T cells differentiate into memory T cells. For 
the first step major cellular programming is required to drive a quiescent naïve T cell 
through 10-15 divisions in just a week and convert these cells into effector T cells 
capable of robust cytokine production and cytoxicity. For the second step, in the absence 
of their stimulating antigen, effector cells differentiate into memory T cells that retain the 
capacity for rapid effector functions, and regain high proliferative potential and acquire 
the unique property of homeostatic proliferation. Homeostatic proliferation, a type of 
self-renewing division, is maintained by IL-7 and IL-15. Furthermore it was also found 
that CD4 T cells help CD8 T cells through the differentiation process and are essential for 
optimal memory CD8 T cell development (discussed in more detail below) (Williams and 
Bevan 2007).  
 
As things stand today we know that CD8 T cells respond to short peptides produced in 
the cytosol, or via cross-presentation, allowing CD8 T cells to form the adaptive response 
against viruses, bacteria and protozoa. Activated CD8 T cells have two main pathways of 
inducing apoptosis in their target cell: via the granule exocytosis pathway, dependent on 
the pore-forming molecule perforin; or by upregulating FasL, which engages Fas on 
target cells. Both these pathways, initiated through stimulation of the TCR, induce cell 
death in the target cell via the caspase cascade (Harty, Tvinnereim et al. 2000).  
 
1.3b. CD4+ T cells 
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CD4+ T cells establish and maximise the capabilities of the immune system, with most of 
their function concerned with activating and directing other cell types. This ability to 
activate and direct the response is generally encapsulated by the term „CD4+ T cell help‟. 
It is often the case that a lack of CD4+ T cell help does not prevent the initiation of 
immune responses by other cell types, but the absence limits the duration and the 
effectiveness of such responses.  
 
Naïve CD4 T cells are maintained in a resting state as they recirculate from blood 
through lymphoid organs, surveying DCs for activating MHC-peptide complexes. Upon 
interaction with activated DCs, and with signals from the cytokine milieu, CD4+ T cells 
are driven through rapid rounds of division and acquire the ability to secrete effector 
cytokines. Eventually daughter cells become fully differentiated and fixed in their 
effector lineages and migrate to sites where their cytokines functionally organise the 
immune response. There are several T helper (Th) subsets that have been characterised, 
and most are defined by the major cytokine that it secretes. The original subsets of Th1 
(IFNγ-secreting) and Th2 (IL4-secreting), have been joined more recently by Tregs 
(either thymically produced or peripherally induced suppressor cells) Tr1 (IL-10-
secreting), Th3 (TGFβ-producing), ThFH (follicular helper cells), and Th17 (IL-17-
producing) subsets (Reinhardt, Kang et al. 2006).  
These subsets each have particular downstream effects. Th1 cells, through IFNγ, recruit 
NK cells and macrophages to mediate effector functions in the periphery. Th2 cells, 
through IL4, recruit eosinophils, basophils and alternatively activated macrophages for 
the same reason. Th17 cells, through IL-17, recruit PMNs to the periphery, and ThFH 
cells activate B cells at T cell-B cell follicular border (Hardtke, Ohl et al. 2005). Treg, 
Tr1 and Th3 cells perform distinct regulatory functions in the immune system. 
 
In the absence of CD4+ T cell help B cell responses can be initiated, but the somatic 
hypermutation, isotype switching, and clonal selection necessary for production of high-
affinity immunoglobulins is restricted (Mills and Cambier 2003). Furthermore, a lack of 
CD4+ T cell help will allow an acute but not a sustained or memory CD8+ T cell 
response. Early experiments investigating the role of CD4+ T cells in CD8+ T cell   15 
responses, involving allograft rejection in vivo experiments and in vitro allogenic mixed 
lymphocyte reactions, concluded that MHC class II-specific CD4+ T cells were necessary 
for the generation of a cytotoxic CD8+ T cell responses and led to the original concept of 
CD4+ T cell help being essential for the clonal expansion of naïve CD8+ T cells (Keene 
and Forman 1982). This concept led to a simple hypothesis that the expansion of naïve 
CD8+ T cell precursors depended on CD4+ and CD8+ T cells being stimulated by 
antigen on the same APC, so that IL-2 secreted by CD4+ T cells can act on a 
neighbouring CD8+ T cell expressing high-affinity IL-2 receptors (Castellino and 
Germain 2006). 
While this model has not been completely disproved, a series of recent studies have 
reached the conclusion that CD4+ T cells are very often dispensable for early clonal 
expansion and the generation of primary CD8+ cytotoxic effectors, but are critical in 
sustaining CD8+ effector response and are required for the generation of an optimal pool 
of functional memory CD8+ T cells (Janssen, Lemmens et al. 2003). Such studies 
showed that depletion of CD4+ T cells did not affect pathogen clearance mediated by 
CD8+ T cells, if mice were infected with low numbers of organisms, but led to persistent 
infection when higher doses of the same agent were used.  
Once it became clear that CD4+ T cells aid in the formation of CD8+ T cell memory 
responses, the questions that remained were when, where and how this CD4+ T cell help 
was delivered. In terms of „when‟, the bulk of evidence available indicates that CD4+ T 
cells must deliver one or more signals to the CD8+ T cells directly or indirectly at the 
time of, or shortly after, initial contact with antigen-bearing APCs (Masopust, Kaech et 
al. 2004). In terms of „where‟ and „how‟, there appears to be at least two alternate models 
to explain this. One is that antigen-stimulated CD4+ T cells activate DCs via CD40L-
CD40 interaction, and the resultant „licensed DCs‟ become fully competent to activate 
naïve CD8+ T cells, even in the absence of an associated CD4+ T cell. CD40 signalling 
on DCs increases MHC display, costimulatory molecule expression, cytokine secretion 
and chemokine production, which will coordinate to amplify or sustain CD8+ T cell 
responses during either the acute or memory phases (Ridge, Di Rosa et al. 1998). 
The other, known as the „three-cell cluster‟ model, is similar to the early hypothesis 
regarding CD4+ and CD8+ T cell interactions in that the two cells need to recognise their   16 
specific antigens simultaneously on the same APC, so that IL-2 secreted by the APC-
bound CD4+ T cell can stimulate the CD8+ T cell (Keene and Forman 1982), or so that 
CD4+ T cells can directly stimulate the CD8+ T cell via CD40L (Bourgeois, Rocha et al. 
2002). The problem with this latter model is that there is a low probability that these three 
rare cells, all bearing the right antigen or antigen-specific TCR, will find each other at the 
same time in the same place. More recent studies have addressed this improbability by 
showing that DC-CD4+ T cell associations can last for many hours (Shakhar, Lindquist 
et al. 2005), increasing the probability that the DC-CD4+ T cell couplet will encounter 
their relevant CD8+ T cell. Furthermore, studies showing that CD8+ T cells 
preferentially accumulate in lymph nodes in which CD4+ T cells were undergoing 
antigen-specific activation, suggest that some combination of chemokinesis and 
chemoattraction can further increase the probability of naïve CD8+ T cells of 
encountering DCs engaged in productive interactions with CD4+ T cells. Further 
blocking antibody experiments suggested that the inflammatory chemokines, CCL3 and 
CCL4, were responsible for the chemoattraction (Castellino and Germain 2006).   
 
These ideas can be simplified into one overall model of CD4+ T cell control of CD8+ T 
cell responses (figure 1.3). When CD8+ T cells recognise their antigen, generally 
presented by DCs, the T cell can make a productive response, or can be rendered anergic 
and possibly even die (Mescher, Agarwal et al. 2007). CD8+ T cell activation thus 
depends on three signals: antigen engagement by the TCR, costimulation via CD28 
engagement of its ligands, and a third signal which is often IL-12 produced by the DC. 
Engagement on CD40 on DC stimulates the cells to produce IL-12, thus CD4+ T cells are 
in control of this first checkpoint for CD8+ T cell response. CD8+ T cells can proliferate 
and generate effector function in the absence of a third signal, but the death of the 
majority of the responding cells that occurs following the peak of clonal expansion is 
more rapid and profound in the absence of a third signal (Curtsinger, Lins et al. 2003). 
Even in the presence of a third signal, at around 72hr after first encountering antigen, and 
in the face of a persistent antigen, the CD8+ T cells can reach activation-induced non-
responsiveness (AINR). This constitutes a second checkpoint, and if the effector CD8+ T 
cells are to continue to expand IL-2 must be provided by helper T cells, which works to   17 
reverse the effects of AINR (Mescher, Agarwal et al. 2007). These checkpoints may be 
the major means by which self-reactive CD8+ T cells are prevented from productively 
responding to cause autoimmune disease or transplant rejection. This idea will be 
discussed further in section 1.5 on tolerance in the immune system. 
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Figure 1.3. The activation of dendritic cells by CD4+ T cells helps stimulate CTL 
responses. Phagocytosed antigen is presented to CD4+ T cells, which activate the DC 
through CD40-CD40L interactions. The activated DC can then promote the CD8+ T cell 
response via antigen engagement of the TCR, costimulation via CD28, and via the production 
of IL-12.  19 
1.4 Generation, structure and function of the ʱβ T cell receptor (TCR) 
 
The T cell receptor is a membrane bound heterodimer composed of two polypeptide 
chains (ʱ and β) linked by a disulphide bond, that forms a complex with a peptide-MHC 
ligand (pMHC). Although TCR recognition of pMHC is functionally similar to antibody-
antigen interaction in the humoral system (Davies and Metzger 1983), T cell recognition 
is a more complex process. Specificity in T cell responses arises from the extensive 
repertoire of TCRs coupled to polymorphism in the MHC that controls the size and 
diversity of the peptide repertoire presented (Garcia, Teyton et al. 1999). Furthermore, 
the TCR does not bind pMHC in isolation but does so in associated with a signalling 
complex that includes membrane-bound proteins including CD3 γ, δ, ε and δ chains, and 
coreceptors CD8 or CD4 (Clevers, Alarcon et al. 1988).  
 
The TCR is composed of constant (C) and variable (V) regions, which are assembled 
together during thymic ontogeny (Alt, Oltz et al. 1992). The diversity of the TCR is 
generated via gene rearrangement within the variable domains of the TCR, which is the 
(V) and junction (J) gene segments in the Vʱ chain, and the V, diversity (D) and J gene 
segments in the Vβ chain. The TCRʱ genes located at chromosome 14q 11-12 consist of 
70 V segments and 61 J segments, while the TCRβ genes located at chromosome 7q 32-
35 consist of 67 V segments, 2 D segments and 13 J segments. During TCR gene 
rearrangement the V and J, or V, D and J segments are brought together in a continuous 
V-J or V-D-J coding block, forming complete V domain exons that are responsible for 
antigen recognition. This process is catalysed by recombination activation genes, RAG1 
and RAG2 (Oettinger, Schatz et al. 1990), and the enzyme terminal deoxynucleotidyl 
transferase (TdT) (Landau, Schatz et al. 1987). However the diversity of the TCR 
depends not only on the recombination of these genes but is also greatly increased by 
nucleotide insertion and deletion at the junctions between these genes. The greatest 
diversity is present at the third complementarity determining region (CDR3), which spans 
the V(D)J junction. The CDRs are regions of greatest sequence variability (CDR1 and 
CDR2 are located within the V domain) and constitute the binding site for the peptide-  20 
MHC complex, with the CDR3 positioned at the centre of the antigen binding site for 
direct contact with the MHC bound peptide (Jorgensen, Esser et al. 1992).     
 
The generation of TCR-pMHC crystal structures has allowed us to visualise the 
interaction of these two molecules in more detail. The MHC molecule is also 
heterodimeric, with the class I molecule composed of a heavy chain and β2 
microglobulin. Antigenic peptide resides within antigen-binding cleft, which is bound by 
two long ʱ-helices (ʱ1 and ʱ2) (figure 6.2) (Gras, Kjer-Nielsen et al. 2008). The TCR and 
pMHC „dock‟ together, so that the TCR Vʱ domain is positioned over the MHC ʱ2-helix 
and the N-terminal end of the peptide, whilst the TCR Vβ domain contacts the MHC ʱ1-
helix and the C-terminal end of the peptide. Within this framework, either or both of the 
CDR3 loops can interact with the peptide and also with the MHC. Likewise whilst the 
CDR1 and CDR2 loops generally interact with the MHC, they have also been observed to 
interact with the peptide (Rudolph, Stanfield et al. 2006). 
 
Once the nature of TCR recognition of MHC and peptide had been more or less resolved, 
the next question was what happens following TCR engagement by pMHC? The earliest 
biochemical events that have been detected after TCR engagement is the phosphorylation 
of immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic domains 
of the TCR/CD3 complex, mediated by the Src family tyrosine kinases, Lck and Fyn 
(Weiss and Littman 1994). This step is believed to be essential for signal transduction by 
the TCR, and consequently there have been many models designed to explain how TCR 
binding to pMHC stimulates the ITAM phosphorylation. These models use one or more 
of three basic mechanisms to explain the transduction of the signal across the T cell 
membrane: aggregation, conformation change, and/or segregation (Choudhuri and van 
der Merwe 2007). 
One of the more rigorously tested models is the kinetic-segregation model, which falls 
into the segregation category. The model depends on the fact that when a T cell and an 
APC come into close contact, they form „close-contact‟ zones that exclude large 
molecules such as CD45 and CD148, which are inhibitory tyrosine phosphatases that 
keep the ITAM regions dephosphorylated and the T cell in a „resting‟ state. TCRs that  Figure 1.4. The interaction of the T cell receptor with MHC class I. Panel (a) shows 
a ribbon schematic of the TCR α and β chains interacting with a ribbon schematic of a 
MHC class I molecule. Panel (b) gives a colour coded representation of the Variable, 
Diversity and Junctional regions that make up the parts of the TCR interface that interact 
with the surface of the MHC class I molecule and the peptide epitope in the peptide 
groove, as shown in panel (c). Reprinted from Current Opinion in Immunology (2008) 
February, volume 20(1), pages 119-25.   22 
bind pMHC in these close-contact zones are able to be phosphorylated by tyrosine 
kinases like Lck, and the signal is transduced. If there are no TCR-pMHC associations 
then the TCRs will diffuse from the close-contact zone and come into contact with CD45 
and CD148 again, and the T cell will remain in a resting state (Davis and van der Merwe 
2006). 
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1.5 Tolerance in the immune system 
 
Our knowledge of the how the TCR is assembled, and the mechanisms used to create 
TCR diversity, allows us to predict the potential number of TCRs that can be formed. Of 
the three CDR loops, which create the binding face that contacts antigen, CDR1 and 
CDR2 are encoded by the V gene segment, and have only the diversity provided by the 
number of germline V region gene segments, around 20-70 Vʱ and Vβ segements in mice 
and humans. If there were only 50 Vʱ and Vβ genes to encode the TCR repertoire, 
combinatorial pairing would provide only 2,500 TCRs (50 x 50). Fortunately the CDR3 
loop, created by the juxtaposition of VJ or V(D)J segments, provides much more 
diversity, as a result of each V segment being able to rearrange to any (D)J segment 
compounded by the fact that the joining of these sequences is imprecise (Goldrath and 
Bevan 1999) (see figure 6.1). These factors boost the number of possible TCRs from the 
thousands to the billions, with a theoretical maximum approximated to be 10
15 possible 
TCRs (Casrouge, Beaudoing et al. 2000). The actual number of TCR clones present in 
the periphery (around 10
7 in humans) is a fraction of this theoretical diversity maximum, 
partly due to structural limitations of harbouring that many T cells, but also due to the 
development and selection process in the thymus known as central tolerance. 
 
1.5a. Central tolerance 
 
Bone marrow stem cells enter the thymus and commit to the T cell lineage in response to 
signals from the microenvironment. The earliest precursors are CD4- CD8- double 
negative cells, at which point the TCRβ chain is assembled. These cells then proliferate 
extensively and become CD4+CD8+ double positive cells, at which point the TCRʱ 
chains rearrange, making these cells the targets for the TCR selective events. These 
selective events are severe, with the consequence that ultimately only about 5% of the 
double positive cells are allowed to emigrate (Goldrath and Bevan 1999). During their 
approximate 3-day lifespan the double positive cells will continue to rearrange their 
TCRʱ chain genes in an attempt to form a heterodimeric ʱβ TCR that can recognise 
MHC molecules expressed on thymic epithelial cells (TECs). Those cells that manage   24 
this are „positively selected‟, and are rescued from apoptic death by neglect of their 
receptor, allowing these cells to switch off further TCRʱ chain gene rearrangement. 
Depending on whether the double-positive cells recognise class I or class II MHC, cells 
then commit to either the CD8 or CD4 lineage respectively (Jameson, Hogquist et al. 
1995). However, the selection of the TCR repertoire is not solely based on the 
recognition of self-MHC molecules, but on the recognition of those structures modified 
by the binding of numerous self-peptides. The number and nature of the self-peptides 
involved in positive selection has been controversial. The data accumulated to date 
suggests that relatively rare, low-affinity self-peptides promote positive selection, giving 
rise to mature T cells having high affinity for foreign peptides that are generally 
structurally related to the self-peptides involved in selection (Starr, Jameson et al. 2003). 
This ensures that a diverse repertoire is created able to bind strongly to pathogen-encoded 
peptides bound by the same MHC molecules in the periphery.  
The weak TCR-self-peptide interactions extend beyond the thymus, as naïve T cells 
continue to depend on continuous survival signals supplied by these interactions in the 
periphery (Freitas and Rocha 1999). Only memory T cells are not dependent on 
recognition of self-antigen in the periphery.  
However, positive selection is only half the story of central tolerance. Whereas low 
affinity interactions with self-peptide and MHC are necessary for the survival of double 
positive cells, high-affinity interactions lead to the death of those T cells through 
„negative selection‟. Almost half of the cells reacting with self-MHC are lost though this 
mechanism (van Meerwijk, Marguerat et al. 1997). The purpose of negative selection is 
to prevent autoreactivity, as any high-affinity peptide-MHC interactions with TCRs in the 
periphery lead to rapid proliferation and generation of effector and memory T cells, 
irrespective of whether the peptide recognised is self or foreign (Goldrath and Bevan 
1999). Positive selection peptides are generally not stimulatory for mature T cells, but 
stimulatory peptides for a given T cell cause clonal deletion if present in thymus during 
thymocyte development. However, a comprehensive negative selection of all potential 
autoreactive T cells would depend on presentation of stimulatory peptides beyond those 
that would be expected to be present during thymocyte development. To this end, TECs 
are able to constitutively synthesise and express many peripheral tissue-specific antigens   25 
that would be otherwise be unavailable to induce thymic tolerance, a function which is 
dependent on expression of the autoimmune regulator (AIRE) gene. Consequently, 
AIRE-deficient humans and mice develop organ specific autoimmunity (Anderson, 
Venanzi et al. 2002). This TEC-mediated central tolerance can be extended by transfer of 
the antigens to bone marrow-derived APCs, which can also mediate negative selection in 
the thymus (Gallegos and Bevan 2006).         
 
1.5b. Peripheral tolerance 
 
Given the careful purging of autoreactive T cells from the repertoire in the thymus during 
central tolerance, it was thought for a time that additional peripheral tolerance 
mechanisms would not be necessary. As the affinity threshold of TCR-pMHC interaction 
that signals thymic deletion is lower than that for activation in the periphery, even T cells 
with low avidity for self-antigens will not be activated in the periphery and instead 
remain „ignorant‟ of their cognate antigen.  
For several reasons however, activation of auto-reactive T cells remains an ever present 
danger. One reason is that in the periphery the immune system is constantly exposed to 
the numerous innocuous environmental antigens, to which immune responses could be 
formed. Secondly, self-antigens that are restricted to immunological privileged sites, and 
are thus physically inaccessible to T cells, may be compromised through injury, exposing 
the immune system to potentially unseen autoreactive epitopes. Furthermore, the 
„ignorance‟ of low affinity autoreactive T cells could be broken given the proper 
stimulatory milieu, leading to the formerly ignored antigens initiating autoimmune 
responses (Redmond and Sherman 2005). Indeed, it has been shown that viral priming 
can break CD8+ T cell ignorance and promote autoimmunity (Ohashi, Oehen et al. 1991). 
Finally, despite the activity of AIRE, not all self antigens are expressed in the thymus. 
For example one autoimmune disease is caused by the normal and tolerising version of a 
peptide being presented in the thymus, while a cryptic stimulatory version of the same 
peptide is presented in the periphery (Badami, Maiuri et al. 2005).      
The tolerance mechanisms that exist to combat the persisting problem of autoreactivity in 
the periphery are numerous and varied. Perhaps the most important peripheral tolerance   26 
mechanism is the requirement for multiple antigen-specific lymphocytes to interact, 
either directly with each other or through the intermediation of DCs (Castellino and 
Germain 2006). This in other words is the need to have DCs, CD8+ T cells and CD4+ T 
cells to initiate an autoreactive response. As examined in section 1.3, a lack of CD4+ T 
cell help will not allow a sustained or memory CD8+ T cell response. It is logical to 
assume that the chance of an autoreactive CD8+ T cell and an autoreactive CD4+ T cell 
firstly both escaping from the thymus and then secondly both meeting their cognate self-
antigens together on the same APC, is much lower than the chances of only a CD8+ T 
cell doing this. Furthermore, T cells require that the DCs presenting their cognate antigen 
have acquired the capacity to effectively trigger T cell responses, and for this to happen 
DCs must be stimulated through receptors such as the TLRs with by-products of foreign 
invasion such as viral DNA (Lee and Iwasaki 2007). In the absence of pathogens 
however, DCs are quiescent and express low levels of costimulatory molecules such as 
CD80 and CD86, which interact with CD28 on T cells to enhance their responsiveness 
and survival. Consequently, T cells recognizing their antigen in the absence of 
costimulation only briefly proliferate and develop effector cell function only 
suboptimally (Redmond and Sherman 2005). This ultimately leads to either the death of 
the antigen-activated CD8+ T cells (deletion), or to the induction of a long-lived non-
responsive state (anergy) (Redmond and Sherman 2005). 
Some believe that the main reason behind the evolution of an immune system with 
critical requirements for cell-cell cooperation as detailed above, is to impose controls on 
the development of autoreactive responses (Bretscher and Cohn 1970). This idea also 
extends to the interaction between CD4+ T cells and B cells bearing potentially 
autoreactive antibody.  
 
Studies that demonstrated that it was possible to develop an effector T cell response in 
the absence of adjuvant (Rocha, Grandien et al. 1995), found that the critical variable was 
the persistence of antigen. Later results also concluded that antigen localisation, dose and 
persistence are the critical factors that determine tolerance induction, rather than just the 
delivery of costimulating signals by APCs (Zinkernagel 2000).  
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The other main peripheral tolerance mechanism is the existence of suppressive cellular 
elements, the most well understood member being the CD25+ regulatory T cell (T reg) 
(detailed in section 1.6). It is clear that T regs play a significant role in maintaining 
peripheral tolerance, not least by the fact that numerous chronic and destructive 
autoimmune diseases that are unleashed by elimination of the T reg population in mice. 
These include gastritis, oophritis, thyroiditis, adrenalitis and insulitis, suggesting that the 
activation and expansion of such self-reactive T cells is normally kept in check by T regs. 
Furthermore, the appearance of various disease-specific autoantibodies in the T reg 
depleted animals implies that the breakdown of this mode of peripheral tolerance, and the 
development of autoimmune CD4+ helper T cells results in breakdown of B cell self-
tolerance as well (Sakaguchi 2004). 
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1.6 Regulatory T cells 
 
The theory of immune regulation via a network of suppressor T cells first gained 
popularity in the 1970s, but the theory experienced several set-backs and only relatively 
recently has the scientific community truly embraced it. Prior to recent key discoveries it 
was believed that the mechanism of negative selection in the thymus was sufficient to 
remove nearly all auto-reactive T cells, rendering the need for any peripheral suppressor 
mechanism redundant. However it is now abundantly clear that in the absence of a 
distinct population of regulatory cells, tolerance to self-tissues is lost and severe multi-
system autoimmune disease results (Sakaguchi, Sakaguchi et al. 1995).  
 
It is now clear that potentially very damaging auto-reactive T cells can escape deletion in 
the thymus and thus must be kept in check by one or more peripheral tolerance 
mechanisms. These include deletion, anergy and ignorance (Mackay 2000), plus the more 
„active‟ mechanism of regulatory T cells. 
 
The purpose of a regulatory T cell is to prevent damaging inflammatory responses in the 
periphery, playing a role in dampening not only autoimmune responses (Sakaguchi, 
Sakaguchi et al. 1995) but also responses to allergens, pathogens, and tumour cells 
(Grindebacke, Wing et al. 2004), (Lundgren, Suri-Payer et al. 2003), (Onizuka, Tawara et 
al. 1999). It is clear therefore, that regulatory T cells can be both beneficial and 
detrimental to the host organism.     
To date there have been several types of regulatory T cell identified (see table 1.6.). 
Regulatory properties are found in gamma-delta cells, NKT cells, CD8+ T cells and 
CD4+ T cells (Bach 2003). Within CD4+ regulatory T cells there are further divisions: 
some such as Tr1 (Levings, Bacchetta et al. 2002) and Th3 cells (Weiner 2001) are 
induced to secrete suppressive cytokines such as IL-10 and TGF-beta; others occur 
naturally like the CD4+CD25+ regulatory T cell (T reg). Other additions to the regulatory 
cell family include double negative T cells (Zhang, Yang et al. 2000), and myeloid 
suppressor cells (Bronte, Apolloni et al. 2000). But the most extensively studied of all 
these cells is the CD4+CD25+ regulatory T cell (T reg).    29 
Table 1.1. Table of common regulatory cell subsets. 
 
 
1.6a. CD4+CD25+ regulatory T cells (T reg) 
 
T regs are often referred to as „naturally occurring‟ regulatory T cells as they exist as a 
distinct subset of T cells in every normal individual, comprising approximately 5-10% of 
the peripheral CD4+ T cells in mice and humans (Sakaguchi, Sakaguchi et al. 1995).    
 
T regs were first identified when it was found that the high affinity IL-2 receptor alpha 
chain (CD25) could serve as a marker for a subset of CD4+ T cells with regulatory 
properties (Sakaguchi, Sakaguchi et al. 1995). Cell suspensions prepared from normal 
BALB/c mice were depleted of the peripheral CD4
+ cells that express CD25, and then 
inoculated into athymic nude mice. Subsequently the recipients spontaneously developed 
autoimmune diseases (throiditis, gastritis, insulitis, adrenalitis, oophoritis, 
glomerulonephritis, polyarthritsis), with some others also developing a graft-versus-host 
Regulatory cell  Phenotype  Regulatory Mechanism 
γδ T cells  γδ T cell receptor  Cytokines 
NKT cells  NK1.1, ʱβTCR  IL-4, IL-10, TGFβ, IFNγ, 
cytoxicity 
Tr1 cells  CD4+  IL-10, (TGFβ) 
Th3 cells  CD4+  TGFβ, (CTLA-4) 
T regs  CD4+ CD25+, Foxp3+  Cell-cell contact (bound 
TGFβ, CTLA-4), IL-2 sink, 
cytokines (TGFβ, IL-10) 
DN T cells  CD3+, CD8-, CD4-  Cell-cell contact, soluble 
mechanism 
MSCs  Gr1+, CD11b+  ARG, iNOS 
CD8+ T regs  CD8+CD25+  Cell-cell contact 
CD8 suppressors  CD8+CD28-  IFNγ, IL-6   30 
like wasting disease. Prompt reconstitution of the CD4
+CD25
+ cells after transfer of 
CD4
+CD25
- cells prevented the autoimmune developments.  
 
Investigations into the phenotype of these cells found that they are generally CTLA
+, 
CD45RB
low, with GITR, CD62L, and membrane-bound TGF-  also sometimes present 
(Sakaguchi, Sakaguchi et al. 1995). However, the majority of the known markers for T 
regs, including CD25, are also upregulated on CD25- T cells after stimulation. Therefore 
no single surface marker is exclusively expressed by or needed for the development of 
functional T reg and such a marker remains to be identified. 
 
Despite this, the idea that T regs are a lineage distinct from other T cells is supported by 
the T reg-specific forkhead/winged helix transcription factor Foxp3. The importance of 
Foxp3 was discovered in scurfy mice, which have a spontaneous X-linked mutation in 
Foxp3 causing a fatal lymphoproliferative disease (Brunkow, Jeffery et al. 2001). The 
human form of Foxp3 is also mutated in patients with IPEX 
(Immunodysregulation, Polyendocrinopathy, and Enteropathy, X-linked), a severe and 
fatal autoimmune/allergic syndrome (Gambineri, Torgerson et al. 2003). Studies suggest 
that Foxp3 is a master regulatory
 gene for T reg-lineage commitment, and is crucial in the 
differentiation
 of T regs in the thymus and the periphery (Hori, Nomura et al. 2003). 
 
It is now generally accepted that T regs are selected during the process of T cell 
differentiation in the thymus. Thymectomy of mice at day 3 of life leads to multi-organ 
autoimmune disease, due to the fact that T regs do not emerge from the thymus until after 
day 3 (Asano, Toda et al. 1996). Studies suggest that T regs require a TCR-self-
peptide/MHC-class II interaction stronger than what is required for normal positive 
selection, but lower than the threshold for negative selection. Where this interaction 
between the T reg and its self-antigen occurs is not certain, but the answer is probably 
either on medullary dendritic cells (Jordan, Boesteanu et al. 2001), or on thymic cortical 
epithelium (Bensinger, Bandeira et al. 2001).    
However, it is also becoming clear that T regs can originate in the periphery. When T 
cells with known TCR specificities from TCR transgenic mice are transferred into wild-  31 
type mice and immunized with low doses of the known peptide (but crucially with no 
adjuvant for costimulation), the transferred T cells develop into CD4+CD25+ T regs with 
regulatory properties (Thorstenson and Khoruts 2001). 
 
Once in the periphery, it is very likely that T regs can and do respond to a number of 
different antigens via their TCR. Analysis of TCR   gene segments of CD25
+ T regs 
suggest that their TCR repertoire is as similarly diverse as CD4
+CD25
- T cells (Kasow, 
Chen et al. 2004). Supporting this is the fact that CD25
+ T regs seem to play a role in 
balancing nearly all immune responses including chronic infection and allergy. For 
example, CD25
+ T regs can suppress responses to foreign antigens including Heliobacter 
pylori peptides (Lundgren, Suri-Payer et al. 2003) and pollen extract in vitro 
(Grindebacke, Wing et al. 2004). The reason behind such a broad TCR repertoire may be 
that T regs need to interact with their specific antigen in order to suppress immune 
responses.  
Peripheral CD4+ T cells, from rats whose thyroids were ablated in utero, were unable to 
prevent autoimmune thyroiditis development upon adoptive transfer into thymectomized 
and irradiated recipients. However, the capacity of these regulatory T cells to protect 
against other autoimmune diseases, like diabetes, remained (Seddon and Mason 1999). 
Significantly, unlike the peripheral CD4+ T cells, CD4+ thymocytes from thyroid-ablated 
donors were still able to prevent thyroiditis upon adoptive transfer. This indicates that it 
is the peripheral autoantigen itself that stimulates the generation of the appropriate 
regulatory cells from thymic emigrant precursors. 
 
Quite how CD25
+ T regs suppress other T cells is still poorly understood, but generally 
the mechanism seems to rely on the inhibition of IL-2 transcription in the effector 
populations, as suppression can be abrogated by the addition of exogenous IL-2 or by 
enhancing endogenous IL-2 production (Shimizu, Yamazaki et al. 1999). The in vitro 
data suggests that suppression by CD25
+Tregs relies on an unknown cytokine-
independent cell-contact-dependent mechanism, involving CTLA-4 (Takahashi, Tagami 
et al. 2000), and/or cell surface TGF- 1. However, the in vitro data contrasts markedly 
with the in vivo data, which implicates several cytokines as mediators of inhibition,   32 
including TGF , IL-10, and IL-4 (Asseman, Mauze et al. 1999), (Seddon and Mason 
1999). The discrepancy between the in vitro and in vivo data may be explained by studies 
in which CD25
+Tregs induce suppressive properties in CD4+CD25- T cells when 
cultured in vitro. This „infectious tolerance‟ causes the CD4+CD25- T cells to become 
anergic and produce IL-10 (Dieckmann, Bruett et al. 2002) or TGF-  (Jonuleit, Schmitt 
et al. 2002). The initial culture of CD4+CD25- T cells and CD25
+ Tregs required cell-
contact for the induction of anergy, but if the anergic cells were transferred to fresh 
cultures, they suppressed naïve T cells in a cytokine-dependent cell-contact independent 
manner.  
 
1.6b. Double negative T cells 
 
Double negative (DN) T regs are a further suppressive subset of T cells, and are CD3+, 
CD4-, CD8- and NK1.1-. They represent a very small number of T lymphocytes in the 
periphery of mice and humans (1-5% in mice and 1-2% in humans). They have a unique 
set of cell surface markers, as they express neither CD4 or CD8 co-receptors, nor the 
costimulatory molecule CD28. They also produce a unique array of cytokines compared 
to other regulatory T cells, including predominantly IFN- , TNF-  and a low amount of 
TGF- , but not IL-2, IL-4, IL-10 or IL-13 (Zhang, Yang et al. 2000). Also unlike other T 
reg cells, DN T regs do not express the activation markers CD44 or CD28 any time after 
activation, but Foxp3 mRNA has been detected in these cells. Furthermore, unlike CD4+ 
or CD8+ cells which are sensitive to activation induced cell death, DN T reg cells are 
resistant to apoptosis induction both in vitro and in vivo (Chen, Ford et al. 2004). 
 
Numerous studies have shown these DN T regs to be a subset of potent immune 
regulatory cells. DN T cells were isolated from Donor Specific Transfusion (DST)-
treated mice and used to suppress and kill CD8+ and CD4+ T cells in an antigen specific 
manner in vitro, and prolonged donor-specific allograft survival when adoptively 
transferred into naïve syngeneic mice (Zhang, Yang et al. 2000). Furthermore, mice 
infused with DN T reg cells were protected from the development of Graft Versus Host 
Disease (GVHD) (Young, DuTemple et al. 2003). The mechanism of this suppression has   33 
shown to be antigen specific and cell-cell contact dependent. The DN T regs acquire 
MHC-peptide complexes from neighbouring antigen presenting cells (APCs), which 
remain expressed on the surface of the DN cells for several days, allowing suppression of 
other T cells by bringing the T cells that are able to recognize the acquired allo MHC-
peptides into cell contact (Zhang, Yang et al. 2000). The suppression/elimination of these 
T cells is at least partially Fas-FasL dependent, because blocking of FasL on DN T reg 
cells using mAb significantly inhibits DN T cell mediated killing (Zhang, Yang et al. 
2000), while DN T cells from gld mice that express mutant FasL showed a reduced 
ability to kill CD8 T cell targets when compared to wild-type FasL (Ford, Young et al. 
2002).  However there is also some evidence that DN T cells are able to partially 
suppress T cell responses in the absence of cell contact, suggesting some soluble factor 
could be involved in the suppression (Chen, Ford et al. 2004). 
 
1.6c. Myeloid suppressor cells 
 
Another potent suppressor of T cell responses is the myeloid suppressor cell (MSC), a 
cell that has been mostly defined in the context of facilitation of tumour growth. MSCs 
represent a heterogenous population of myeloid suppressor cells comprising immature 
macrophages, granulocytes, dendritic cells and other myeloid cells at an early stage of 
differentiation, and are identified in mice by the expression of CD11b and Gr-1. In 
healthy mice MSCs are only present in large numbers in the bone marrow, but they can 
be detected in small numbers in the blood and the spleen. These cells become suppressive 
cells only in the correct cytokine environment (with the Th2 cytokines IL4 and IL10), 
and will develop into functional APCs in other circumstances (Bronte, Apolloni et al. 
2000).   
 
Numerous findings have indicated the importance of tumour-derived factors (TDFs) in 
encouraging the suppressive aspects of MSCs, by both recruiting MSCs and promoting 
their maturation towards a suppressive phenotype. Such TDFs include: Colony 
stimulating factor 1 (CSF-1), IL-6, IL-10, VEGF, and GM-CSF (Serafini, Borrello et al. 
2006). Once activated MSCs inhibit the immune system and promote tumour growth by   34 
expressing ARG and iNOS. ARG is an enzyme that converts L-Arginine into L-
Ornithine, which aids cell transformation and tumour proliferation (via 
neovascularisation) (Serafini, Borrello et al. 2006). Inducible Nitric oxide synthase 
(iNOS) expression increases super-oxide and NO production which inhibits the mitogenic 
and peptide-specific responses of the CTL response (Xia, Roman et al. 1998).  
 
1.6d. CD8 suppressor T cells 
 
A further group of regulatory cells are those that express the CD8 coreceptor. In 
particular, two distinct subpopulations of CD8+ T suppressor lymphocytes have been 
identified.  
The first characterized CD8+ T suppressors induce an antigen-specific immune 
suppression through cell-to-cell contact with antigen presenting cells (APC) after antigen 
presentation (Liu, Tugulea et al. 1998). One report demonstrated that xenospecific 
suppressor CD8+ T cells can be generated by multiple in vitro stimulations of human T 
cells with pig PBMCs, which then specifically recognize xenogeneic MHC class I 
antigens and suppresses the proliferative response of CD4+ cells to MHC class II 
antigens expressed by the xenogeneic APCs (Ciubotariu, Colovai et al. 1998).  
The second population of CD8+ Ts mediates a nonantigen specific suppression of T-cell 
proliferation via soluble factors, such as interferon-  (IFN ) and interleukin-6 (IL-6) 
(Balashov, Khoury et al. 1995). These non-antigen-specific CD8+ T suppressor 
lymphocytes originate from circulating CD8+CD28- T lymphocytes after stimulation 
with interleukin-2 and interleukin-10 (Filaci, Fravega et al. 2004). Interestingly, the 
nonantigen specific CD8+ Ts have been found functionally impaired in patients affected 
by relapsing phases of multiple sclerosis (Balashov, Khoury et al. 1995), and in patients 
with systemic lupus erythematosus in relapse (Filaci, Fravega et al. 2004), suggesting 
their possible direct involvement in the pathogenesis of autoimmune diseases. 
CD8 suppressor T cells have also been implicated in being involved in tumor-induced-
immunosuppression, as they have been found among tumour-infiltrating lymphocytes 
(Filaci, Fravega et al. 2004). 
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1.7 The current state of tumour “immune surveillance” 
 
In Hanahan and Weinberg‟s landmark review in Cell (Hanahan and Weinberg 2000) the 
cell-intrinsic characteristics of cancer cells were articulated for the first time. They 
concluded that successful oncogenesis depended on six essential alterations, or 
“hallmarks”, in cell physiology that collectively dictate malignant growth. These were: 
self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis. Each of these changes represents a successful breaching of an anticancer 
defense mechanism hardwired into cells and tissues. There is accumulating evidence that 
„avoidance of immunosurveillance‟ might be the seventh hallmark of cancer. Avoidance 
of immunosurveillance takes the form of immunoselection, the selection of non-
immunogenic tumour variants also known as immunoediting; or immunosubversion, 
which is the active suppression of the immune response (Zitvogel, Tesniere et al. 2006).  
 
It is well established that mice that lack the essential components of the innate or 
adaptive immune system are more susceptible to the development of spontaneous or 
chemically induced tumours. From the current scientific literature it is possible to identify 
several cell types and a range of effector molecules that are involved in cancer 
immunosurveillance, including T and B cells, perforin, tumour necrosis factor-related 
apoptosis inducing ligand (TRAIL) (Takeda, Smyth et al. 2002) NK and NKT cells 
(Smyth, Wallace et al. 2005) and IFN-producing killer DCs (Taieb, Chaput et al. 2006).  
 
But what is the evidence that immunosurveillance plays a role in suppressing human 
cancer? In patients the presence of immunosurveillance is indicated by responses to pre-
malignant or early cancerous lesions. Examples include T cell responses to pre-malignant 
B cells in patients with monoclonal gammopathy (Dhodapkar, Krasovsky et al. 2003), 
and the presence of CD8+ T cells specific for peptides derived from breast cancer 
associated proteins in the bone marrow of patients with operable breast cancer 
(Beckhove, Feuerer et al. 2004). Notably however, whereas tumours may induce at least   36 
transient immune responses, cancer can still develop. These immune responses fail to 
prevent the development of cancer either because tumour cells that evade the immune 
response are selected or because tumour-antigen-specific tolerance is induced (Willimsky 
and Blankenstein 2005). Despite this immune responses to tumours remain at the very 
least as useful diagnostic and prognostic factors. Antibodies specific to tumours (also 
known as antibody signatures) can be used detect cancers such as prostate cancer at early 
stages (Wang, Yu et al. 2005). In many cancers the presence of tumour-infiltrating 
lymphocytes (TILs) is a useful prognostic marker, especially in melanoma, ovarian 
carcinoma and colon carcinoma (Zitvogel, Casares et al. 2004).     
 
1.7a The current state of cancer vaccines 
 
The logical extension to the idea that the immune system could play a crucial role in 
controlling cancer is the development of tumour vaccines. To date the only clinically 
successful vaccine designed to combat cancer is the human papillomavirus (HPV) 
vaccine that has been shown to protect against the development of cervical cancer caused 
by HPV (Siddiqui and Perry 2006). Of course this has more in common with traditional 
vaccines, and a bona fide tumour vaccine has yet to be developed. However the 
advantages a tumour vaccine would have over traditional cancer treatments are clear. 
Their unique mechanism of action, recalibrating the patient‟s immune system to seek out 
and destroy cancer cells, overcomes the barrier of intrinsic drug resistance limiting 
current therapies. The immunisation would be relatively non-toxic when compared to the 
side effects of current therapies, presuming autoimmune reactions are not induced. The 
immune response induced by the vaccine would be very specific, further reducing 
toxicity and increasing efficacy. Perhaps most significantly a tumour vaccine would 
induce immunological memory, so that the immune system would be reactivated to clear 
any recurrence of disease. This would remove the need for the damaging repeated cycles 
of treatment typical of current therapies (Emens 2006).  
 
The promise of tumour vaccines is somewhat undermined by the very different 
challenges that they face compared to traditional viral vaccines. Firstly cancers arise from   37 
endogenous tissues that have acquired genetic mutations that disrupt the regulatory 
pathways governing cell division, and thus are viewed by the immune system as self 
rather than foreign. This also means that anti-tumour response is curtailed by the 
mechanism of self-tolerance that normally exists to prevent autoimmunity. Secondly 
tumours do not present foreign well-defined targets that vaccines are traditionally made 
against, and often present unaltered or only subtly altered endogenous molecules. 
Vaccine development is also complicated by the fact that traditional vaccines utilise 
antibodies as the main effector mechanism, whereas the key effector of anti-tumour 
responses are T cells (Emens 2006). Furthermore anti-tumour vaccines will be often 
faced with treating already established disease that may be too large a burden for the 
immune response to overcome (Perez-Diez, Spiess et al. 2002). 
 
Thus the successful development of therapeutic vaccines depends on overcoming these 
challenges.   
Perhaps the most simple is to use cancer vaccines at the same time as traditional 
treatment, the advantages being not only that disease burden would be reduced but also 
with the side-effect that chemotherapy-induced tumour cell death augments vaccine-
mediated immune priming (Broomfield, Currie et al. 2005);(Lake and Robinson 2005). 
Besides this however there are many ways in which the host-tumour interaction can be 
tipped in favour of the immune response by increasing the effectiveness of the T cell 
response itself. This could be done by manipulating the events that regulate T cell 
priming, or by removing the regulatory systems that maintain tolerance to tumours.  
 
1.7b. Tumour evasion of immune responses 
 
However, it is not a simple task to simply „remove‟ the tolerance to tumours, as it is now 
evident that tumours can create a multi-faceted immune suppression network to maintain 
tolerance. This is mediated by soluble factors derived from the tumours such as IL-10, 
TGF-β and VEGF, which induce immature myeloid cells and regulatory T cells to inhibit 
DC maturation and T cell activation that would otherwise have mediated an anti-tumour 
response (Kim, Emi et al. 2006) (see figure 1.4). Tumour
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Figure 1.5. The cancer immunosuppressive network. Tumour derived soluble factors such 
as VEGF, IL-10 and TGFβ induce immature myeloid cells (iMCs) from the bone marrow. 
The iMCs are recruited to the tumour site where they are biochemically and functionally 
modulated to become tumour-associated immature DCs (TiDCs), which gain 
immunosuppressive activity and become resistant to apoptosis. TiDCs can secrete  
immunosuppressive factors such as prostaglandin E2 (PGE2), or recirculate to peripheral 
tissues where they can inhibit DCs or promote T regs.
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Among their weapons is the fact that cancer cells can exploit the anti-inflammatory and 
pro-inflammatory response to escape the immune response. On the one hand, tumour-
derived soluble factors (TDSFs) induce immature myeloid cells (iMCs), including 
immature dendritic cells (iDCs) and immature macrophages. These cells are recruited to 
the primary tumour site where they release the anti-inflammatory mediators IL-10, TGF-
β and prostaglandin E2, which inhibit the activation of DCs and T cells. At the same 
time, clearance of apoptotic cells is impaired by tumour-derived soluble 
phosphatidylserine (sPS). This interacts with the PS receptor on DCs and macrophages, 
inhibiting engulfment by these cells. This defective clearance of apoptotic tumour cells 
induces auto-antibodies to be made against released self-antigens. This „pseudo-
autoimmune‟ status is pro-inflammatory, and thus in an effort to control this apparent 
self-reaction CD25+ T regs are induced that inhibit T cell function (Kim, Emi et al. 
2005). Therefore both anti-imflammatory and pro-inflammatory responses can lead to 
reduced T cell activation against the tumour, due to the factors that the tumour can 
produce. In autoimmune diseases such as SLE, defective apoptotic cell clearance also 
causes a pro-inflammatory response involving autoantibodies, although the defect is due 
to a hereditary complement deficiency rather than sPS. The production of auto-antibodies 
does not induce an increase in CD25+ T regs in SLE, due to the reduced number and 
dysfunction of T regs in these patients (Wraith, Nicolson et al. 2004). This emphasises 
the key role of CD25+ T regs in deciding the outcome of immune responses in both 
autoimmunity and tumour immunity. 
Immunological ignorance and tolerance of tumour cells is aided further by the fact that 
tumours are surrounded by non-tumour cells, including iMCs, fibroblasts, endothelium 
and extracellular matrix. These cells act as a barrier to sufficient tumour antigen reaching 
effector cells, either by binding tumour antigen (extracellular matrix) (Juprelle-Soret, 
Wattiaux-De Coninck et al. 1988), or by competing with DCs for the antigen (fibroblasts, 
endothelium) (Savinov, Wong et al. 2003). This reduced level of tumour antigen, coupled 
with the anti-inflammatory effects of iMCs leads to immunological tolerance of the 
tumour. 
Tumour „educated‟ anti-inflammatory iDCs and immature macrophages can also migrate 
to secondary lymphoid organs, such as the lymph nodes and the spleen, extending the   40 
immunosuppressive network beyond the primary tumour site, assisting tumour 
progression and metastasis. Recent studies indicate that increased suppressive iMCs were 
observed in peripheral blood and LNs of patients with breast, head and neck, or lung 
cancer (Almand, Resser et al. 2000).  
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1.8 Autoimmunity: The other side of tumour immunology. 
 
Classically, autoimmune diseases are characterised by the activity of autoreactive 
lymphocytes, which cause tissue or organ damage through the formation of antibodies 
that react against host tissues, or effector T cells, which are specific for endogenous self-
peptides (Sinha, Lopez et al. 1990). These diseases occur when the central and peripheral 
tolerance mechanisms, detailed in section 1.5, break down. Although the reasons why this 
occurs are not always clear, phenomena such as molecular mimicry, where T and B cell 
responses to foreign antigens cross-react with self antigens, are implicated in some 
autoimmune diseases such as multiple sclerosis (Olson, Croxford et al. 2001). 
Autoimmune diseases are broadly classified as either systemic, such as systemic lupus 
erythromacytosis (SLE), or organ specific, such as multiple sclerosis (MS), type I 
diabetes, and Hashimoto‟s thyroiditis (Stassi and De Maria 2002).  
 
In some respects immune responses to tumours are effectively autoimmune responses, 
not least because they are both responses to „self‟. Mutations in tumour cells may create 
alterations to self-proteins, but in all cases these alterations are against a background of 
normal gene products (Turk, Wolchok et al. 2002). Importantly the immune system is 
mostly tolerant of tumour cells, like it is of normal cells generally. Immunological 
tolerance in cancer and autoimmunity has opposite effects on the patient: in cancer 
patients tolerance stimulates the growth of tumours and is detrimental to the patient, and 
in autoimmune patients tolerance may stop the attack by the mediators of the disease and 
be beneficial to the patient. Thus it is perhaps inevitable that tumour immunology and 
autoimmunity have been generally viewed as separate subjects and have been 
investigated independently by separate groups. From the point of view of a biologist 
studying autoimmunity, self-reactive T cell responses are unfortunate aberrations in 
immune regulation that need to be suppressed. For tumour immunologists, the immune 
system appears full of potential autoreactive (but perhaps low-avidity) T and B cells that 
frustratingly ignore tumour cells. Understanding the basis of tumour immunity and 
autoimmunity need not be mutually exclusive pursuits, in fact there are often interesting 
insights gained when the two are compared. These two fields should always be kept close   42 
together, not least because effective treatment in one area can have detrimental effects on 
the other. Inducing tumour immunity would be a more useful treatment if it did not also 
induce autoimmunity, and treatment of autoimmune disease would ideally not decrease 
the potency of tumour immunotherapy.  
 
There are instances when the mechanisms that control tolerance in both tumour 
immunology and autoimmunity are very similar. As mentioned in section 1.7, the 
immunosuppressive environment that protects the tumour can be due to the induction of 
pseudo-autoimmunity. Clearance of apoptotic cells is impaired by tumour-derived soluble 
phosphatidylserine (sPS), which inhibits engulfment by DCs and macrophages. This 
defective clearance of apoptotic tumour cells induces auto-antibodies to be made against 
released self-antigens (that could also be classed as tumour antigens). This „pseudo-
autoimmune‟ status is pro-inflammatory, and thus in an effort to control this apparent 
self-reaction CD25+ T regs are induced that inhibit T cell function (Kim, Emi et al. 
2005). In autoimmune diseases such as SLE, defective apoptotic cell clearance also 
causes a pro-inflammatory response involving autoantibodies, although the defect is due 
to a hereditary complement deficiency rather than sPS. The production of auto-antibodies 
does not induce an increase in CD25+ T regs in SLE, due to the reduced number and 
dysfunction of T regs in these patients (Wraith, Nicolson et al. 2004).  
 
There are other instances where autoimmune responses and anti-tumour responses 
happen concurrently, even apparently in response to the same antigen. The melanocyte 
differentiation factor gp75 has been identified as an autoantigen of melanoma in both 
mice and humans (Vijayasaradhi, Bouchard et al. 1990). Immunisation with antibody that 
induced the development of gp75 autoantibodies in mice led to concurrent tumour 
immunity and autoimmunity (Hara, Takechi et al. 1995). The tumour immunity induced 
by immunisation dramatically reduced or even abrogated B16 melanoma metastases in 
the lung upon intravenous tumour challenge, and it was further demonstrated with 
depletion experiments that CD4+ T cells and NK cells were required for the tumour 
immunity. The vitiligo autoimmunity, manifested by depigmentation of hair, was 
different in that it was not dependent on NK cells or CD4+ T cells. Furthermore, the   43 
immune threshold for depigmentation was substantially higher than for tumour rejection, 
shown by the fact that 5 times more antibody was required to achieve vitiligo than to 
prevent tumour growth.  
Other studies have used xenogeneic immunisations of other melanoma differentiation 
antigens such as TYRP-2 to give further insights into concurrent autoimmune and tumour 
responses. In contrast to gp75, tumour immunity and autoimmunity elicited by human 
TYRP-2 vaccination of mice required CD8+ T cells (Bowne, Srinivasan et al. 1999). 
Interestingly tumour immunity, but not autoimmunity, could occur in the absence of 
perforin or fas ligand, suggesting a perforin-independent mechanism of tumour cell 
killing. This would probably be IFNγ production by CD8+ T cells, although both tumour 
and autoimmune responses required the presence of this cytokine.  
These studies suggest the existence of overlapping, but alternative antigen-specific 
mechanisms that mediate tumour rejection and autoimmunity. Both responses can use 
either the cellular or humoral arm of the immune system in recognition and elimination of 
tumour or normal cell targets. Overall they suggest that active immunisation could lead to 
tumour immunity without necessarily evoking concurrent autoimmunity. There seems to 
be distinct pathways that lead to tumour immunity and autoimmunity, indicating that the 
immune system can react differently towards an antigen, depending on where that antigen 
is expressed. These differences could reflect qualitatively different responses to 
malignant vs. normal cell counterparts (Turk, Wolchok et al. 2002).        
 
The information that is gathered about the similarities and differences between tumour 
immunology and autoimmunity can only assist the understanding of both fields. 
Mechanisms that are shared by both autoimmunity and tumour immunology can only 
help our further understanding of the fundamentals of tolerance in the immune system. 
The differences between these two spheres should indicate how these seemingly 
intertwined mechanisms may be uncoupled, benefiting our ability to translate our 
knowledge into effective treatments that do not cause damaging side effects.  
 
 
1.8a. Autoimmune thyroiditis    44 
 
Thyroid autoimmune diseases represent more than 30% of all organ-specific 
autoimmunity. Hashimoto‟s thyroiditis is the first described and most common 
organ-specific autoimmune disease, which affects about 3% of the population and 
represents the archetype for other T-cell-mediated degenerative diseases, 
such as type 1 diabetes and multiple sclerosis. Hashimoto‟s thyroiditis is characterized by 
an inflammatory infiltrate of immunocytes that replace the parenchyma and induce 
thyroid enlargement, which eventually leads to gland fibrosis. Progressive 
thyrocyte depletion results in impaired thyroid hormone production and clinical 
hypothyroidism, a condition that involves a marked reduction of metabolic 
activity in various cells and tissues (Weetman and McGregor 1994). 
 
A relatively recently created animal model promises to shed new light on 
hypothyroidism. This new model is a humanised mouse model of spontaneously arising 
autoimmune thyroiditis, the TAZ10 mouse (Quaratino, Badami et al. 2004). The 
transgenic mice express the TCR of the autoreactive human T cell clone 37, isolated from 
a patient with autoimmune thyroidits. T cell clone 37 is specific for the dominant 
autoantigen thyroid peroxidise (TPO), TPO535-551. Within this peptide, two contiguous 
epitopes are differentially recognised by T cell clone 37, TPO536-547, an agonistic highly 
stimulatory epitope, and TPO537-548, a naturally occurring antagonistic epitope. TPO536-547 
is a cryptic epitope preferentially displayed after endogenous processing during 
inflammation. Conversely, the antagonistic epitope induces in vitro anergy in clone 37 
when presented by dendritic cells and preferentially displays when whole TPO is 
presented. There is a possibility that this T cell clone may be anergic and possibly 
regulatory in the patient, but in the mice it causes spontaneous histological, hormonal and 
clinical changes comparable to human destructive thyroiditis. 
Clone 37 was a CD4+ T cell isolated from the thyroid infiltrate of an autoimmune patient 
specific for the cryptic TPO536-547 epitope restricted by the histocompatibility leukocyte 
antigen (HLA) DQB1*0602-DQA1*0102 allele. As splenocytes from the CBA (H-2
k) 
strain of mice were able to present the TPO536-547 to the T cell clone 37, the TAZ10 
transgenic strain was established on the CBA (H-2
k) background. To exclude the   45 
presence of endogenous TCR ʱ chains, the TAZ10 strain was backcrossed onto the Rag1-
/- H2
k background. Experiments showed that TCR
+ Rag1
-/- T cells, expressing either CD4 
or CD8 co-receptors, are restricted by H2-A
k, and the cryptic epitope TPO536-547 proved 
more efficient at inducing T cell proliferation than the TPO535-551 epitope. Molecular 
modelling showed that this „xenoreactivity‟ (i.e. that the TAZ10 TCR could be activated 
by human TPO peptides restricted by mouse H2-A
k molecules) is because the binding of 
human TPO536-547 to HLA-DQB1*0602 and H2-A
k is similar, due to the structural 
homology of both molecules. Crucially the modelling also showed that the human 
TPO536-547 epitope (N-DPLIRGLLARPA-C) and the homologous mouse TPO524-535 
epitope (N-DPIVRGLLARAA-C) presented by H2-A
k, would display a similar antigenic 
surface, despite the conserved residue differences. This explains why mouse TPO 
peptides presented by H2-A
k induce specific activation of the TAZ10 T cells, and cause 
spontaneous autoimmune thyroiditis.      
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1.9. Subject of the thesis 
 
The goal of the project was to evaluate the immune response generated by the challenge 
of „irradiated‟ CT26 tumour in Balb/c mice. This project would build upon the 
knowledge gained previously about the CT26 tumour model, and was based on two 
studies in particular. Huang et al (Huang, Gulden et al. 1996) immunised mice with the 
carcinogen-induced colorectal tumour, CT26, which was also engineered to secrete 
granulocyte/macrophage colony stimulating factor (GMCSF), generating CTL lines that 
were able to lyse the tumour in-vitro, and cure mice of established tumour in-vivo. The 
group went on to conduct experiments that demonstrated that virtually all the CT26-
specific CTLs recognised a single peptide, which contrasted with other tumour systems 
where multiple bioactive peptide fractions have been detected. The bioactive peptide was 
identified as a non-mutated nonamer derived from the envelope protein (gp70) of an 
endogenous ecotropic murine leukaemia provirus, an epitope that became known as AH1. 
In subsequent work, Gogher et al (Golgher, Jones et al. 2002), showed that untransfected 
CT26 tumour cells are rejected in Balb/c mice following depletion of CD25+ regulatory 
T cells, and that this rejection led to the development of long-lived tumour immunity. 
They also suggested that this immunity was based on a shared-tumour antigen, as this 
long-lived tumour immunity also included tumours of distinct histological origin, such as 
A20, a Balb/c B cell lymphoma line derived from a spontaneous reticulum cell neoplasm. 
This antigen must be different from AH1 as immunisation with CT26-GMCSF tumour 
does not lead to protection from other tumours such as A20. They concluded that the 
selected expression of this shared antigen in multiple non-viral induced tumours provided 
evidence for a unique class of shared immuno-dominant tumour associated antigens as 
targets for anti-tumour immunity.   
Thus my investigation seeks to build upon this work and so use an „irradiated‟ CT26 
model sought to define more precisely the mechanisms that govern both the anti-CT26 
and „cross-protective‟ responses. 
 
Among the questions that I intended to address were whether the irradiation of the CT26 
tumour altered the nature of the response compared to the live tumour; whether a robust   47 
response to CT26 and cross-protective antigens can be seen in the presence of T regs in 
the irradiated model; and the relative contribution of CD8+ and CD4+ T cells in the 
irradiated model. Additionally I sought to evaluate the importance of NK cells in the live 
CT26 model, and to analyse the clonal composition of CD8+ T cell responses in the live 
tumour model.  
 
Additional work was carried out with a model of autoimmune thyroiditis, which sought to 
investigate the spontaneous response to self-protein in the context of an anti-tumour 
response. In this humanised transgenic model thyroid peroxidise (TPO) peptides are 
recognised by every T cell, leading to destruction of the thyroid, despite the fact that the 
animals contain TPO-specific T regs. I sought to see whether this defective suppression 
of a self-response extends to tumour cells manipulated to express TPO protein.       
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Chapter 2. Materials and methods. 
 
Table 2.1. All media and solutions 
Media   Contents 
R0  RPMI 1640 (Invitrogen) 
R10  RPMI 1640 (Invitrogen) + 10% FCS 
Phoenix media  IMDM medium (Invitrogen) + 10% HI FCS, 1% 10 mM Non 
Essential Amino Acids, 1% 100 mM Sodium Pyruvate, 1% 200 
mM L-Glutamine, 1% Pen/Strep (10,000 U/ml) 
DC media  RPMI 1640 (Invitrogen) with 10% FBS, 1% pen/strep (10,000 
U/ml), 1% 10 mM Non Essential Amino Acids, 1% 100 mM 
Sodium Pyruvate, 1% 200 mM L-Glutamine, 0.1% 2-ME 
Cold buffer  PBS with 0.5% BSA plus 2mM EDTA pH7.2 
Complete DMEM  DMEM (Invitrogen) + 10% FCS 
FACS buffer  PBS with 0.5% BSA 
SOC medium  0.5% Yeast Extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4. 
 
 
2.1 Depleting cell populations of Balb/c mice. 
   
2.1a. Depleting CD25+ cells (PC61). 
 
8-10 week old BALB/c mice were given two interperitoneal (i.p) injections of 1mg of 
PC61 in 200μl PBS to deplete the mice of CD25
+ regulatory T cells. Figure 5.1 shows 
that PC61 treatment reduced the percentage of T regs from 2.47% to 1.07%. These 
injections were given 3 days and 1 day prior to any tumour challenge at day 0. For the 
controls age-matched BALB/c mice were given two i.p. injections of 1mg of GL113 3 
days and 1 day prior to any tumour challenge at day 0.   
 
2.1b. Depleting NK cells (anti-GM1) 
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For the first experiment (5.3), BALB/c mice were injected i.p with 200ul of anti-GM1 
serum, 1 and 3 days prior to subcutaneous inoculation of 5x10
4 CT26 cells. Figure 5.1 
shows that anti-GM1 antibody reduced the percentage of NK cells from 5.77% to 1.67%. 
For the rechallenge experiment (5.4), BALB/c mice were injected i.p with 200ul of anti-
GM1 serum 1 and 3 days prior to the CT26 re-challenge and 3 and 7 days post re-
challenge. As a control another group of BALB/c mice were injected i.p. with 200ul 
normal rabbit serum.  
 
Table 2.2. Antibodies used 
Antibody  Isotype  Source  Production 
PC61  Rat IgG1  ATCC  Hybridoma cells were grown in tissue culture 
and antibody purified by precipitation in 
saturated ammonium sulphate 
GL113  Rat IgG1  ATCC  See PC61 production 
Anti-GM1  Rabbit  Wako Chemicals, 
GmbH, Germany 
Ammonium sulphate precipitation of serum, 
followed by dialysis with PBS 
 
 
2.2 Challenging with live and irradiated tumour. 
 
2.2a. irradiated CT26. 
 
Prior to irradiated CT26 challenge, mice were treated with PC61 or control antibody 
GL113 as detailed in 2.1a. For the tumour challenge at day 0 mice were injected 
subcutaneously in the flank with 1x10
6 CT26 tumour cells suspended in 100μl PBS. The 
tumour was irradiated prior to immunization with 24 minutes in the cell irradiator (eq. 50 
Gray). See figure 2.1 for schematic of immunisation and tumour challenge protocol. 
 
2.2b. live CT26 and A20. 
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For the re-challenge experiments (4.2a and 4.2b) live tumour was administered 42 days 
after irradiated CT26 challenge at day 0. For both live CT26 and live A20 5x10
4 cells 
were administered subcutaneously to the flank. Mice were then carefully observed for 
over 100 days, with mice that succumbed to the tumours culled and recorded. See figure 
2.2 for schematic of immunisation and tumour re-challenge protocol. 
For the NK depletion experiments (5.3 and 5.4), 5x10
4 cells of live CT26 were 
administered subcutaneously to the flank at day 0, and mice observed for over 60 days, 
with mice that succumbed to the tumours culled and recorded.  
 
2.2c. irradiated CT26-GM 
 
Irradiated CT26-GM is CT26 tumour stably transfected with the GMCSF gene, so that 
the tumour secretes GMCSF which acts as an adjuvant when tumour is injected into 
mice. 
Mice were challenged subcutaneously in the flank with 1x10
6 irradiated CT26-GM cells, 
with or without PC61 treatment, in the TCR repertoire experiments (6.2). Cells were 
irradiated prior to immunization with 24 minutes in the cell irradiator (eq. 50 Gray).  
 
2.2d. live EL4 and EL4 TPO+. 
 
In the tumour therapy experiment (Figure 7.14), 8 to 9 week old C57BL/6 mice and 
TAZ10 Rag1+ mice were challenged subcutaneously in the flank with 1x10
5 EL4 or 
1x10
5 EL4 TPO+ cells suspended in 100ul PBS. Mice were observed for 3 to 4 weeks, 
recording the survival of mice, until all mice succumbed to tumour. 
 
2.2e. Tumour end-points 
 
Mice  were  sacrificed  when  mean  tumour  diameter  was  >15mm  in  accordance
  with 
humane  end  point  guidelines  (United  Kingdom  Coordinating
  Committee  for  Cancer 
Research). If mice were observed to be in distress, due to ulceration of the tumour or  
 PC61(day -3)
irrCT26 (day 0)
PC61(day -1)
GL113(day -3)
irrCT26 (day 0)
GL113(day -1)
Figure 2.1. Immunisation protocol in preparation of irrCT26 tumour challenge.
(a)  1mg of PC61 injected i.p. depletes T regs; (b) 1mg of  GL113 is injected i.p. as an 
isotype control antibody. 1x106 irrCT26 tumour cells are injected subcutaneously at day 0. 
a
b
PC61(day -3/-1) irrCT26 (day 0)
42 days
Live CT26/A20
GL113(day -3/-1) irrCT26 (day 0)
42 days
Live CT26/A20
a
b
Figure 2.2. Immunisation protocol in preparation of CT26 or A20 tumour re-
challenge. (a)  PC61 depletes T regs; (b) GL113 is isotype control antibody. 1x106 irrCT26 
tumour cells are injected subcutaneously at day 0, followed 42 days later by subcutaneous 
injection of 5x104 live CT26 or live A20 cells.   52 
because of any other factor, before the tumour diameter was >15mm, they were culled by 
schedule 1 methods before the end point was reached.   
 
2.3 Isolation of T cell populations from spleen using MACS. 
 
2.3a. For ELISPOT experiments. 
 
Mice were culled 8 days after challenge with irradiated CT26 (with or without CD25 
cells). Surgically removed spleens were placed in R0 medium (RPMI 1640) and then 
mashed through a strainer to make a single cell suspension of splenocytes. The cells were 
then applied to ficoll solution and spun at 800 x g for 15 minutes to separate the 
lymphocytes from the red blood cells and other debris. The lymphocytes were retained 
and the remainder disposed of. If further purification of lymphocyte subsets was 
necessary then MACS beads were added and MACS columns were used as described in 
the MACS protocol provided in the kits. To summarise: Cells were suspended in 90μl of 
cold buffer and 10μl of CD8 (or CD4) Microbeads, and incubated at 4-8°C for 15 
minutes. Cells were then washed with cold buffer, resuspended in 500μl per 10
8 cells, and 
applied to the appropriate MACS column. Unlabelled cells pass through the column as 
eluate, which allows magnetically labelled cells bound to the column to be collected by 
flushing out the column by applying a plunger. CD8
+, CD4
+ and CD25
+ regulatory T 
cells were isolated in this way using MACS.  
 
2.3b. For adoptive transfer. 
 
Balb/c mice were treated with PC61 antibody, and then challenged with 1x10
6 irradiated 
CT26 cells. After 70 days mice were culled and spleens harvested. Either 3x10
6 whole 
splenocytes; or 3x10
6 CD4 or CD8 T cells, obtained by MACS enrichment (see above for 
details); were adoptively transferred into SCID mice, upon which these mice were re-
challenged with 5x10
4 of either live CT26 or live A20. 
 
2.4 In vitro assays of cytokine production.   53 
 
2.4a. ELISPOTs. 
 
Millipore  Multiscreen-IP  plates  (MAIP  S45  10),  were  prepared  by  washing  with  5% 
ethanol, washing with PBS, then applying IFNγ capture antibody. Plates were incubated 
at 37°C for 2 hours, then plates were blocked by adding R10 medium (RPMI + 10% 
FCS), R10 disposed after 2 hours. Cell suspensions plus antigen were added and plates 
were incubated for 36 hours at 37°C. After this cell suspensions are flicked off and the 
plate is washed with PBS-tween before applying IFNγ capture antibody. After 2 hours at 
room temperature plates were washed again with PBS-tween and streptavidin was added 
for 1 hour at RT. Spots were developed using the Zymed® BCIP/NBT substrate kit, and 
the plates were read on the Transtec 1300 ELISPOT reader (AID Diagnostika, Germany).  
 
 
2.4b. IFNγ cytokine secretion assay. 
 
(A) In vitro restimulation of the cells: 1x10
6 of enriched CD8 T cells were suspended 
in 100ul R10 medium per well of a 96 well plate. Co-cultured with 3x10
5 CT26 
cells. Cells were incubated over night (37°C, 5% CO2).  
(B) Labelling with Cytokine Catch Reagent: Cells collected by careful pipetting, and 
wells washed with cold buffer (see table 2.1). Cells transferred to 2ml closable 
tube per sample. Cells washed twice with 1-2ml cold buffer, centrifuged at 300xg 
for 10 minutes at 4-8C, and then supernatant pipetted off completely. Pellet was 
re-suspended in 90μl of cold R10 medium. 10μl of Cytokine Catch Reagent was 
added to the cell mix, and incubated for 5 minutes on ice.  
(C) Cytokine secretion period: 1ml of R10 medium warmed to 37°C was added to cell 
mix. Cells were incubated in closed tube for 45 minutes at 37°C, turning the tube 
every five minutes to re-suspend settled cells. 
(D) Labelling cells with Cytokine Detection Antibody: The tube was put on ice and 
then washed twice with cold buffer, centrifuged at 300 x g for 10 minutes. The 
cell pellet was resuspended in 90μl cold buffer, to which was added 10μl   54 
Cytokine Detection Antibody (IFNγ). This was mixed and incubated for 10 
minutes on ice. Cells were washed in cold buffer, and then re-suspended in 500μl 
of cold buffer for FACS analysis. 
 
2.5 FACS analysis. 
 
Splenocytes were added at 1x10
6 per FACS tube and were washed once with FACS 
buffer. The supernatant was discarded and the cellular pellet was resuspended in 200μl 
FACS buffer. Antibody for a particular surface marker and attached to a fluorochrome 
(CD4 APC/ CD8 PE/ CD25 FITC) was added and incubated on ice for 30 minutes. 
Excess antibody was washed off with FACS buffer and the pellet was resuspended in 
200μl FACS fix. Samples were left overnight and then analysed on the FACS machine. 
 
2.6 CDR3 spectotyping  
 
2.6a. Selection of stimulated clones. 
 
In vitro restimulation of the cells:  
 
Three months after the CT26-GM challenge described in 2.2c, spleens were removed 
from mice, homogenised in vitro, and then depleted of CD4+ cells and B cells using 
Dynabeads. To summarise: Splenic cells were suspended in 100μl of cold buffer, 20μl of 
FCS and 20μl of antibody mix per 10
7 cells, and incubated at 2-8°C for 20 minutes. Cells 
were washed in cold buffer and resuspended in 800μl of cold buffer and 200μl of 
Dynabeads per 10
7 cells, and incubated at RT for 15 minutes. Then a further 1ml of cold 
buffer was added per 10
7 cells and the tube was placed in the magnet for 2 minutes. The 
supernatant can then be removed which contains the isolated CD8+ T cells. 10
6 of these 
enriched CD8 T cells were suspended in 100μl medium (5% serum) per well of a 96 well 
plate. The T cells were co-cultured with 3x10
5 CT26 cells, or no tumour as a control. 
Cells were incubated over night (37°C, 5% CO2). The following day an IFNγ capture   55 
assay (see 2.4b) was performed in order to distinguish wells from which there were T 
cells that had sufficiently responded to the CT26 cells. 
 
2.6b. mRNA extraction (from CD8 T cells and EL4/B6-SJ003 cells) 
 
Cells remaining from the wells deemed positive from the IFNgamma capture assay were 
used as the source of mRNA. Cells were pelleted with centrifugation and were lysed in 
TRIzol reagent (Invitrogen) by repetitive pippeting. 1ml of TRIzol reagent was used per 
5-10 x 10
6 cells. Cell-TRIzol mix was incubated for 5 minutes at room temperature to 
permit the complete dissociation of nucleoprotein complexes. 0.2ml of chloroform was 
added per 1ml TRIzol reagent. Tubes were vigorously shaken for 15 seconds and 
incubated at room temperature for 3 minutes, and then centrifuged at 12,000 x g for 15 
minutes at 4°C. The colourless upper aqueous phase (containing the RNA) was 
transferred into a fresh tube, and the RNA precipitated using 0.5ml of isopropanol per 
1ml of TRIzol used in the original mix. The samples were incubated at room temperature 
for 10 minutes and then centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant 
was removed and the RNA pellet washed with 75% ethanol (vortexed and centrifuged at 
8,900 x g for 5 minutes). The pellet was left to partially air-dry, and then dissolved in 
20μl depc RNase-free water. 
 
2.6c. cDNA synthesis. 
 
Promega RT buffer 5x    4 μl 
Promega oligodT      1 μl 
  dNTPs (10mM)    2.5 μl 
  RNA inhibitor     1 μl 
Promega Reverse Transcriptase  1 μl 
  DPTC water      5.5 μl 
  RNA        5 μl__ 
          20 μl 
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This mix was incubated in a 37°C water bath for 2 hours. The enzyme was denatured by 
heating to 72°C for 2 minutes. The mix was then made up to 100 μl with water. 
 
2.6d. PCR using V-, J- and C-beta primers. 
 
First the cDNA was used as a template for PCR using multiple Vβ primers with a single 
Cβ primer. Primers were used from the following Vβs: 1, 3, 4, 5, 12.1, 13.1, 14, 15, 16, 
26, and 29. Primer concentration was 100pmol/μl. Q-solution is an additive that improves 
suboptimal PCRs caused by templates that have a high degree of secondary structure or 
that are GC-rich. 
 
This PCR was set up as follows: 
cDNA     1μl 
Cβ primer    1μl 
Vβ primer    1μl 
dNTP      5μl 
10x buffer    5μl 
Q solution    10μl   
Water      26μl 
Taq                1μl__ 
      50 μl 
 
 
The PCR cycle was a follows: 94˚C for 10 mins, 35 cycles of 94˚C for 1 minute, 68˚C for 
1 minute and 72˚C for 1 minute, then a final 10 minutes at 72˚C. 
 
These Vβ-Cβ PCR products were then used as templates themselves for the next round of 
PCR, where dye-labelled-Jβ primers were used with the relevant Jβ primer for each Vβ-
Cβ PCR product. The J primers have dyes attached to them so that the DNA fragments 
produced from the PCR can be visualised. Three different dyes were used: HEX (green), 
FAM (blue) and NED (black). Primers were used for the following Jβs: 1.1 (NED), 1.2   57 
(NED), 1.3 (NED), 1.4 (NED), 1.5 (FAM), 1.6 (FAM), 1.7 (FAM), 2.1 (FAM), 2.2 
(HEX), 2.3 (HEX), 2.4 (HEX), 2.5 (HEX), 2.7 (HEX).  
 
The PCRs were set up as follows: 
Vβ-Cβ PCR product    1μl 
Vβ primer      1μl 
Jβ primer      1μl 
dNTP        2μl 
10x buffer      2μl 
Q solution      4μl 
Water        8μl 
Taq        1μl_ 
        20μl 
 
The PCR cycle was as before. 5μl of each PCR product was used for analysis with 
Genescan.  
 
2.6e. GeneScan 
 
The GeneScan Analysis Software analyzes the data collected by the ABI PRISM 310 
Genetic Analyzer to size and quantitate DNA fragments. The results were displayed as 
electropherograms that show fluorescence intensity as a function of fragment size. Each 
electropherogram represents a single injection and provided precise sizing and 
quantitative information.  
 
2.7 TPO work 
 
2.7a PCR and primers for mTPO cloning  
 
5‟ end of A segment of mTPO primer (containing XhoI restriction site): 
CACTCGAGATGAGAACACTTGGAGCTATGGC   58 
 
3‟end of A segment of mTPO primer: 
TCACTATCGGATCCAAACCAC 
 
5‟ end of B segment of mTPO primer: 
CAGTCCATCCACTGGTGAGAC 
 
3‟ end of B segment of mTPO primer (containing EcoRI restriction site): 
CGGAATTCTCTATTCGCACAGGAGGAC 
 
PCR was set up as follows: 
 
Mouse thyroid cDNA     4μl 
dNTPs (1.25mM)      4μl 
10x NH4        5μl 
MgCl2 (25mM)      1.5μl 
BioTaq         1μl 
DMSO         2.5μl 
5‟primer (25μM)      2μl 
3‟primer (25μM)      2μl 
Water          27μl_ 
          50μl 
 
PCR cycle: 92˚C for 2 minutes, 35 cycles of 92˚C for 20 seconds, 55˚C for 70 seconds, 
and 72˚C for 3 minutes, followed by a further 72˚C for 5 minutes.   
 
2.7b XhoI, EcoRI, Sac I and BglII endonuclease digestion 
 
17μl of the PCR product of portion A of mTPO was cut with 0.5μl XhoI and 0.5μl SacI 
enzymes in a 25μl solution containing 2.5μl NE buffer 4 and 2.5μl 10xBSA.   59 
17μl of the PCR product of portion B of mTPO was cut with 0.5μl EcoRI and 0.5μl SacI 
enzymes in a 25μl solution containing 2.5μl NE buffer 1 and 2.5μl 10xBSA. 
17μl of the MIGR1 vector (100ng/μl) was cut with 0.5μl EcoRI and 0.5μl XhoI enzymes 
in a 25μl solution containing 2.5μl NE buffer 2 and 2.5μl 10xBSA. 
The final construct of MIGR1-TPO plasmid DNA was cut with 1μl BglII in a 10μl 
solution containing 1μl NE buffer 3 with 1μl 10xBSA. 
All reactions were incubated at 37˚C for 2 hours.  
 
2.7c T4 ligase 
 
The T4 ligase reaction combined 4 moles of each insert (A and B) with 1 mole of MIGR1 
vector, all previously cut with their relevant restriction enzymes. The final reaction mix 
contained 10.5μl of DNA with 1.5μl T4 buffer, and 1μl of T4 ligase in a total volume of 
15μl. This was incubated overnight at 4˚C.    
 
2.7d Transformation of DH5ʱ cells 
 
To 50μl of DH5ʱ competent bacteria solution was added 5μl of the ligation reaction mix 
in a 1ml tube. This tube was put on ice for 30 minutes, then it was kept at 42˚C for 30 
seconds. 250μl of warm SOC medium was then added to the tube, and then kept on ice 
for 2 minutes, followed by 1 hour at 37˚C. The mix was then spread on a Petri dish of 
agar infused with ampicilin. The dish was then left overnight at 37˚C. The colonies that 
grow on the dish have taken up the retroviral plasmid containing ampicilin resistance. 
These colonies can be picked and used to make bacterial culture solutions. 
 
2.7e Caesium chloride maxiprep and Phenol:cloroform miniprep. 
 
Phenol miniprep: To 0.5ml of bacterial culture in a microfuge tube was added 0.5ml of 
phenol:chloroform:isoamylalcohol. The mix was vortexed at maximum speed for 1 
minute. It was then centrifuged at 12,000 x g for 5 minutes. After this the upper aqueous 
phase was removed (approximately 400μl) and added to 0.5ml of isopropanol in a fresh   60 
tube. This was mixed well and centrifuged at 12,000 x g for 5 minutes. The supernatant 
was poured off, and the pellet washed by slowly pipetting 70% ethanol to the side of the 
tube and pouring off. The pellet was air-dried and was suspended in 100μl of water.  
 
Caesium chloride maxiprep: 500ml of bacterial culture was centrifuged at 3,000 x g for 
30 minutes. The pellet was resuspended in 30mls resuspension buffer (25mM Tris pH 
8.0, 50mM glucose, 20mM EDTA), and placed into 3 sorvall tubes, 10ml per tube. To 
each tube was added 10mls of freshly made 0.2M NaOH + 1% SDS, and the tubes were 
mixed by inversion and left in ice for 10 minutes. Then 10mls of cold sodium acetate was 
added and the tubes were mixed and left on ice for 20 minutes. Then the tubes were 
centrifuged at 13000RPM (SS-34 rotor in a Sorval RC6) for 30 minutes. The 3 tubes 
were then emptied into 3 separate falcon tubes via a 0.7μM filter and filled up to 50mls 
with isopropanol and mixed by inversion. Tubes were then left at -20˚C for 20 minutes 
and centrifuged at 3,000 x g for 10 minutes at 4˚C. The supernatant was poured away and 
the pellet mixed with 50mls of 100% ethanol per tube, and centrifuged again at 3,000 x g 
for 10 minutes at 4˚C. The pellet was then dissolved in 3mls of T.E. solution per tube, 
and then all 9mls was collected and put into two small sorvall tubes. 18g of CsCl was 
added to 12mls of T.E. until dissolved and added to each sorvall tube. 315μl of Ethidium 
Bromide was then added to each sorvall tube without mixing. Both tubes were then 
centrifuged at 42000RPM (T-865 rotor in a Sorvall Discovery 100S) for 42 hours.  
After 42 hours the tubes were removed and the supercoiled plasmid DNA, present as a 
pink layer in the middle of the tube, was removed using a micro-tube attached to a 
peristalsis pump. The recovered DNA was mixed with 10ml of AnalaR water and 40ml 
of 100% ethanol in a falcon tube. The tube was mixed by inversion and stored at -20˚C 
for 20 minutes. The tube was centrifuged at 3,000 x g and the pellet resuspended in 300μl 
of water. This DNA solution was mixed with 40μl sodium acetate and 1ml of 100% 
ethanol in a 1.5ml eppendorf tube. This tube was left at -20˚C for 20 minutes and then 
centrifuged at 1,800 x g for 15 minutes. The pellet was then resuspended in enough water 
to resuspend it, maintaining a high concentration of final plasmid DNA.  
 
2.7f  Phoenix cell transfection   61 
 
Before the transfection the phoenix cells were plated in a 6 well plate: 3x10
5 cells in 2ml 
phoenix medium per well. This plating was done when phoenix cells were at 70-80% 
confluence in its flask, and once plated cells are left overnight to achieve 70-80% 
confluence in the 6 well-plate for effective transfection. The transfection mix consisted of 
94μl of DMEM, 6μl of fugene-6 reagent (obtained from Roche), 2μg of retroviral 
construct DNA and 2μg pCleco (all per well). This mix was vortexed in a small 
eppendorf, left at room temperature for 15 minutes, then applied dropwise to the plated 
phoenix cells and incubated at 37˚C for 48 hours. 
 
 
2.7g Harvesting of retroviral and target cell infection  
 
Once transfection of the phoenix cells was confirmed by fluorescence microscopy, the 
supernatant was pooled from all the transfected wells, centrifuged at 200 x g for 2 
minutes to remove cell debris, and then hexadimethrine bromide (5mg/ml) was added 
(1μl per ml of S/N). The supernatant was then added dropwise to wells containing the 
target cells. The plates were then centrifuged at 800 x g  for 90 minutes at 37˚C. The HBr 
added to the supernatant should bind and add weight to the viral particles so that this 
centrifuge step brings the viral particles and target cells into close contact (this is called 
„spinoculation‟). The target cells were then incubated at 37˚C for 48 hours. After this the 
target cells were collected and analysed on the flow cytometer, and positively infected 
cells fluoresced in the FL1 channel 
 
2.7h Production of DCs from bone marrow 
 
Leg bones of C57BL/6 mice were removed and purified from surrounding muscle tissue. 
Intact bones were left in 70% ethanol for 2-5 minutes for disinfection and washed with 
PBS. Both ends were cut with scissors and the bone marrow flushed with PBS using a 
syringe with a 0.45 mm diameter needle. Washed with PBS and resuspended pellet in DC 
medium – counted and seeded bacteriological Petri dishes at day 0 at a concentration of 2   62 
x 10
6 per dish in 10 ml DC medium containing 200 U/ml rGM-CSF. At day 3 another 10 
ml DC medium containing 200U/ml rGM-CSF were added to plates. At days 6 and 8 half 
of the culture supernatant was collected, centrifuged, and the cell pellet resuspended in 10 
ml fresh medium containing 200 U/ml rGM-CSF, and given back to the original plate. At 
day 10 cells can be used or continued to reduce granulocyte contamination. Then plates 
were fed as day 6/8 but with 30-100 U/ml. For complete maturation at day 10 non-
adherent cells were collected with gently pipetting, centrifuged at 300 x g for 5 min at 
RT, and resuspended in fresh medium in a fresh dish containing 100U/ml rGM-CSF and 
LPS at 1μg/ml. Cells were cultured for 1 more day. 
 
 
2.7i Lysis of tumour cells and feeding of DCs 
 
2x10
6 DCs were fed the lysate of either 4x10
5 mock-transfected EL4 cells or 4x10
5 
TPO+EL4 cells. To lyse the tumour cells, the small eppendorf containing the cells was 
dipped into liquid nitrogen for 30 seconds, then allowed to thaw in a 37˚C water bath for 
3 minutes. This was repeated two more times to ensure effective lysing of the cells. This 
lysate was then mixed with the DCs in 5ml RPMI, and incubated in a Petri dish for 2 
hours at 37˚C.  
 
2.7j CFSE labeling and analysis 
 
Lymph node cells, harvested from TAZ10 and C57BL/6 mice in the animal house, were 
homogenized and washed in complete DMEM, then pelleted and resuspended in 1ml 
PBS. To this was added 1ml of FCS-free medium containing 2ul of CFSE solution, 
making CFSE at a final concentration of 1:1000 in the cell mix (5μM final 
concentration). This was incubated at 37˚C for 10 minutes, then the CFSE washed from 
the cells using complete RPMI. The assay was then set up with LN cells mixed with DCs 
fed with tumour lysate. At day 3 of the assay, cells were harvested and analysed for 
CFSE dilution on the flow cytometer.  
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Results Chapter 3  
 
Irradiated CT26 induces immune responses similar to live CT26. 
 
3.1 Introduction 
 
The original observations that preceded this project were made in the investigation of 
tumour responses to live CT26 in Balb/c mice (Golgher, Jones et al. 2002). A challenge 
of live CT26 cells overcame all the mice inoculated. However it was observed that Balb/c 
mice that were initially depleted of CD25+ cells (using PC61 antibody) were capable of 
rejecting the live tumour challenge. Furthermore surviving mice were able to 
subsequently reject live tumour challenges of different histological origin (A20, RENCA, 
C26, and BCL1). This “cross-protective” response was not seen if the mice were 
challenged with live CT26 tumour transfected with GM-CSF (known as CT26-GM) 
subsequent to CD25+ cell depletion. Thus it was hypothesised that the depletion of the 
CD25+ cells (assumed to be primarily CD25+ regulatory T cells) and subsequent 
challenge of live CT26 cells revealed a “new” response that not only recognised CT26 
tumour cells, but also the cells of the tumours of different histological origin. This 
response must be different to the anti-AH1 response induced by the CT26-GM tumour 
challenge, which was capable of rejecting CT26 tumour but not the tumours of distinct 
histological origin.  
 
This study suggested that normal mice challenged with CT26 were able to mount an 
immunosuppressive response to the tumour, resulting in its unchecked proliferation. 
Furthermore, amelioration of this situation by the depleting antibody PC61 suggested that 
the mechanism was via antigen specific T regs. In order to study the regulatory 
mechanisms inhibiting an anti-tumour response to CT26, it was necessary to seek a 
model system in which the CT26 tumour could be transplanted without it subsequently 
proliferating to a lethal level. To this end, I examined the response to irradiated CT26 in 
the presence and absence of T regs. Among the questions that the irradiated CT26 model 
would answer is whether the “cross-protective” response requires the depletion of T regs,   64 
or whether it is induced by the tumour challenge alone. Another advantage of the 
irradiated CT26 model is that the variability of response in the live CT26 model, which 
meant that survival rates of mice depleted of T regs and challenged with live CT26 was 
also unpredictable, would be reduced by the non-fatal irradiated CT26 challenge. This 
would remove concerns over whether some of the live challenges were sub-optimal, and 
also allow in-vitro analysis of the response generated in the days immediately following 
the challenge. 
 
The irradiated CT26 model will inform on the regulatory mechanisms of the live CT26 
model only if the basic features of the response induced by both tumours are similar. It is 
possible that this might not be the case, either in the protection against a subsequent live 
CT26 challenge or in the cross-protection against an unrelated tumour. Furthermore the 
effect of depleting T regs prior to the irradiated challenge may be different to the effect 
on the live challenge. As the two models should represent an identical antigenic 
exposure, differences in the responses generated by these two challenges would indicate a 
greater importance for the context of the tumour delivery. In this case we would have to 
expand our current hypothesis to differentiate the irradiated CT26 model from the live 
CT26 model. Such a conclusion could be relevant to the design of vaccines based upon 
killed autologous tumours or autologous tumour lysates.  
 
3.2 Adoptive transfer experiments 
 
To compare the live and irradiated CT26 challenges adoptive transfer experiments were 
performed. In this procedure both the ability to protect against a subsequent live CT26 
challenge and a live A20 (cross-protective) challenge would be tested. It was only 
possible to do these adoptive transfers in the absence of T regs, as the initial live CT26 
always proliferates to a lethal level in the presence of T regs so that undepleted mice 
would not be able to provide cells for transfer.  
 
To compare these two tumour models SCID mice were adoptively transferred with 
whole, CD8 or CD4 fractions of splenocytes obtained from mice depleted of CD25+   65 
regulatory T cells and challenged with either irradiated or live CT26, and then the SCID 
mice challenged themselves with live CT26 and live A20. Significantly the whole spleen 
and CD4 fractions would include T regs that had recovered from the original depletion, 
but the antigen-specific T regs that would have been generated at the point of initial 
challenge should still be absent. Severe Combined Immunodeficiency (SCID) mice are 
mice that possess a genetic mutation in chromosome 16, which confers a deficiency that 
impairs rearrangement of separate gene elements of the immunoglobulin and T cell 
receptor genes. This disrupts the differentiation of B and T-lymphocyte progenitor cells, 
with the consequence that SCID mice are born lacking all their B and T cells. This allows 
us to reinstate either wholly or partially the immune system in the recipient SCID mice, 
informing on the efficacy of separate parts of the immune system without worry of 
„contamination‟ from the host B and T cells.  
 
To make the initial tumour challenges as comparable as possible, 1x10
6 irradiated CT26 
cells were injected compared to 5x10
4 live CT26 cells, as the irradiated cells would not 
be able to divide in the mice whereas the live cells would divide very rapidly. 
Furthermore the inflammatory environment that would normally be caused by an 
aggressive tumour like CT26 growing rapidly in the mouse, with the associated turnover 
of the tumour cells, would be at least partially mirrored by the 1x10
6 cells that were 
irradiated and would be therefore dead or dying when injected subcutaneously into the 
mice.  
 
Before adoptive transfer of T cell fractions into SCID mice, the purity of the MACS 
isolated CD4 and CD8 fractions were analysed on FACS. The average CD8 purity after 
MACS separation was 89%, and the average CD4 purity after MACS separation was 
95%. The results of the challenges of SCID mice receiving whole spleen, CD4 or CD8 
fractions from mice treated with PC61 and challenged with irradiated CT26 are shown in 
figure 3.1. The results show that the SCID mice survived the live CT26 or live A20 
tumour challenges whether they had received CD4 cells, CD8 cells or whole spleen cells.  
This indicates that the anti-CT26 response and „cross-protective‟ response induced by the 
irradiated CT26 was transferable by either CD4 or CD8 T cells.    66 
The results of the challenges of SCID mice receiving whole spleen, CD4 or CD8 
fractions from mice treated with PC61 and challenged with live CT26 are shown in figure 
3.2. As in figure 3.1 all SCID mice that had received CD4 cells, CD8 cells or whole 
spleen cells remained tumour free after either the live CT26 or the live A20 challenges. 
Consequently as with the irradiated CT26 challenged adoptive transfer experiment, it 
appears that either the anti-CT26 or the „cross-protective‟ responses can be transferred 
either in the CD8 or the CD4 populations.  
Overall these results indicate that it is likely that the challenge of 1x10
6 irradiated CT26 
cells is comparable to 5x10
4 live CT26 cells (at least in the absence of T regs). It suggests 
that the increased number of irradiated cells compared to the live cells satisfactorily 
ensures that the antigen load of the two challenges is broadly equivalent once the division 
of the live tumour is taken into account. Furthermore it suggests that the inflammatory 
context that the two antigen loads are presented is broadly similar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.1. Survival of SCID mice to CT26 or A20 challenge after adoptive 
transfer of cells from irrCT26 challenged mice. 3x106 CD4+ T cells, CD8+ T 
cells,or a mixed population of CD4+ and CD8+ T cells (WS), purified from mice that 
had been vaccinated with 1x106 irradiated CT26 T cells after PC61 treatment, were 
adoptively transferred into SCID mice. All groups are made up of 3 mice, except CT26 
control and A20 control, which have 2 mice per group. The percentage of tumour-free 
SCID mice after an A20 or CT26 challenge (5x104 cells) is shown. 
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Figure 3.2: Survival of SCID mice to CT26 or A20 challenge after adoptive 
transfer of cells from live CT26 challenged mice. 3x106 CD4+ T cells, CD8+ T cells, 
or a mixed population of CD4+ and CD8+ T cells (WS), purified from mice that had 
been vaccinated with 5x104 live CT26 T cells after PC61 treatment, were adoptively 
transferred into SCID mice. CD4 CT26 and CD4 A20 groups have 4 mice per group, 
the control groups have 2 mice per group, and all other groups have 3 mice per group. 
The percentage of tumour-free SCID mice after an A20 or CT26 challenge (5x104 
cells) is shown.
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3.3 Discussion 
 
Now that it seems that irradiated CT26 does induce a similar response to live CT26 it 
points towards me being able to use irradiated CT26 to answer a number of the questions 
that arose from the original live CT26 experiments. Such questions include whether the 
absence of T regs is essential to the generation of a cross-protective response. This 
conclusion also removes some of the technical concerns that accompanied the use of live 
tumour as a vaccine.   
 
Beyond the overall conclusion that the irradiated and live challenges seem to be 
comparable, these results are interesting in that they are a slight departure from the work 
done by Golgher et al, upon which this project was based. These results suggest that the 
responses generated by the tumour challenges are more robust than thought previously, 
such that CD4 cells or CD8 cells alone can confer cross-protection (Golgher, Jones et al. 
2002). Previously only weak cross-protection was seen with individual subsets, with 
optimal cross-protection when the subsets were co-transferred. To account for this we 
could speculate that perhaps the course of time has changed the phenotype of the CT26 
and A20 tumours sufficiently so that CD4 rejection antigens are more prominent, 
allowing rejection of the tumours with CD4 T cells alone. Or maybe there are technical 
differences between the way the old and more recent experiments were carried out, which 
are subtle enough to be not easily accounted for.  
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Results Chapter 4:  
 
The effect of CD25 depletion on the immune responses induced by irradiated CT26 
challenge 
 
4.1 Introduction 
 
The previous chapter indicated that the response generated to irradiated CT26 tumour 
cells by subcutaneous challenge of 1x10
6 cells is comparable to the response generated 
by a live CT26 challenge of 5x10
4 cells. However, by further investigation using both in 
vivo and in vitro experiments, I aimed to get a more precise idea of the nature of the 
response generated by irradiated CT26 challenge. In particular the previous chapter 
lacked an experiment in which splenocytes were adoptively transferred from mice 
challenged with irradiated CT26 without depleting T regs with PC61 antibody. Without it 
I couldn‟t conclude whether the absence of T regs is essential to the generation of a cross-
protective response by the irradiated CT26 challenge. This was one of the main questions 
that I sought to address in this chapter.  
In the in vivo setting, the aim was to do re-challenge experiments where the initial 
irradiated CT26 exposure (in the presence or absence of CD25+ T regs) is followed by 
live CT26 or A20 challenges. The CT26 rechallenge assesses whether the irradiated 
CT26 challenge can evoke a response that will reject the live CT26 tumour, and whether 
this response requires the absence of T regs at the point of irradiated CT26 challenge. The 
A20 rechallenge assesses whether the irradiated CT26 challenge can evoke a response 
that is cross-protective against tumours of different histological origin, and whether this 
cross-protective response requires the absence of T regs at the point of the original 
irradiated CT26 challenge.  
The hypothesis formed from previous work with live CT26 was that although a 
potentially cross-protective CD4+ and CD8+ T cells can develop in live CT26 challenge 
with T regs, it develops into a robust anti-tumour response only in the absence of T regs. 
This is due to the suppressive effect of T regs, which keeps these responses below the 
level of activation which would be needed to be exceeded to see an effector response. It   70 
remained to be seen whether this hypothesis could be carried over to irradiated CT26 or 
whether a new hypothesis was needed. If there was an expectation either way it was to 
see cross-protection induced by the irradiated CT26 challenge when T regs have been 
initially been depleted by PC61 antibody. 
 
4.2 In vivo re-challenge experiments 
 
In order to evaluate the level of anti-tumour immunity evoked by irradiated CT26 in the 
presence or absence of T regs, mice were immunized with irradiated CT26 after being 
depleted of CD25+ cells (PC61), or not depleted (GL113), and were challenged with 
liveCT26 subcutaneously. A group of control mice that were not immunized were also 
challenged with live CT26 tumour.  
As seen in figure 4.1, the in vivo response to live CT26 challenge indicates that depletion 
of CD25+ cells prior to irradiated CT26 challenge offers complete protection from the 
subsequent live CT26 challenge. However, approximately 65% of the mice that were 
challenged with irradiated CT26 but without CD25+ cell depletion also survives the live 
CT26 challenge. The difference between the PC61 and GL113 groups was significant 
with a p value < 0.01. 
The same experiment was performed with the exception that mice immunized with 
irradiated CT26 after being depleted of CD25+ cells (PC61), or not depleted (GL113), 
were challenged with live A20 to assess the cross-protective in vivo response that the 
irradiated CT26 exposure evokes. A group of control mice that were not immunized were 
also challenged with live A20 tumour. 
As seen in figure 4.2, the in vivo response to live A20 challenge indicates that depletion 
of CD25 cells prior to irradiated CT26 subcutaneous challenge makes a small difference 
to the survival to the live A20 challenge, with the survival being almost identical for the 
first 130 or so days, but by the end of the experiment the mice receiving PC61 had a 20% 
better survival rate than the mice that received GL113. A T-test showed that this 
difference was significant, with a p value < 0.05. However compared to the naive control, 
even the irradiated CT26 challenge itself (without PC61) offers significant protection   71 
from the A20 challenge, with the mice taking significantly longer to succumb to the A20 
challenge, and 20% surviving the A20 challenge completely. 
 
This data suggests that as a vaccine irradiated CT26 performs well in protecting mice 
against subsequent tumour rechallenges. For live CT26 challenge, irradiated CT26 offers 
good protection, with its efficacy enhanced by CD25 depletion. The attractiveness of 
irradiated CT26 as a vaccine is increased because it is partially cross-protective, and the 
cross-protective response is modestly enhanced by T reg depletion.  
These observations also show that irradiated CT26 provokes a different response to live 
CT26. In the case of irradiated CT26 the generation of a cross-protective (A20) response 
is not absolutely dependent on the absence of T regs at the time of initial challenge, 
although survival is slightly improved by depletion.  
Thus the hypothesis formed from previous results, that the checks that the regulatory cells 
hold over the cross-protective response remain intact when immunising with the live 
CT26 tumour; checks that are only removed when the regulatory T cells are depleted 
(Golgher et al, 2001), may not extend to the response induced by irradiated CT26, where 
the tumour challenge itself seems to be sufficient to generate a cross-protective response 
in at least some of the mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.1. Survival of mice challenged with live CT26, 42 days after vaccination. Balb/c 
mice were challenged with 5x104 live CT26 tumour cells 42 days after an irradiated 1x106 CT26 
challenge either in the presence (GL113) or absence (PC61) of T regs. A control group of naïve 
mice were also challenged with 5x104 live CT26 tumour cells. PC61 and GL113 treated groups 
consist of 6 mice per group, with the control group consisting of 4 mice. The development of 
tumours was observed for 130 days and mice culled when tumours were judged to be terminal. A 
t-test shows that the difference between the PC61 group and the GL113 group was significant 
with a p value < 0.01.
Figure 4.2. Survival of mice challenged with live A20, 42 days after vaccination. Balb/c 
mice were challenged with 5x104 live A20 tumour cells 42 days after an irradiated 1x106 CT26 
challenge either in the presence (GL113) or absence (PC61) of T regs. A control group of naïve 
mice were also challenged with 5x104 live A20 tumour cells. PC61 and GL113 treated groups 
consist of 5 mice per group, with the control group consisting of 3 mice. The development of 
tumours was observed for 130 days and mice culled when tumours were judged to be terminal. 
A t-test shows that the difference between the PC61 group and the GL113 group was significant 
with a p value < 0.05.
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4.3 In vitro IFNγ assays (ELISPOTS). 
 
To gain further understanding of the irradiated CT26 model and the regulatory 
mechanisms that control the anti-tumour response, I examined the early effector 
response. The aim was to see whether there was a difference in the early responses made 
to an irradiated CT26 challenge in the absence of T regs compared to in the presence of T 
regs. I also wanted to see whether the IFNγ produced by the early responses would 
broadly correspond to the full effector response seen in the protection experiments in 
section 4.2. 
  
In order to assess the early response to irradiated CT26 in the presence or absence of T 
regs, mice were immunized with irradiated CT26 after being depleted of CD25 cells 
(PC61), or not depleted (GL113), and were culled eight days after immunization and the 
lymphocytes were purified from the spleen. 100,000 lymphocytes were mixed with 
25,000 tumour cells in each well of the ELISPOT plate. The number of spots counted at 
the end of the procedure reflected IFNγ production by the lymphocytes in response to the 
tumours. Figure 4.3 indicates that depleting of CD25+ cells prior to immunization boosts 
the subsequent in vitro response of splenocytes to both CT26 and the unrelated tumour 
A20, with a t-test indicating that these differences are significant. 
This matches results from the protection experiments, where T reg depletion improved 
survival to CT26 and A20 challenges. The higher IFNγ levels in response to CT26 
compared to A20 also mirrors the protection data, where survival to CT26 challenge was 
also greater than survival to A20 challenge.  
 
In order to understand these results more fully, I next evaluated the sensitivity of the 
CD4+ and CD8+ anti-tumour response to the presence of T regs independently in order 
to determine the main correlate with the protection data in section 4.2.  
In order to assess the CD8 T cell anti-tumour response, mice were immunized with 
irradiated CT26 after being depleted of CD25 cells (PC61), or not depleted (GL113), and 
were culled eight days after immunization and the lymphocytes were purified from the 
spleen. Then the whole spleen lymphocytes were further purified by MACS columns to   74 
isolate the CD8
+ T cells. In the wells 50,000 CD8
+ T cells were mixed with either 25,000 
CT26 cells or 25,000 A20 cells and the IFNγ production measured by counting the spots 
(average per well shown). Figure 4.4 shows that depleting CD25+ cells prior to 
immunization boosts the in vitro CD8
+ T cell response to CT26 (with a very clear 
significance) but much less significantly to A20. An identical experiment was carried out 
on purified CD4+ T cells and figure 4.5 indicates that depleting CD25+ cells prior to 
immunization boosts the in vitro CD4
+ T cell response to A20 (with a high significance) 
but not significantly to CT26. 
The data shows that the CD8+ T cell data broadly correlates with the protection data as it 
indicates that the anti-CT26 response is made more efficacious by the depletion of T regs, 
whereas the cross-protective response isn‟t enhanced nearly as much by the depletion. 
The CD4+ T cell data partially correlates with the protection data as it indicates that the 
depletion of the T regs makes a difference to the efficacy of the cross-protective 
response, but no difference to the efficacy of the anti-CT26 response.  
 
Another conclusion that this data suggests is that the best protection to tumour challenge 
is supplied by a strong CD8+ T cell response. The protection data (section 4.2) indicates 
that CD25
+ depletion prior to irradiated CT26 challenge increases survival to a 
subsequent live CT26 challenge (figure 4.1), which fits with the IFNγ data (section 4.3) 
showing CD25
+ depletion increases both total lymphocyte (figure 4.3) and CD8
+ T cell 
(figure 4.4) response to CT26. The protection data also indicates that CD25
+ depletion 
prior to irradiated CT26 challenge enhances protection against A20 above that of the 
mice not depleted but still immunized, but to a lesser extent than to CT26 (figure 4.2). 
Seeing as CD25
+ depletion doesn‟t enhance the IFNγ response of CD8
+ T cells to A20 
(figure 4.4) it would seem that a good CD8
+ T cell response is preferable for full cross-
protection, and that a good CD4
+ T cell response to A20 (figure 4.5) is less able to cross-
protect. 
 
 
 
 Figure 4.3. IFNγ response of splenocytes to tumour challenge in ELISPOT assays. CT26 
or A20 tumour cells were mixed with whole spleen cells obtained 8 days after Balb/c mice 
were challenged with irradiated 1x106 CT26 cells and either depleted or not depleted of T 
regs. 100,000 splenocytes were mixed with 25,000 tumour cells in each well of the ELISPOT 
plate and the number of spots counted at the end of the procedure. The error bars indicate the 
standard deviation (SD) from the mean (n=3). This is a single experiment representative of a 
trend. Significance: * = p<0.05; **= p<0.01; ***= p<0.001.
Figure 4.4. IFNγ response of CD8+ T cells to tumour challenge in ELISPOT assays.
CT26 or A20 tumour cells were mixed with CD8 T cells purified from splenocytes obtained 
8 days after Balb/c mice were challenged with irradiated 1x106 CT26 cells and either 
depleted or not depleted of T regs. 50,000 CD8 T cells were mixed with 25,000 tumour cells 
in each well of the ELISPOT plate and the number of spots counted at the end of the 
procedure. The error bars indicate the standard deviation (SD) from the mean (n=3). This is a 
single experiment representative of a trend. Significance: * = p<0.05; **= p<0.01; ***= 
p<0.001.
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* ***Figure 4.5. IFNγ response of CD4+ T cells to tumour challenge in ELISPOT assays
CT26 or A20 tumour cells were mixed with CD4 T cells purified from splenocytes obtained 
8 days after Balb/c mice were challenged with irradiated 1x106 CT26 cells and either 
depleted or not depleted of T regs. 50,000 CD4 T cells were mixed with 25,000 tumour 
cells in each well of the ELISPOT plate and the number of spots counted at the end of the 
procedure. The error bars indicate the standard deviation (SD) from the mean (n=3). This is 
a single experiment representative of a trend. Significance: * = p<0.05; **= p<0.01; ***= 
p<0.001.
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4.4 Discussion 
 
Our previous comparisons of the responses generated from live CT26 with and without T 
regs suggested that antigen-specific T regs were responsible for creating an 
immunosuppressive environment that allowed the unchecked proliferation of the live 
tumour. Only when the T regs were depleted were the mice able to survive the tumour 
challenge. Comparisons with the response induced by CT26-GM also indicated that in 
the absence of T regs the response to CT26 broadens to include cross-reactive antigens, 
allowing rejection of unrelated tumours. However, the data collected in this chapter 
complicates the conclusions that we can draw from this CT26 model. 
It indicates that both anti-CT26 and cross-reactive T cells are generated in response to 
irradiated CT26 with T regs, but with the difference that both responses are partially 
protective to both live CT26 challenge and a challenge of an unrelated tumour. 
Furthermore, the cross-protective response is only modestly improved by first depleting T 
regs, although the anti-CT26 response is significantly boosted by the depletion. 
It may be that the anti-CT26 and cross-reactive CD4+ and CD8+ T cells develop in 
response to the live CT26 with T regs, but only in the absence of T regs are these 
responses robust enough to be protective. This kind of conclusion can not be completely 
certain when none of the immunotherapy experiments described here using irradiated 
CT26 have direct live CT26 controls. This is due to the fact that with the live tumour 
challenge in order for the mice to survive, and thus allow re-challenge experiments, mice 
must be depleted of T regs.  
 
The fact that the anti-CT26 response is boosted by the depletion of T regs in the 
irradiated CT26 model may prove to be the most valuable of all these conclusions. In the 
field of whole-cell tumour vaccines the aim is to develop a vaccine that presents multiple 
tumour epitopes to the immune response in the hope that a much more potent response is 
generated. Other cancer immunotherapy research has concentrated on a „single target‟ 
approach in which a tumour antigen or epitope is identified, which is either uniquely 
expressed or overexpressed in tumour tissue, and targeted. This approach is limited by 
the chosen antigen continually being expressed and not down-regulated, and that this   78 
antigen being expressed on all the tumour cells in the patient, some of which may have 
metastasised and differentiated from the primary tumour. The whole-cell tumour vaccine 
should in theory induce responses to multiple antigens and even unknown antigens, and 
also should provide the necessary determinants for CD4+ T cell help. A recent study 
where patients with renal-cell carcinoma received autologous renal tumour cell vaccines 
indicated that some clinical benefit from the procedure (Jocham, Richter et al. 2004). 
Despite this and a few other successes it is probable that the future of tumour-cell 
vaccines may lie in their combination with other modes of treatment. The data in this 
chapter indicates that depletion of T regs may increase the effectiveness of tumour cell 
vaccines. Thus the depletion of T regs (or some other means of immune-modulation) 
used in conjunction with a tumour-cell vaccine, along with perhaps soluble cytokines or 
chemotherapy drugs may lead to us being able to vaccinate patients to effectively cure 
them of existing tumours.  
 
Another interesting conclusion from this data is that T regs have only partial control over 
the cross-protective response when challenging with irradiated CT26. It is a possibility 
that the irradiated CT26 exposure, at approximately 1x10
6 cells, is so large as to 
overcome the checks that regulatory T cells hold over any response made to cross-
protective epitopes. When faced with such an overwhelming load in an inflammatory 
context (as it would be with irradiated and thus a largely dying or dead tumour mass), the 
antigen exposure and positive feedback signals the immune response would receive may 
be so strong that, what ever control regulatory T cells held over the cross-protective T 
cells, it would be overcome. However, the live CT26 tumour challenge would also, given 
the passage of time and the aggressive nature of the tumour, lead to a substantial tumour 
load, which would also be in an inflammatory context.  
Therefore, it may be due to the kinetics of the exposure as well as the overall load that is 
the crucial difference. With the irradiated CT26 challenge the tumour exposure is 
overwhelming right from the outset, whereas the with the live CT26 challenge the tumour 
exposure is comparatively low at the outset. While the live CT26 load is relatively small 
it would be able to recruit regulatory cells to the tumour site that would offer the tumour 
some protection as it establishes itself, with the result that the response made to the   79 
tumour is relatively weak. Therefore when the tumour load is as large as the irradiated 
load is at the outset, the tumour response is insufficient to reject the tumour. It would 
seem that in the face of an overwhelming irradiated CT26 exposure the T regs are less 
able to affect the strength of the anti-tumour response, explaining why the responses, 
particularly the cross-protective response, is unaffected by T reg depletion.  A way of 
further investigating this model, while avoiding these problems, may be to reduce the 
irradiated exposure at the outset, perhaps even to the same level as the live CT26 
challenge. At first one could try several separate irradiated CT26 challenges of different 
number, a „titration of immunogenicity‟ in other words, and investigate the result of that 
on subsequent tumour responses. Alternatively, in a more subtle approach, the growth of 
the live CT26 tumour could be mirrored by repeated subcutaneous injections of irradiated 
CT26 cells over time, with perhaps incremental increases in cell number. In fact several 
experiments could run co-currently, one with the same level of irradiated CT26 cells 
injected at equal increments, and one where the number of irradiated CT26 cells in each 
challenge continuously increases over time.  
 
Another possible explanation for why the large irradiated CT26 challenge evokes a 
different response to the live CT26 challenge is that the large irradiated CT26 load could 
activate the innate immune response. Thus the role of the innate immune response in this 
CT26 model, in particular the role of NK cells, is addressed in the next chapter.    
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Results Chapter 5:  
 
The effect of NK cells on priming the anti-CT26 response. 
 
5.1 Introduction 
 
An important bridge between the innate and adaptive immune system is the natural killer 
(NK) cell. Their main function is to defend the host against foreign invaders such as 
viruses, parasites, bacteria and transformed cells, via the production of 
immunostimulatory cytokines, like IFNγ and TNFʱ, and cytotoxicity against particular 
target cells using the perforin/granzyme pathway (Trinchieri 1995). NK cells identify 
their targets through a set of activating or inhibitory receptors that recognize foreign 
antigens encoded by pathogens, the increased expression of target molecules (induced 
self), or the decreased expression of target molecules (missing self), such as MHC class I 
molecules (Hoebe, Janssen et al. 2004). Depending on the balance between inhibitory and 
activating signals NK cells are triggered to kill or ignore target cells.  
Although NK cells are characterised as innate cells, they also participate directly in 
adaptive immune responses. In fact, according to the literature, NK cells‟ interaction with 
the adaptive immune system is extensive and multi-faceted. Although NK cells may act 
directly on T cells via the secretion of cytokines like IFNγ (Kelly, Darcy et al. 2002), the 
main way that NK cells might influence the adaptive response is by interacting with DCs. 
This interaction can be positive or negative (either by maturing immature DCs or killing 
them), and this interaction is bidirectional with DCs also acting on NK cells (Raulet 
2004). We wanted to assess therefore whether NK cells played a significant role in the 
rejection of a live CT26 challenge, especially in the primary response to the tumour.  
  
5.2 FACS analysis of the effectiveness of PC61 and anti-GM1 depleting antibodies. 
 
In order to assess whether NK cells are playing a role in the rejection of tumours in our 
CT26 model we repeated the normal vaccination procedure with live CT26 after NK cell 
depletion. NKs are depleted with antibody against GM1, which is a glycolipid on the   81 
surface of mouse natural killer cells. GM1 is expressed on mouse NK cells in high 
concentration, and it has been shown that the GM1 antiserum specifically eliminates NK 
cells, but not other lymphocytes (Kasai, Iwamori et al. 1980). Firstly however, I needed 
to assess the efficacy of the two depleting antibodies I was to use (PC61 and anti-GM1) 
and whether these antibodies could be used effectively in conjunction. Figure 5.1 shows 
the effect of the depleting antibodies PC61 and GM1 on Balb/c splenocyte populations. 
PC61 antibody reduced the proportion of CD4+ CD25+ cells in the spleen from 2.5% to 
1%, and the anti-GM1 antibody reduced the proportion of GM1+ cells in the spleen from 
nearly 5.8% to 1.7%. While these are not complete depletions, experience with this 
model suggests that depletions to this extent are sufficient to see significant changes 
when it comes to tumour challenge experiments. It also appears clear that these 
antibodies do not hinder each others function, allowing me to use these antibodies in 
conjunction.  
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Figure 5.1. Depletion of cell subsets with antibody. Treatment  of Balb/c 
mice with PC61 and anti-GM1 depletes both CD4+CD25+ T cells and NK  
cells from splenocyte populations.  
Figure 5.2. Survival to live CT26 with or without NK cells and T regs at the point of 
initial challenge. Mice were injected i.p. with 1mg of PC61 (which depletes T regs) and 
i.p. with 200ul of anti-GM1 serum (which depletes NK cells), 1 and 3 days prior to sc 
inoculation of 5x104 CT26 cells. Some mice (pink) were depleted of only NK cells (B), 
others were depleted only of T regs (dark blue) (A) and others were depleted of both 
(yellow) (C). One group were left undepleted (light blue) (D). The percentage of tumour-
free mice in each group is shown over time (days).
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5.3 Effect of depleting NK cells (with/without CD25 cells) prior to inoculation with live 
CT26 tumour cells. 
 
Firstly I wanted to test the role of NK cells in the primary response to CT26. NK cells 
would be depleted prior to the initial challenge with live CT26, and thus the NK cells 
would be absent at the point at which the immune response is first primed with the 
tumour antigens. This depletion of NK cells prior to initial challenge was done in 
conjunction with T reg depletion. Thus, Balb/c mice were challenged with 5x10
4 CT26 
cells subsequent to four different depletion combinations: no depletion; anti-PC61 only; 
anti-GM1 only; and both PC61 and anti-GM1. Depletions were carried out 1 and 3 days 
prior to live CT26 challenge, and survival was followed over the next 60 days. Therefore 
as well as assessing the effect NK cells have on the response, we could also assess the 
effect T regs have on NK cells. A few studies have indicated that NK cell function may 
be modulated by T regs, including one where anti-CD25 antibody administration before 
tumour inoculation abolished tumour growth and promoted the generation of cytotoxic 
cells including NK cells (Shimizu, Yamazaki et al. 1999), and we wanted to see whether 
this was the case in this CT26 model.  
As shown in figure 5.2, the mice depleted of NK cells but with regulatory T cells had the 
shortest survival time, approximately 32 days. This was followed with the group without 
any cell depletion, with all mice dying by approximately 36 days. Mice that had been 
depleted of both regulatory T cells and NK cells had approximately 45% of mice 
surviving the tumour challenge. But the mice that had been depleted of regulatory T cells 
but who still had NK cells had the best survival, with approximately 70% completely 
rejecting the tumour challenge.  
These results show that in this model, the efficacy of the anti-tumour response is 
decreased if NK cells are depleted prior to the initial live CT26 challenge. This occurs 
whether CD25+ cells are depleted as well or not. The conclusion is that NK cells are 
important in the anti-tumour response in the presence or absence of regulatory T cells. In 
the presence of regulatory T cells the effect of the absence of NK cells is shown by the 
difference in survival of the light blue and pink lines (figure 5.2). Although both groups 
of mice die, the survival rate is poorer in the group of mice without NK cells (pink). The   84 
effect of CD25+ cells on the anti-tumour response is shown by the difference in survival 
between the dark blue and light blue lines (figure 5.2). Mice challenged in the absence of 
CD25+ cells have a much greater survival rate (70%), compared to the mice challenged 
in the presence of CD25+ cells (0%). However, if NK cells are also depleted prior to 
challenge, as shown in the yellow line, the positive effect of the CD25+ cell depletion is 
reduced, with only 45% of mice surviving the challenge (see table 5.1). Thus not only are 
the NK cells important in the anti-tumour response in the presence of regulatory T cells, 
but also in the absence of regulatory T cells.  
Clearly the effect of removing the T regs does not solely affect the action of the NK cell 
population as even without NK cells the survival rate of 45% compares well with mice 
that have T regs and NK cells (0%). This particular positive effect must be mainly down 
to the adaptive immune response in these mice.  
 
5.4 Effect of depleting NK cells before and after rechallenge with live CT26. 
 
While it was apparent that NK cells have a role in the primary response to tumour, it was 
not thought that NK cells would be as influential once the response had been formed. 
Therefore I assessed the role of NK cells in the secondary response to CT26, and thus 
whether NK cells affect the memory T response or not. To do this, Balb/c mice that had 
been injected with PC61 antibody and survived a 5x10
4 live CT26 cell challenge were re-
challenged 42 days later with 5x10
4 live CT26 cells. 1 and 3 days prior to and 3 and 7 
days post the CT26 re-challenge, mice were treated with anti-GM1 antibody or a control 
rabbit serum. As a control mice naïve to CT26 tumour were also challenged with 5x10
4 
live CT26 cells. Thus NK cells would be absent at the point when the memory cells, 
formed during the primary response to the tumour, are attempting to eliminate the 
subsequent tumour challenge. As figure 5.3 shows, whereas all control mice had died 
approximately 35 days after challenge, all the mice that were being re-challenged 
survived, whether they had been treated with anti-GM1 antibody or not. 
These results show that in terms of survival rates the importance of NK cells in the anti-
tumour response diminishes to nothing once a good adaptive immune response has been 
generated. In the rejection of the CT26 rechallenge, the tumour growth is visible for a   85 
time then it recedes, and it may be worth considering for future experiments that the rate 
of either the initial growth or the recession might be affected by the absence of NK cells. 
However, overall the inference is, once a primary response has been made to a tumour, 
the memory T cells produced during that primary response are sufficient to eliminate the 
tumour in a secondary response even in the absence of NK cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.3. Survival to live CT26 with or without NK cells at the point of rechallenge.
Mice injected with PC61 and that had been challenged with 5x104 live CT26 cells were 
re-challenged 42 days later with 5x104 live CT26 cells. 1 and 3 days prior to the CT26 re-
challenge and 3 and 7 days post CT26 re-challenge, mice were injected i.p. with 200ul 
anti-GM1 rabbit serum or control normal rabbit serum. Mice were not depleted of T regs a 
second time. A group of tumour-naïve mice were also challenged with 5x104 live CT26 
cells as a control. The percentage of tumour-free mice each group is shown over time 
(days).
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Table 5.1: Survival data from figure 5.2, in tabulate form. 
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5.5 Discussion 
 
From these results it is clear that the absence of NK cells, as well as the absence of T 
regs, impacts on the primary response to CT26 tumour challenge. These data, together 
with the literature that already exists on this subject, means that I can suggest several 
models of cell interaction that could be at work during priming in this CT26 model. 
These models must encompass the conclusions that depletion of NK cells, either 
combined with T reg depletion or not, impacts negatively on Balb/c survival to CT26 
challenge, and that depletion of T regs, either combined with NK depletion or not, 
impacts positively on Balb/c survival to CT26 challenge.  
 
NK model A (T regs suppress effector T cells only), shown in figure 5.4, suggests that 
depletion of NK cells deprives the anti-tumour response of a cell type that would target 
tumour cells directly, but also of cells that would act to directly positively influence the 
response to the tumour made by T cell effectors. To support this, NK anti-tumour activity 
and the consequent production of IFNγ by the NK cells has be shown in mice to evoke 
the subsequent development of a specific cytotoxic T lymphocyte (CTL) and T helper 
type 1 (Th1) responses against RMA tumour cells (Kelly, Darcy et al. 2002). Some 
evidence also exists to show that human NK cells express MHC class II and TCR co-
stimulatory molecules, thus enabling them to act as APCs and present antigens directly to 
T cells, a phenomenon that may extend to mice (Hanna, Gonen-Gross et al. 2004). NK 
model A also suggests that the depletion of T regs would affect the anti-tumour response 
by removing suppression of the effector T cell response, which leads then to the 
increased survival of mice to CT26 challenge.  
 
NK model B (T regs suppress NKs and T cells) differs from model A only in one respect, 
which is that the depletion of T regs also releases suppression of NK cells. This would 
release the NK cells to target more tumour cells and have a greater positive effect on the 
effector T cell response. There is good evidence that the removal of T regs might 
positively impact NK cell responses. In one of the early studies of the effect of T reg 
depletion on tumour responses, anti-CD25 mAb administration before tumour inoculation   88 
abolished tumour growth and promoted the generation of cytotoxic cells including NK 
cells. Furthermore, tumour-naïve splenic cell suspensions, depleted of regulatory T cells, 
contained NK cells capable of killing a broad spectrum of tumours. This may be 
explained by the fact that the removal of regulatory T cells might be activating self-
reactive CD4 cells that then secreted IL-2, which would then activate NK cells to kill 
tumour cells. The subsequent release of tumour antigens, coupled with the IL2 from the 
CD4 cells, might then aid the development of tumour-specific CD8+ CTLs (Shimizu, 
Yamazaki et al. 1999). More recent studies have shown that NK cell proliferation was 
significantly enhanced in the absence of T regs, and that this suppression was TGFβ 
dependent (Ghiringhelli, Menard et al. 2005). Furthermore, in the murine model of 3LL 
lung carcinoma, depletion of T regs before tumour inoculation reduced the number of 
lung metastases, yet co-depletion of NK1.1+ cells restored the establishment of 
metastases (Smyth, Teng et al. 2006).  
 
NK model C (NKs act indirectly on T cells) suggests that the DC functions as an 
interface between the NK and the effector T cell, and implies that the NK cell influences 
the state of the DC which in turn positively affects the T cell effectors. There is 
significant support for the existence of NK – DC cross-talk in the literature. Firstly 
activation of NK cells in vivo may be in large part due to interactions with DCs. DCs 
prestimulated with IFN-ʱ upregulate the MICA and MICB NKG2D ligands, which 
contribute to activating NK cells in coculture (Dokun, Kim et al. 2001). Furthermore, in 
mice infected with MCMV, CD8ʱ+ DCs are necessary for the expansion of Ly49H+ NK 
cell populations and blocking Ly49H prevents NK population expansion (Andrews, 
Scalzo et al. 2003). In the other direction the maturation of DCs stimulated by NK cells 
represents a key mechanism to bridge the NK response to the stimulation of T cell 
responses. Studies have shown that in co-culture with NK cells, immature DCs undergo 
maturation, produce TNF and interleukin 12, and upregulate costimulatory ligands such 
as CD86 (Gerosa, Baldani-Guerra et al. 2002). Other studies also conclude that efficient 
DC activation in cell culture requires contact with NK cells, with the NKp30 receptor 
being important in this interaction (Ferlazzo, Morandi et al. 2003). Furthermore, an in 
vivo study showed that NK cells activated by encounters with MHC class I low tumour   89 
cells stimulate DCs to produce interleukin 12 and enhance the induction of CD8+ T cell 
responses (Mocikat, Braumuller et al. 2003). Overall, there is ample evidence that NK 
cells, via the DC interface, are effective at inducing T cell responses. NK model C also 
expands the role of the T reg to include the suppression of DCs as well as NK cells and T 
cell effectors.   
 
These data alone cannot for certain determine which model is the correct one, although 
further experiments could reveal this. One way to further investigate the immunological 
interactions in this model would be to perform a series of in-vitro co-culture experiments 
with purified cell subsets. Purified T regs co-cultured with NK cells or T cells and 
assessing the effect on CT26 killing could elucidate the suppression mechanisms in this 
model. Furthermore T cells co-cultured with DCs or DCs previously co-cultured with NK 
cells, possibly using trans-well cultures, could elucidate the contribution of NK cells to 
the anti-CT26 T cell response.  
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Figure 5.4. The potential role of NK cells in anti-CT26 responses. Below are three potential 
models of the effects NK cells have on the anti-CT26 response. In model A, NK cells and effector T 
cells both target the tumour, but NK cells also positively affect effector T cells directly. T regs
suppress effector T cells but do not affect NK cells. Model B shares the features of model A but the 
T regs also suppress NK cells as well as effector T cells. In model C, NK cells positively affect 
effector T cells indirectly via DCs. T regs suppress effector T cells, and may negatively affect NK 
cells or DCs (indicated by dashed lines).  91 
Results Chapter 6:  
 
Is the number of T cell clones induced by CT26 different in the absence and presence of 
regulatory T cells? 
 
6.1 Introduction 
 
The TCR is composed of constant (C) and variable (V) regions, which are assembled 
together during thymic ontogeny (Alt, Oltz et al. 1992). The diversity of the TCR is 
generated via gene rearrangement within the variable domains of the TCR, which is the 
(V) and junction (J) gene segments in the Vʱ chain, and the V, diversity (D) and J gene 
segments in the Vβ chain. During TCR gene rearrangement the V and J, or V, D and J 
segments are brought together in a continuous V-J or V-D-J coding block, forming 
complete V domain exons that are responsible for antigen recognition (shown in figure 
6.1). However the diversity of the TCR depends not only on the recombination of these 
genes but is also greatly increased by nucleotide insertion and deletion at the junctions 
between these genes. The greatest diversity is present at the third complementarity 
determining region (CDR3), which spans the V(D)J junction. The CDRs are regions of 
greatest sequence variability (CDR1 and CDR2 are located within the V domain) and 
constitute the binding site for the peptide-MHC complex, with the CDR3 positioned at 
the centre of the antigen binding site for direct contact with the MHC bound peptide 
(Jorgensen, Esser et al. 1992). The generation of TCR-pMHC crystal structures has 
allowed us to visualise the interaction of these two molecules in more detail (see figure 
6.2) (Gras, Kjer-Nielsen et al. 2008). The TCR and pMHC „dock‟ together, so that the 
TCR Vʱ domain is positioned over the MHC ʱ2-helix and the N-terminal end of the 
peptide, whilst the TCR Vβ domain contacts the MHC ʱ1-helix and the C-terminal end of 
the peptide (Rudolph, Stanfield et al. 2006). 
 
 
 
 Figure 6.1.  The rearrangement of Variable, Diversity and Junctional gene regions to form 
the T cell receptor gene complex.  Reprinted from the Journal of Clinical Pathology (2003) 
Volume 56, pages 1-11 (BMJ publishing group).   93 
In every immune response the T cell repertoire will skew towards TCRs that recognise 
the peptides that are presented by the particular infection. Depending on the breadth of 
the peptides presented to the immune response, and the strength of the response to these 
peptides, the diversity of TCRs will be decreased to a greater or lesser extent. The clonal 
composition of the CD8+ T cell response has been evaluated for viral infections such as 
human cytomegalovirus (HCMV). Peripheral blood lymphocytes (PBLs) from HCMV-
seropositive donors were cultured for two weeks with autologous DCs and exogenously 
added CMV antigen (Peggs, Verfuerth et al. 2002), which increased the percentage of 
HCMV-specific CD8+ T cells from 0.3% to 8.0%. TCR CDR3 spectratypic analysis was 
carried out on the cultured CD8+ T cells, using 22 TCRβ chain V gene family primers 
and the β chain C region primer. The PCR product lengths thus reflect the CDR3 lengths 
of the input TCR RNA, being dependent on the Jβ and Dβ usage as well as the variation 
in the junctional regions. This analysis showed that while there was a restriction in the 
CDR3 length repertoire postculture, the repertoire of Vβ usuage was not particularly 
restricted postculture.  
 
6.2 Analysis of Vβ-Jβ DNA lengths from CD8 T cells stimulated by CT26GM tumour. 
 
We wanted to assess the clonal composition of CD8+ T cells present post CT26 tumour 
challenge either in the presence or absence of T regs to further test the idea that in the 
absence of T regs the activation threshold is lowered which allows the broadening of the 
response against the tumour, including presumably the cross-protective antigen among 
others. As well as CT26, CT26GM was also used at the point of initial challenge, as we 
wanted to look at unfocussing of the response to CT26GM in the absence of T regs as 
well.  
To start this procedure, Balb/c mice were challenged with CT26-GM tumour at day 0, 
prior to which the mice were depleted of T regs with PC61 antibody, or not (by using a 
control antibody GL113). Spleens from these mice were removed 3 months later, 
depleted of CD4 T cells and B cells with dynabeads to leave a principally CD8 T cell 
population, and these cells then either re-stimulated with 3x10
5 irradiated CT26 tumour 
cells per well, or left unstimulated. Of those cells restimulated, positive responders were   94 
identified using an intracellular IFN-gamma assay, and the mRNA extracted from these 
cells. Otherwise mRNA was extracted from the unstimulated splenocytes. This meant 
there were four groups (plus a group of naïve unstimulated splenocytes) that were 
analysed for the number of T cell clones:  
 
1. Challenge of CT26-GM with T regs and CD8 T cells unstimulated in vitro.  
2. Challenge of CT26-GM with T regs and CD8 T cells restimulated with CT26 in vitro. 
3. Challenge of CT26-GM without T regs and CD8 T cells unstimulated in vitro.  
4. Challenge of CT26-GM without T regs and CD8 T cells restimulated with CT26 in 
vitro.  
 
In the next step of the procedure the cDNA made from the mRNA extracts was used as a 
template for a particular Vβ primer and several Cβ primers. Primers were used from the 
following Vβs: 1, 3, 4, 5, 12.1, 13.1, 14, 15, 16, 26, and 29. Of those PCR runs that were 
positive for a Vβ-Cβ product, those sequences were then used as templates for another set 
of PCRs that used the Vβ primer in conjunction with several Jβ primers. This reaction 
would produce various lengths of DNA that would indicate the amount of N-terminal 
addition between the Vβ region and the various Jβ regions. The J primers have dyes 
attached to them so that the DNA fragments produced from the PCR can be visualised. 
Three different dyes were used: HEX (green), FAM (blue) and NED (black). Primers 
were used for the following Jβs: 1.1 (NED), 1.2 (NED), 1.3 (NED), 1.4 (NED), 1.5 
(FAM), 1.6 (FAM), 1.7 (FAM), 2.1 (FAM), 2.2 (HEX), 2.3 (HEX), 2.4 (HEX), 2.5 
(HEX), 2.7 (HEX). The GeneScan Analysis Software analyses the data collected by the 
ABI PRISM 310 Genetic Analyser to size and quantitate DNA fragments automatically, 
allowing faster and more accurate analysis than traditional methods such as radiolabeling. 
The software displays the results as profiles (as seen in figure 6.2), which show 
fluorescence intensity as a function of fragment size. Each profile represents a single 
injection. Figure 6.2 shows examples of such profiles produced by the software, and 
importantly the examples are separated into their various interpretations of the breadth of 
the response that these Vβ-Jβ fragments represent: polyclonal, oligoclonal, clonal and not 
interpretable. Each peak corresponds to an additional nucleotide present at the junction   95 
between the V and J regions that form the CDR3, and so more peaks indicates a greater 
variability at the CDR3, ultimately indicating more TCR variants are present. The results 
shown in tables 6.1, 6.2 and 6.3 were interpreted with the help of skilled and experienced 
technical assistance from SUHT Wessex Regional Immunology service who specialize in 
analyzing cancer patients with diseases such as T cell lymphoma.  
 
The diversity of the response can be interpreted at several levels. The first is at the level 
of Vβ usage, as a greatly focused response might reduce the presence of certain Vβ 
subfamilies to an extent that they no longer show up on the profiles. It is unlikely that in 
the case of these experiments that this will be an instructive level of analysis, as even in 
the analysis of the HCMV response mentioned above, where you would expect a greater 
focusing compared to a tumour response, there was almost no cases where Vβ 
subfamilies were lost as a result of the HCMV stimulation of CD8+ T cell responses.  
In any case, of all the Vβ primers used in these experiments time constraints meant that 
only the Vβ1, Vβ13.1 and Vβ5 regions were analysed and all were positive. Tables 6.1, 
6.2 and 6.3 show the tabulated results of the interpretations from the profiles, with Vβ1 
(6.1) being the most complete of these data sets.  
The next level of interpretation is at the level of Jβ usuage, and here there is a much 
greater chance that certain combinations of Jβ and Vβ primers will no longer amplify 
sequences and thus indicate a focusing of the response. This is due to the fact that instead 
of one highly variable region (the V region) being paired with the single C region, you 
have the V region paired with the variable J region. However, as figure 6.4 shows, of the 
65 profiles only 10 are negative, and of those, half were in Vβ1-Jβ1.7 which is negative 
in the naïve control. Furthermore negative results are hard to interpret as they can either 
be evidence of a loss of a Jβ subfamily, or just a bad assay. A series of repeat experiments 
would be necessary to differentiate, and again time constraints prevented those.   
The final level of interpretation, and the one which is the most instructive here, is at the 
level of junctional diversity, or in other words the variability in the CDR3 region. This is 
indicated by the number of peaks in each of the profiles, which allows each profile to be 
judged to be either polyclonal, oligoclonal or clonal.  Table 6.1 shows that at this level of 
junctional diversity there appears to be a trend of polyclonal profiles in the naïve control   96 
(1
st column), being replaced by oligoclonal profiles in the group where T regs were 
present (3
rd column), and then reverting back to polyclonal profiles in the group where T 
regs were depleted (5
th column). Notably the 3
rd and 5
th columns represented groups 
primed in the presence or absence of T regs which were then restimulated in vitro with 
CT26 tumour cells. This trend is present in Vβ1 –Jβ1.6, –Jβ2.3, and –Jβ2.7. This trend is 
evidence that depletion of T regs at the point of CT26GM challenge leads to the 
broadening of the immune response, as indicated by an increased polyclonality of the 
CD8+ T cell response. This trend is only countered in –Jβ1.3, where a polyclonal 
response reverts to an oligoclonal one. Otherwise, for the remaining Jβ subfamiles the 
profiles for the T reg depleted and non-depleted groups are the same. This trend can be 
articulated in a different way, which is to look at the percentage of recorded profiles in 
the 1
st, 3
rd and 5
th columns that are polyclonal or oligoclonal. In the naïve control, 100% 
of positive profiles are polyclonal, which is not surprising given as this represents the 
clonal composition background of the naïve Balb/c mouse. In the CT26GM challenged 
mice (3
rd column), 66% of the positive profiles are oligoclonal, with 33% polyclonal, 
representing a significant focusing of the T cell response from the background. Finally in 
the CT26GM challenged, T reg depleted mice (5
th column), 27% of the positive profiles 
are oligoclonal, and 73% polyclonal, representing a significant shift back towards the 
„unfocused‟ response.    
Table 6.2 and 6.3 are incomplete data sets and so are more difficult to interpret. Table 6.2 
lacks any data where T regs were depleted, and there are a number of „No result‟ entries 
in the second column, which further hampers analysis of this data. The only thing to note 
in this table is that CT26 challenged mice show a much more focused response than the 
naïve control, with 8/13 profiles being oligoclonal and 2/13 profiles clonal, compared to 
12/13 polyclonal profiles in the naïve control. Table 6.3 has more data than table 6.2, but 
there appears no difference between any of the conditions, which makes this dataset 
much less interesting than table 6.1. There are exclusively polyclonal profiles in table 6.3, 
whether T regs were present or depleted, or whether mice were challenged with CT26 or 
left naïve. An explanation may be that this particular V  region, V  5, is not a region 
involved in producing TCRs that make a prominent response to CT26 antigens, and so 
are not more focused in response to CT26 challenge.  Figure 6.2. Examples of the different types TCR variability. (a) Polyclonal; (b) Oligoclonal; 
(c) Clonal; (d) Not interpretable. Each of the graphs represents a particular Vβ gene segment, 
with all the differences between the unique TCRs restricted to the CDR3 region, where there are 
differences in length due to the imprecision of the rearrangement process. Using primers specific 
for an individual V gene segment at one end and for a conserved part of the C region at the other, it 
is possible to generate a set of DNA fragments that span the CDR3 region. These fragments can be 
labelled with fluorochromes, and analysed by automated gel readers, so they can be displayed as a 
series of peaks corresponding to the different length fragments (this is a spectratype). More peaks 
on the spectratype indicates an expansion of the number of  clones generated in response to a 
particular antigenic challenge.  Three or more peaks = polyclonal;  two peaks = oligoclonal; one 
peak = clonal;  not interpretable = no clear distribution.
b
ac
dVβ 1 -
Jβ
Naïve 
control
CT26GM 
with T regs 
(Unstim)
CT26GM 
with Tregs 
(Restim)
CT26GM
w/o Tregs
(Unstim)
CT26GM
w/o T regs
(Restim)
1.1 Polyclonal Polyclonal Oligoclonal Clonal Oligoclonal
1.2 Polyclonal Polyclonal Oligoclonal Polyclonal Oligoclonal
1.3 Polyclonal Polyclonal Polyclonal Polyclonal Oligoclonal
1.4 Polyclonal Polyclonal No result Polyclonal Polyclonal
1.5 Polyclonal Oligoclonal No result Polyclonal Polyclonal
1.6 Polyclonal Oligoclonal Oligoclonal Polyclonal Polyclonal
1.7 No result No result No result No result No result
2.1 Polyclonal Oligoclonal Oligoclonal No result No result
2.2 Polyclonal No result Polyclonal Polyclonal Polyclonal
2.3 Polyclonal Oligoclonal Oligoclonal Oligoclonal Polyclonal
2.4 Polyclonal Polyclonal No result Polyclonal Polyclonal
2.5 Polyclonal Polyclonal Polyclonal Oligoclonal Polyclonal
2.7 Polyclonal Oligoclonal Oligoclonal Polyclonal Polyclonal
Table 6.1. Results of the Vβ1 regionVβ 13.1 – Jβ Naïve control CT26GM with 
T regs 
(unstim)
CT26GM with 
T regs 
(restim)
1.1 Polyclonal polyclonal clonal
1.2 Polyclonal No result oliogclonal
1.3 Polyclonal No result oligoclonal
1.4 Polyclonal No result oligoclonal
1.5 Polyclonal No result polyclonal 
1.6 Polyclonal polyclonal Polyclonal
1.7 No result No result No result
2.1 Polyclonal No result Oligoclonal
2.2 Polyclonal Clonal Oligoclonal
2.3 Polyclonal Polyclonal Oligoclonal
2.4 Polyclonal Clonal Clonal
2.5 Polyclonal No result Oligoclonal
2.7 Polyclonal Clonal Oligoclonal
Table 6.2. Results for the Vβ 13.1 regionVβ5 - Jβ Naïve 
control
CT26GM 
with Tregs 
(unstim)
CT26GM 
with Tregs 
(restim)
CT26GM 
w/o T regs 
(unstim)
1.1 Polyclonal polyclonal polyclonal No result
1.2 Polyclonal polyclonal polyclonal Polyclonal
1.3 Polyclonal No result No result No result
1.4 Polyclonal Polyclonal Polyclonal Polyclonal
1.5 No result Polyclonal polyclonal  Polyclonal
1.6 Polyclonal Polyclonal Polyclonal Polyclonal
1.7 No result No result No result No result
2.1 Polyclonal Polyclonal Polyclonal Polyclonal
2.2 Polyclonal Polyclonal Polyclonal Polyclonal
2.3 Polyclonal Polyclonal Polyclonal Polyclonal
2.4 Polyclonal Polyclonal No result No result
2.5 Polyclonal No result Polyclonal No result
2.7 Polyclonal polyclonal polyclonal Polyclonal
Table 6.3. Results for the Vβ 5 region   102 
6.3 Discussion 
 
There are several variables in this procedure that may or may not affect the validity of the 
conclusions made. 
One variable is whether this method is accurately reflecting the number of T cell clones. 
It may be that analysing the clonal composition of CD8+ T cells derived from the spleen 
may not give an accurate impression of the specificity of T cell clones induced by tumour 
cells injected subcutaneously in the flank.  
Another variable is the elapse of time from the point of CT26-GM challenge to the 
extraction of splenocytes. This was a consequence of one lab operator starting the 
procedure and it being revived by another operator. This could have the effect of 
lessening the skewing of the response of the T cells to the original CT26GM challenge. 
However against that the memory cells produced during that primary response should be 
expanded by the CT26 restimulation, and the fact that the T regs would have regained 
their normal levels by the time of the restimulation shouldn‟t distort the effect the original 
depletion had on the preference of the T cell response to the tumour challenge.  
 
Ultimately it is likely that the conclusions from these results would have been 
strengthened by more data. Originally mice were challenged with CT26-GM or CT26 in 
the absence or presence of T regs. The plan was to use numerous primers corresponding 
to many of the Vβ and Jβ regions present in the mouse genome, in order to create a more 
complete picture of the T cell response to these tumours and the effect T reg depletion 
had on these responses. Time constraints meant that only a fraction of the possible data 
that could have been collected was collected, and of that only one table had analysis for 
all the conditions including the controls. It happened that this was the response to CT26-
GM, which although important, hasn‟t been the focus of the rest of the experiments that I 
have carried out. However, the fact that these results have indicated that the clonal 
composition in response to CT26GM is less focused in the absence of T regs, in a model 
where survival to challenge is not dependent on T reg depletion, it could be reasonably 
extrapolated that the clonal composition in response to CT26, where T reg depletion does 
provide protection, would also be broadened by the absence of T regs.     103 
 
The original hypothesis, formed in relation to the live CT26 model, stated that it was the 
breadth of the T cell response that is changed by the depletion of T regs, and that certain 
T cell responses (like the cross-protective response) would be invisible in the presence of 
T regs. Data from this chapter seems to back this up as it indicates that the response 
induced by CT26GM is able to recognise a greater variety of epitopes in the absence of T 
regs (although a broader repertoire does not necessarily mean that there will be an 
increase in cross-reactivity with other tumours). Interestingly, chapter 4 also shows that 
the anti-CT26 response, induced in the presence of T regs, is actually boosted in their 
absence. These data taken together may suggest that the in addition to the effect that T 
regs have on broadening the response, T regs may also be significant in controlling the 
quality of the anti-tumour T cell responses. It is quite possible that cross-reactive T cells 
are induced by live CT26 challenge, but that to make them effective cross-protective T 
cells would probably need the absence of T regs. The fact that the T reg control of 
responses in the live CT26 model appears to be different to the T reg control of responses 
in the irradiated model is an intriguing conclusion, but it also means that it is difficult to 
see how I could use these models to further investigate the T reg control of T cell 
responses to tumour cells. To successfully do this may require the use of a different 
model.  
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Results Chapter 7:  
 
Investigating regulatory control of T cell tumour responses in a model of autoimmune 
thyroiditis. 
 
7.1 Introduction 
 
The CT26 model was chosen in an attempt to better define the role of regulatory T cells 
in the control of anti-tumour responses, in particular the suppression of the cross-reactive 
response. During the course of the investigation, it became clear that the response to the 
irradiated CT26 was qualitatively different to the response to live CT26. While this 
provided some mechanistic insight into the value of immunotherapeutic approaches 
involving irradiation of autologous tumour and T reg depletion, it did not permit a 
mechanistic study of the immune response to the transplanted live tumour. Some cancer 
vaccine candidates are overexpressed self-antigens (eg. Tyrosinase, hTERT etc) and a 
concern over their use in immunotherapy is the induction of autoimmune responses. Also 
T cell responses to these and others may be under peripheral tolerance so a special 
problem with cancer vaccines is breaking tolerance without inducing autoimmunity. I 
sought an informative model in which a spontaneous immune response to a self protein 
could be studied in the context of both autoimmune pathology and anti-tumour response.  
 
This new model was a humanised mouse model of spontaneously arising autoimmune 
thyroiditis, the TAZ10 mouse (Quaratino, Badami et al. 2004). The transgenic mice 
express the TCR of the autoreactive human T cell clone 37, isolated from a patient with 
autoimmune thyroidits. T cell clone 37 is specific for the dominant autoantigen thyroid 
peroxidise (TPO), TPO535-551. Within this peptide, two contiguous epitopes are 
differentially recognised by T cell clone 37, TPO536-547, an agonistic highly stimulatory 
epitope, and TPO537-548, a naturally occurring antagonistic epitope. TPO536-547 is a cryptic 
epitope preferentially displayed after endogenous processing during inflammation. 
Conversely, the antagonistic epitope induces in vitro anergy in clone 37 when presented 
by dendritic cells and preferentially displays when whole TPO is presented. There is a   105 
possibility that this T cell clone may be anergic and possibly regulatory in the patient, but 
in the mice it causes spontaneous histological, hormonal and clinical changes comparable 
to human destructive thyroiditis. 
Clone 37 was a CD4+ T cell isolated from the thyroid infiltrate of an autoimmune patient 
specific for the cryptic TPO536-547 epitope restricted by the histocompatibility leukocyte 
antigen (HLA) DQB1*0602-DQA1*0102 allele. As splenocytes from the CBA (H-2
k) 
strain of mice were able to present the TPO536-547 to the T cell clone 37, the TAZ10 
transgenic strain was established on the CBA (H-2
k) background. To exclude the 
presence of endogenous TCR ʱ chains, the TAZ10 strain was backcrossed onto the Rag1-
/- H2
k background. Experiments showed that TCR
+ Rag1
-/- T cells, expressing either CD4 
or CD8 co-receptors, are restricted by H2-IA
k, and the cryptic epitope TPO536-547 proved 
more efficient at inducing T cell proliferation than the TPO535-551 epitope. Molecular 
modelling showed that this „xenoreactivity‟ (i.e. that the TAZ10 TCR could be activated 
by human TPO peptides restricted by mouse H2-IA
k molecules) is because the binding of 
human TPO536-547 to HLA-DQB1*0602 and H2-IA
k is similar, due to the structural 
homology of both molecules. Crucially the modelling also showed that the human 
TPO536-547 epitope (N-DPLIRGLLARPA-C) and the homologous mouse TPO524-535 
epitope (N-DPIVRGLLARAA-C) presented by H2-IA
k, would display a similar antigenic 
surface, despite the conserved residue differences. This explains why mouse TPO 
peptides presented by H2-IA
k induce specific activation of the TAZ10 T cells, and cause 
spontaneous autoimmune thyroiditis.      
 
TAZ10 mice were found to develop disease spontaneously as early as 12 weeks after 
birth, with many of the histological and hormonal changes very similar to the human 
disease. A contributing factor to the spontaneous nature of this disease is the fact that 
(TPO specific) regulatory T cells are recruited to the lymph nodes draining the thyroid, 
and then subsequently die, probably via activation induced cell death (AICD) (Badami, 
Maiuri et al. 2005). This means that over time the self-antigen specific T reg population 
that is able to suppress the anti-thyroid response is gradually depleted, and the TPO 
antigen becomes gradually more immunogenic. All these factors make this model a good 
one for investigating anti-tumour responses. This is because tumour antigens are   106 
effectively self-antigens in the same way TPO is in autoimmune thyroidits, and 
consequently anti-tumour responses could be considered to anti-self-responses just like 
autoimmune responses. We could use this situation to study tumour responses by 
manipulating tumour cells to produce TPO protein, thus making the cells a target for the 
anti-TPO T cells that make up the immune system of the mouse. Furthermore TPO could 
be introduced both into a MHC class II
+ tumour cell line to study direct effector 
mechanisms, and also into a MHC class II
– tumour to look at indirect effector 
mechanisms. The TPO+ tumour cell could then be injected subcutaneously into the 
mouse and the result studied in the same way as other tumour challenge experiments. If 
the same mechanism that caused the death of the self antigen-specific T regs in the 
draining lymph nodes of the thyroid causes the death of the T regs in the draining lymph 
node of the tumour, then the anti-tumour response could resemble the anti-thyroid 
response (where the thyroid is extensively damaged). This would add support to the idea 
that local or global depletion of T regs would be an effective treatment of tumours in 
humans.    
  
7.2 Cloning TPO into a retroviral vector 
 
The first goal in this work was to clone the TPO gene and ligate the gene into the MIGR1 
retroviral vector. There were no restriction sites present in the TPO gene that matched the 
ones present in the multiple cloning site of the retroviral vector (figure 7.1), thus 
necessitating that restriction sites be added the 5‟ and 3‟ end of the cloned TPO gene. It 
was decided that a XhoI restriction site be added at the 5‟ end of the TPO gene, and an 
EcoRI restriction site at the 3‟ end. At the outset of this work I had attempted to clone 
TPO in one chunk from human TPO in an existing plasmid, and then in multiple parts 
from that plasmid. All those attempts failed, probably due to primers annealing to the 
plasmid instead of the gene, which no amount of primer variation seemed to eradicate. To 
solve this problem I decided to try and clone the mouse TPO gene. One drawback with 
the use of mouse rather than human TPO is that there is not a readily available antibody 
that recognises mouse TPO, whereas there is one for human TPO. This would  
 MIGR1
(6 kb)
BglII
EcoRI
XhoI
HpaI
Figure 7.1. Map of the MIGR1 vector, showing the multiple cloning site.
Mouse thyroid cDNA
TPO
1 Sal I (752) Sac I (1506) BglII (2368) 2750
A
Xho I B
EcoRI
Figure 7.2. Schematic showing how the TPO gene was cloned. Mouse TPO was cloned 
using PCR from mouse thyroid cDNAin two parts, adding the restriction sites XhoI and 
EcoRI. The overlapping fragments were ligated together using the shared SacI restriction 
site.   108 
make it more difficult to test whether the transfected tumour cells are producing TPO 
protein in later experiments.  
 
The source of the mouse TPO gene sequence was mouse thyroid cDNA, made from 
mRNA extracted from lysed mouse thyroid cells. Although thyroid cDNA would contain 
many gene sequences, PCR should be able to easily amplify the TPO sequence from the 
mix. As initial attempts to clone the gene from mouse thyroid cDNA in one 3kb fragment 
failed (data not shown), I had to clone TPO in two parts (figure 7.2). This necessitated 
that the two parts overlap at a unique restriction site at the centre of the TPO gene, which 
turned out to be a SacI restriction site, so that the two parts could be ligated together. 
Figure 7.3 shows an agarose gel of the result of the PCR reaction to clone the TPO gene 
in two parts, which indicated that the reaction had been successful. These two products, 
along with the MIGR1 retroviral vector were then cut with the relevant restriction 
enzymes and ligated with T4 ligase. The ligation mix was then used to transform DH5ʱ 
bacterial cells, which are particularly receptive of plasmid DNA. By virtue of the 
ampicillin resistance gene contained in the MIGR1 vector any bacteria that took up the 
ligated MIGR1-TPO plasmid would become resistant to ampicillin, while those that did 
not should remain susceptible. Consequently transformed bacteria were grown on 
ampicillin-enriched agar overnight, and the surviving colonies picked and grown in 
separate ampicillin-enriched medium 5ml tubes, again overnight. Minipreps were made 
of the separate tubes, and the resulting DNA run on an agarose gel. Figure 7.4 shows the 
result of this gel, with one lane showing a plasmid running at 9kb, which corresponds to 
the size of the MIGR1 vector plus the two parts of TPO. This could be confirmed by 
cutting the MIGR1-TPO plasmid with BglII restriction enzyme, which would cut a site in 
the MIGR1 vector and a site in the TPO gene (Figure 7.5). A correctly ligated plasmid 
would be predicted to be cut into two parts by BglII. Figure 7.5 also shows the impurities 
that were removed by the caesium chloride maxiprep that was done on the original DNA 
seen in lane 6 of figure 7.4. This maxiprep produced sufficient amounts of the MIGR1-
TPO plasmid to move on to the next step, the transfection of a packaging cell line. 
 
 1,500
1,000
800
600
400
A     B
Figure 7.3. Cloning mouse TPO in two parts 
from mouse thyroid cDNA. Part A has a 
predicted size of 1582 bases, while part B has a 
predicted size of 1295 bases. The primer at the 5’ 
end of part A adds the XhoI restriction site to the 
sequence, and the primer at the 3’ end of the part 
B adds the EcoRI restriction site to the sequence. 
Part A and part B overlap at a SacI restriction 
site.
1      2     3      4     m     5      6      7       
10,000
8,000
6,000
Figure 7.4. Miniprep of the MIGR1-TPO 
construct. Part A and part B are cut with SacI, 
EcoRI and XhoI restriction enzymes, allowing 
ligation of the two fragments to each other, and to 
the MIGR1 retroviral plasmid which was also cut 
with EcoRI and XhoI enzymes. This ligation was 
catalysed by T4 ligase. The ligation mixture was 
used to transform bacteria grown on ampicillin 
enriched agar. As uptake of the MIGR1-TPO 
construct conferred ampicillin resistance, 
transformed bacteria could be picked and grown 
in medium overnight. Minipreps were made of the 
transformed bacteria medium, and lane 6 shows a 
plasmid running at approximately 9kb, 
corresponding to 3kb TPO + 6kb MIGR1. ‘m’ 
refers to the empty MIGR1 vector which runs at 
approximately 6kb. Lanes 1-4, 5 and 7, show 
bands of incorrect size to be the ligated construct 
or no discernable band at all. (All plasmids were 
cut with EcoRI).
Mini-preps
5ml           1l
Maxi-
prep
8,000
6,000
2,500
2,000
Figure 7.5. Maxiprep of the MIGR1-TPO 
construct. The bacteria that carried the 9kb 
construct were grown in 2 litres of medium, and 
used to make a maxiprep using caesium chloride. 
The maxiprep greatly increased DNA yield purity. 
The resulting maxiprep was cut with BglII 
enzyme to produce fragments of approximately 
6.5kb and 2.5 kb, these were run alongside the 
original miniprep to ensure the construct had not 
been lost. The arrows show where impurities have 
been removed. This maxiprep DNA was then used 
to transfect the Phoenix packaging cell line.   110 
7.3 The transfection of the phoenix packaging cell line with the MIGR1-TPO vector to 
generate TPO carrying virus. 
 
Retrovirus vectors are used to integrate genes into the genome of the host cell, and effect 
long-term expression through cell division. To do this though the viral vector with the 
gene of interest must be processed through a packaging cell line. Packaging cell lines 
produce all the necessary trans-proteins – gag, pol and env – that are required for 
packaging, processing, reverse transcription and integration of recombinant genomes. 
The Phoenix packaging cell line was designed to remove the potential of replication 
competency that was present in the early packaging cell lines. This is where 
recombination events in the packaging cell line leads to the production of replication 
competent virus. Notably high titre production of virus by the Phoenix cell line can be 
enhanced by co-transfecting retroviral constructs with the pCLeco helper plasmid, which 
also contains cDNA encoding the viral structural proteins “gag, pol and env”, but without 
these genes being packaged into retroviral particles. In my experiments Phoenix cells 
were transfected with the TPO-retrovirus DNA using the fugene-6 method. The 
successful transfection of these cells was shown by the expression of GFP, a fluorescent 
protein that can be seen under the microscope, which would co-express with any gene 
present in the retrovirus. Thus because expression of the TPO gene is also driven from 
the same viral promoter in the MIGR1 construct that expression of GFP protein is driven 
from, one can be confident that if GFP is being expressed, so is TPO protein. Figure 7.6 
shows a successful transfection as scored by fluorescence microscopy. As a control 
experiment, phoenix cells were transfected with the empty vector, in which only GFP is 
expression is driven from the viral promoter. The transfection efficiency was better 
assessed by measuring GFP expression in the FL1 channel of a flow cytometer. Figure 
7.7 shows that a typical transfection with the transfection efficiency at approximately 
70% of the total cells.  
Successfully transfected phoenix cells should produce retrovirus into the medium that the 
cells reside in. The retroviral particles were harvested from the supernatant of the phoenix 
cell culture, and used to infect splenocytes, very susceptible cells that served as a test of  
 No plasmid added MIGR1 plasmid
All Cells 
GFP positive cells
All Cells 
GFP positive cells
All Cells 
GFP positive cells
MIGR1 TPO plasmid
Figure 7.6. The transfection of the Phoenix cell line with the MIGR1 and MIGR1-
TPO plasmids (fluorescent microscope). Plasmid DNA mixed with fugene-6 reagent to 
mediate the transfection and pCLeco plasmid to aid production of retrovirus. Successful 
transfection indicated by GFP expression of cells, visualised under a fluorescent 
microscope. 
Figure 7.7. The transfection of the Phoenix cell line with the MIGR1 and MIGR1-
TPO plasmids (flow cytometer). As in figure 7.6., but the GFP expression recorded as 
fluorescence in the FL1 channel of a flow cytometer. This indicates that approximately 
70% of phoenix cells have been transfected.  112 
the procedure. The average infection efficiency of splenocytes, as measured by flow 
cytometry, was approximately 20%.  
 
 
7.4 The infection of susceptible tumour cell lines with virus, to generate tumour cells 
stably expressing the TPO gene. 
  
The first tumour cell line that was the target of infection with harvested MIGR1-TPO 
retrovirus was B16, a mouse melanoma. This was a well characterised tumour that grows 
predictably in vivo, just below the skin making evaluation of growth relatively easy. 
However, this tumour line was unexpectedly resistant to infection with the retrovirus I 
generated. The next two tumour cell lines that I attempted to infect, EL4 (a mouse T cell 
lymphoma), and B6-SJ003 (a mouse B cell lymphoma), were found to be susceptible to 
infection however. These tumours were characterised according to their cell surface 
markers (figure 7.8). Crucially EL4 was confirmed as being a class II negative tumour, 
and B6-SJ003 was confirmed as being a class II positive tumour. The class II-restricted 
TAZ10 TCR will consequently only be able to interact directly with the B6-SJ003 
tumour, and will rely on antigen presenting cells for indirect interaction with the EL4 
tumour.  
Figure 7.9 shows the infection efficiency of the two tumour cell lines with the MIGR1 
retrovirus alone, and with the MIGR1 retrovirus carrying the TPO gene. Again using 
flow cytometry to evaluate GFP expression, figure 7.9 shows that varying levels of 
infection were achieved. In order to make the GFP expression, and by association the 
TPO gene expression, as high and as equal as possible in the tumour cell lines I used a 
flow cytometer to sort for GFP+ cells. Figure 7.10 shows that six weeks post the sort, 
high levels of GFP expression is present in all cell lines. This suggests that the retrovirus, 
either with TPO or without, is stably introduced into the genomes of both tumour cell 
lines. Figure 7.11 shows the evaluation of mRNA expression in infected EL4 tumour 
cells showed that TPO mRNA was being produced in the cells infected with MIGR1-
TPO retrovirus, but not in the cells infected with retrovirus alone. This was done by 
producing cDNA from the mRNA extracts from the EL4 cells and mouse thyroid cells,  Class II
FL1-H
0
10
1
10
2
10
3
10
4
10
S
S
C
-
H
0
256
512
768
1024
0.21%
CD4
FL1-H
0
10
1
10
2
10
3
10
4
10
S
S
C
-
H
0
256
512
768
1024
99.74%
TCR beta chain
FL1-H
0
10
1
10
2
10
3
10
4
10
S
S
C
-
H
0
256
512
768
1024
99.76%
TCR alpha chain
FL2-H
S
S
C
-
H
10
0 10
1 10
2 10
3 10
4
0
256
512
768
1024
0.00% 0.00%
99.91% 0.09%
CD19
FL2-H
S
S
C
-
H
10
0 10
1 10
2 10
3 10
4
0
256
512
768
1024
0.00% 0.00%
0.79% 99.21%
MHC class II b
FL2-H
S
S
C
-
H
10
0 10
1 10
2 10
3 10
4
0
256
512
768
1024
0.00% 0.00%
2.43% 97.57%
TCRα chain CD19 MHC class II
TCRβ chain CD4 MHC class II
E
L
4
 
c
e
l
l
s
B
6
-
S
J
0
0
3
 
c
e
l
l
s
Figure 7.8: The characterisation of the tumour cells EL4, a mouse T cell lymphoma; 
and B6-SJ003, a mouse B cell lymphoma. EL4 cells are positive for a TCR and CD4, 
but negative for class II. B6-SJ003 cells are negative for a TCR, but positive for CD19 
and class II.
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Figure 7.9: The flow cytometry analysis of EL4 cells and B6-SJ003 cells transduced 
either with retrovirus alone (MIGR1) or retrovirus containing TPO (MIGR1-TPO).
GFP fluoresces in the FL1 channel. These populations would subsequently be sorted to 
enrich for GFP+ cells.EL4-TPO
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Figure 7.10. Sorting tumour cells for high GFP expression. Panels A and B 
are an example of a FACSAria sort, pre-sort on the left (A), and post-sort on the 
right (B), with the blue population being greatly enriched. The same was done 
to the transduced EL4 cells and B6-SJ003 cells, with the GFP+ population 
enriched. Panels C-F show flow cytometry plots indicating that this enrichment 
was maintained post the sort (6 weeks), and further analysis (not shown) 
indicated that GFP expression never dropped from this level.
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Figure 7.11: PCR of cDNA made from mRNA extracted from EL4 cells infected 
with TPO containing retrovirus, compared to EL4 cells infected with retrovirus 
alone, and mouse thyroid tissue (the native cell of TPO). Circled products indicate 
the presence of TPO mRNA, corresponding to the predicted size (757 bp) of two 
primers amplifying a short portion of the TPO sequence.   116 
and then using PCR to amplify a short sequence from the TPO sequence. This was also 
done for B6-SJ003 cells and the cell line that was infected with MIGR1-TPO retrovirus 
was also positive for TPO mRNA.  
 
 
7.5 Assessing whether the TAZ10 T cells can recognise the TPO+ tumours, in vitro and 
in vivo. 
 
Once it was clear that TPO mRNA was being made in the cell lines infected with TPO 
carrying retrovirus, I sought to assess whether the TAZ10 TCR could now recognise 
either of these TPO+ tumour cell lines. In the first instance this assessment involved 
mostly in vitro experiments, where Rag1
-/- TAZ10 lymph node (LN) cells were used in 
proliferation experiments (CFSE dilution), either directly against TPO+ tumour cells, or 
indirectly via dendritic cells (DCs) fed with tumour lysate. The B6-SJ003 tumour, which 
is class II+, was used for the direct experiments, whereas the EL4 tumour, which is class 
II-, was used with the DCs. This is important because the TAZ10 T cells are exclusively 
IAb restricted.  
From the first experiment, in figure 7.12, it seemed that the DCs fed with TPO+ EL4 
lysate induced proliferation of TAZ10 LN cells above DCs fed with mock infected EL4 
lysate. The positive control, where DCs were mixed with the TAZ10 TCR agonist 
peptide p3, stimulated approximately 29% of the LN cells to divide above the 
background of 9%. The DCs fed with TPO negative EL4 lysate only stimulated 9% of the 
LN cells, whereas the DCs fed with TPO positive EL4 lysate stimulated 19% of the LN 
cells.   
As shown in figure 7.13, the direct presentation with TPO+ B6-SJ003 cells failed to 
induce proliferation of TAZ10 LN cells above that of B6-SJ003 cells infected with 
retrovirus alone. The positive control, where p3 peptide was mixed with the antigen 
presenting cell CX81, stimulated 33% of the LN cells to divide above the background of 
1%. The B6-SJ003 cells negative for TPO stimulated only 4% of the LN cells, and the 
B6-SJ003 cells positive for TPO stimulate only 1% of the LN cells. 
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Figure 7.12: The in-vitro 
analyses of the responses of 
TAZ10 lymph node (LN) cells 
to DCs, fed with EL4 tumour 
lysate and then matured, 
using CFSE dilution. Panel A 
shows the background response 
of TAZ10 LN to unfed DCs. 
Panel B shows the positive 
control where anti-CD3 and 
anti-CD28 is added to the LN 
and DC mix. Panel C shows the 
response of TAZ10 LN if DCs 
are mixed with p3 peptide, 
which is the peptide that the 
TAZ10 TCR recognises. Panel 
D shows the response with DCs 
fed with lysate from EL4 
tumour cells that had been 
transduced with retrovirus 
alone. Panel E shows the 
response with DCs fed with 
lysate from EL4 tumour cells 
that had been transduced with 
the retrovirus-TPO construct. 
The response is measured by 
the reduction of the CFSE 
signal, which would be diluted 
as the TAZ10 LN cells divide. 
The R5 gate in the far left 
panels exclude some 
unidentified background, 
perhaps unlabelled dendritic 
cells, from the CFSE panels on 
the right. The panel at the 
bottom right shows a typical 
SSC - FSC plot, the cells in the 
R4 gate represent the 
lymphocytes. 
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dilution. Panel A shows the 
background response of 
TAZ10 LN alone. Panel B 
shows the positive control 
where anti-CD3 and anti-
CD28 is added to the LN 
cells. Panel C shows the 
response of TAZ10 LN if 
p3 peptide is added with the 
CX81 APC to present the 
peptide. Panel D shows the 
response when LN cells 
were mixed with B6-SJ003 
cells that had been 
transduced with retrovirus 
alone. Finally panel E 
shows the response when 
LN cells were mixed with 
B6-SJ003 cells that had 
been transduced with the 
retrovirus-TPO construct. 
The response is measured 
by the reduction of the 
CFSE signal, which would 
be diluted as the TAZ10 LN 
cells divide.
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Figure 7.14 shows an in vivo experiment where wild-type C57BL/6 mice or Rag+ 
TAZ10 mice were challenged either with 10
5 TPO+ or TPO- EL4 cells. The hypothesis 
was that the EL4 tumour cells would die due to natural turnover of cells, releasing 
antigen that would be presented to the class II-restricted T cells by APCs. In the case of 
the TPO+ EL4 cells in the TAZ10 mice, this would lead to activation of TPO-specific 
CD4+ T cells by the TPO peptides presented by the APCs in these mice, leading to 
killing of the TPO+ EL4 cells, presumably by a cytokine-mediated method of killing.   
The result showed that there was no difference in the rejection of TPO+ or TPO- EL4 
tumours the wild-type, indicating that the addition of the TPO gene did not affect the 
normal response to the EL4 tumour. However the result also showed that there was no 
advantage to the survival of the TAZ10 mice if the EL4 tumour they were challenged 
with was TPO+. Overall, mice of all groups began succumbing to tumour after 17 days, 
and all were dead after 22 days. 
This short survival time, and lack of difference between the TPO+ and TPO- EL4 
rejection, might be explained by the relatively large dose that the mice received of the 
tumour. However, a repeat of this experiment with a dose of 10
4 EL4 cells, proved non-
fatal to the mice. This may have been due to the disparate nature of this T cell lymphoma 
upon sub-cutaneous injection. A B16 mouse melanoma tumour forms a small dense lump 
of cells at the point of injection, whereas the 10
5 dose of EL4 cells forms a larger, flatter 
subcutaneous mass as it is not a melanoma and so does not share the cell adhesion 
molecules that are expressed by B16 tumour cells. It is possible that with a lower dose, 
the tumour is disparate enough to be disseminated to various parts of the animal, making 
rejection easier for the host immune system. Ultimately this in vivo result suggests that 
TPO+ EL4 cells do not evoke a similar response to the tumour as seen in vitro, or that 
this response is not sufficient to reject an aggressive and large tumour dose. 
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Figure 7.14. The in-vivo response TAZ10 mice make to TPO+ EL4 cells. Four 
groups of mice were challenged with 105 EL4 cells. Wild type black mice were 
challenged with normal EL4 tumour cells (dark blue); wild type black mice were 
challenged with EL4 tumour cells transduced with the TPO carrying retrovirus 
(pink); TAZ10 mice were challenged with normal EL4 tumour cells (yellow); and 
TAZ10 mice were challenge with EL4 tumour cells transduced with the TPO 
carrying retrovirus. Mice of all groups began succumbing to tumour after 17 days, 
and all were dead after 22 days.   121 
7.6 Discussion 
 
After all this work had been completed it was discovered that the TPO gene that was 
cloned into the retrovirus lacked a signal sequence at the 5‟ end of the gene, which alters 
the conclusions that can be made from this data. A lack of signal sequence would mean 
that the TPO polypeptide would not be exported to the cell surface, as occurs in the 
thyroid cell, the native home of this protein. This would explain the absence of 
proliferation induced by the direct presentation experiments with B6-SJ003 tumour cells, 
and why the tumour lysate fed to DCs is antigenic. It also shows that TPO is not 
processed and TPO peptide is not associated with MHC class II molecules via an 
endogenous (cytosolic) pathway, shedding light on previous work that shows that 
„endogenous‟ TPO can be presented and is processed differently to „exogenous‟ TPO. 
Previous studies had indicated that if whole TPO was endocytosed by an APC then the 
antagonist peptide TPO537-548 was presented, but endogenous processing of TPO that was 
made by thyroid epithelial cells produced the stimulatory peptide TPO536-547.  
Like other transmembrane proteins, TPO is first synthesised in the endoplasmic reticulum 
(ER). After folding to the native state within the ER, intracellular transport of TPO to the 
cell surface occurs via the Golgi complex, a compartment typically associated with N-
glycan processing of many cell surface glycoproteins. The data in this chapter indicates 
that the endogenous processing is dependent on the signal peptide, suggesting that at 
some point in the intracellular transport of TPO the pathway diverges into the pathway 
that allows the processing of TPO and the association of MHC class II molecules with 
TPO peptides. This divergence could be at several points along the intracellular transport 
pathway, for example before the trans-Golgi, pre-secretion, or post secretion. What the 
new model of endogenous TPO processing may look like is shown in figure 7.15. 
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Figure 7.15. Simple schematic of the possible models of how secreted TPO enters the 
endosomal pathway, allowing TPO peptides to bind to MHC class II molecules. The 
secreted TPO could enter the endosomal pathway at three points: (A) Pre-transgolgi. (B) 
Pre-secretion. (C) Post-secretion.
MHC II
TPO peptide
TPO  123 
Despite the lack of the signal peptide there are some additional conclusions that can be 
made from this work. In vitro, DCs fed with TPO+ EL4 cells are capable of inducing 
proliferation of TAZ10 T cells as measured by CFSE dilution. However in vivo, 
challenging TAZ10 mice with TPO+ EL4 cells does not lead to tumour rejection, despite 
the fact that most of the T cells in that mouse express TCR that recognises TPO peptide.  
This lack of a rejection might be explained by the context of autoimmune disease 
pathology at the point of challenge. In the tumour therapy experiment the TAZ10 mice 
were challenged at 8-9 weeks old, and the experiment was concluded when the mice were 
11-12 weeks old. All TAZ10 Rag+ mice develop spontaneously autoimmune thyroiditis 
by the age of 4-5 months, but the cellular changes can be seen before then. In a paper by 
Badami et al, the activation levels of CD4 T cells in TAZ10 Rag+ mice were shown to be 
comparable to wildtype at 3 weeks of age, but by 20 weeks the CD4 T cells of TAZ10 
Rag+ mice show signs of activation, characterised by upregulation of PD1 and CD69, 
and down regulation of CD62L and CD45RB. The levels of CD4+CD25+ T regs were 
reduced in TAZ10 mice at 3 weeks of age compared to wildtype, and decreased even 
further by the age of 20 weeks (Badami, Maiuri et al. 2005). Figure 7.16, shows 
representations of data from another paper on TAZ10 mice, but this time on the Rag-/- 
version (Quaratino, Badami et al. 2004). This paper indicates the clinical and hormonal 
signs of thyroiditis in the TAZ10 Rag -/- mouse, but as the disease progression and 
weight gain in TAZ10 Rag-/- model is similar to the Rag+ model, it is fair to apply this 
data to the Rag+ TAZ10 model as well. The data indicates that in the TAZ10 mouse 
hormonal signs, T4 and TSH levels, are altered from the wild-type levels steadily from 
birth to beyond 18 weeks, and that weight gain in the TAZ10 mice relative to the wild-
type mice really only becomes apparent after 12 weeks of age. 
The clinical, hormonal and cellular changes are indicators of the progression of the 
autoimmune disease in these transgenic mice, and therefore also the activation state of the 
anti-TPO T cells in these mice. The cellular indicators lead me to conclude that at 8 
weeks the anti-TPO response is becoming more active but it is by no means at the limit of 
its activation. The continued deterioration of the clinical and hormonal signs well after 8 
weeks also backs up this conclusion. Overall, whereas there must be a balance so that the 
mice are not challenged with tumour when they are very sick, it is likely that the in vivo   124 
response to a TPO+ tumour may have been more robust if the mice were challenged at an 
older age, perhaps approximately 12-16 weeks. 
The lack of a response in the tumour therapy experiment could be due to the presence of 
the numerous regulatory cells that are present in these mice, although subsequent work 
would be needed to fully explore that possibility. The TAZ10 model has been found to 
contain a functioning immunoregulatory network beyond just CD25+ Foxp3+ regulatory 
T cells, with suppressive CD8-CD4- T cells and myeloid suppressor cells also present. 
All three subtypes have been found to be capable of suppressing T cell responses in vitro, 
and yet in vivo the disease still spontaneously occurs. 
These discoveries are one of the reasons why there are several ways that this model could 
be further exploited in the future. The presence of these different regulatory elements 
presents an opportunity to investigate the role of these cells in a model that effectively 
mirrors a human autoimmune disease. There has already been novel discoveries made in 
this model concerning double negative (CD4-CD8-) suppressor cells and myeloid 
suppressor cells, and there can only be further discoveries made in the future. 
Additionally this model still represents a good opportunity to investigate tumour 
immunity in a model of autoimmunity. Perhaps the manipulation of various tumours to 
synthesise smaller portions of the TPO protein, in particular the portion that carries the 
immunostimulatory peptide, may be a more efficient means of generating host immune 
responses to the tumour. Once this is done in vivo experiments could include challenging 
TAZ10 mice with TPO+ tumour either simultaneously with or followed by a challenge of 
untransfected (TPO-) tumour to test whether an anti-tumour response can broaden from 
being focused on a single antigen to reject a tumour based on multiple antigens. Or 
wildtype mice could be challenged with TPO+ tumour and then adoptively transferred 
with TAZ10 T cells to test the significance of the anti-TPO response in rejecting the 
tumour challenge.   
 
 
 
 
 Figure 7.16. The clinical and hormonal signs of thyroiditis. These figures 
approximate data in a paper by Quaratino et al  (Nature medicine, vol 10, no. 9, p920), 
that indicates the clinical and hormonal signs of thyroiditis in the TAZ10 Rag -/-
mouse,  though these can be approximately applied to the Rag+ TAZ10 mouse too. 
Panel A shows the level of T4 in the serum in TAZ10 Rag-/- mice, showing a steady 
decrease of T4 over time (WT levels do not decrease). Panel B shows the level of TSH 
in TAZ10 Rag-/- mice, showing a steady increase over time (WT levels do not 
increase). Panel C shows the weight in grams of TAZ10 mice (open circles) compared 
to wildtype mice (closed circles). After 12 or so weeks the weights of the two mice are 
beginning to diverge and by 20 or so weeks the weights are radically different. Red 
arrows indicate 8 weeks, which is the age at which TAZ10 Rag+ mice were 
challenged with EL4 tumour. As this data was collected in Rag-/- mice this can only 
be an approximate guide to the hormonal levels at that point. Rag+ mice were 
challenged before weight gain changes were evident.  
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Chapter 8: General Discussion 
 
8.1 Defining the irradiated CT26 model 
 
One of the main obstacles to immunotherapy of cancer in humans is the 
immunosuppressive environment that surrounds the tumour mass, preventing any 
effective immune response from halting or reversing the threat of the tumour. Thus much 
research has been focused on understanding the anti-tumour response, and the ways in 
which it is controlled. Early experiments with the carcinogen-induced colorectal tumour, 
CT26, indicated that all CT26-specific CTLs induced by CT26 engineered to produce 
GMCSF, recognised a single peptide, and these CTLs could lyse the tumour in-vitro, and 
cure mice of established tumour in vivo (Huang, Gulden et al. 1996). This peptide was 
identified as a non-mutated nonamer derived from the envelope protein (gp70) of an 
endogenous ecotropic murine leukaemia provirus, an epitope that became known as AH1. 
In subsequent work it was shown that untransfected CT26 tumour cells are rejected in 
Balb/c mice following depletion of CD25+ regulatory T cells, and that this rejection led 
to the development of long-lived tumour immunity (Golgher, Jones et al. 2002). It was 
suggested that this immunity was based on a shared-tumour antigen, as this long-lived 
tumour immunity also included tumours of distinct histological origin, such as A20, a 
Balb/c B cell lymphoma line derived from a spontaneous reticulum cell neoplasm. This 
antigen must be different from AH1 as immunisation with CT26-GMCSF tumour does 
not lead to protection from other tumours such as A20.  
The original aim of this project was to investigate further this apparent shared immune-
dominant tumour associated antigen and to examine in greater detail the 
immunosuppressive response generated by CT26, following immunisation with the 
irradiated tumour thereby allowing the measurement of T cell responses in the absence of 
overwhelming tumour growth. Initial adoptive transfer experiments, shown in chapter 3, 
suggested that irradiated CT26 induces a similar response to live CT26 in the absence of 
T regs.  
One question that was not addressed by these initial experiments however, was whether 
the „cross-protective‟ response requires the depletion of T regs. This was investigated in   127 
further experiments shown in chapter 4, which indicated that both anti-CT26 and cross-
reactive T cells are generated by irradiated CT26 challenge in the presence of T regs, 
with the anti-CT26 response being significantly boosted by depletion of T regs, and the 
A20 response boosted more modestly by the depletion of T regs. Our previous hypothesis 
for the CT26 model suggested that although potentially cross-protective CD4 or CD8 T 
cells can develop from live CT26 challenge with T regs, it develops into a robust anti-
tumour response only in the absence of T regs. In contrast the irradiated CT26 challenge 
generates partial CT26-protection and partial cross-protection even in the presence of T 
regs. This suggested that the irradiated CT26 challenge is inducing a different response to 
the live CT26 challenge, possibly because the irradiated tumour exposure delivers a large 
antigen bolus in an inflammatory context soon after injection. The difference may also be 
due to differences in the activation of the innate response, and to get a clearer picture of 
such activation the role of NK cells was investigated in the live CT26 model. The data in 
chapter 5 indicates that the absence of NK cells impacts on the primary response to live 
CT26 tumour challenge, adversely affecting survival rates, but the situation is 
ameliorated if the NK depletion is accompanied by the depletion of T regs. This 
suggested that the live CT26 challenge activates the innate response to a significant 
extent, and that the innate response plays an important role in live tumour rejection. From 
this data I could speculate that the irradiated CT26 challenge may activate the innate 
response to an even greater extent than the live challenge, due to the fact that the large 
amount of dead or dying tumour cells would release factors that would recruit and 
activate many cells of the innate immune response.  
Finally, chapter 6 investigated the idea that in the CT26 model, cross-protection is due to 
a broadening of reactivity leading to a more diverse TCR response. To accomplish this, 
the clonal diversity of the response to the tumour, as shown by the CDR3 lengths of the 
TCR, was investigated in the absence and presence of T regs. The conclusion was that the 
response induced by CT26GM is broader in the absence of T regs (compared to the 
presence of T regs), as indicated by the replacement of several oligoclonal responses in 
the presence of T regs with polyclonal responses in their absence. Although these data 
support the idea that T regs are necessary for the broadening of the response in this   128 
model, by itself it can not prove that more diverse TCR structures leads to broader 
reactivity or that this indicates cross-reactivity with other tumours. 
 
Overall these studies indicate that, despite being essentially an equivalent antigen 
exposure, the response induced in the irradiated CT26 model is different to the live CT26 
model. In the live CT26 model T reg depletion is critical to the survival of the tumour 
challenge, as well as the generation of the cross-protective response. In the irradiated 
CT26 model, the cross-protective response is not dependent on the T reg depletion, but 
the absence of T regs does boost the anti-CT26 response. Ultimately these discrepancies 
are difficult to resolve, due to the problem that live CT26 proliferates to a lethal level in 
the presence of T regs. The live CT26 challenge may be generating cross-reactive T cells 
in the presence of T regs, as irradiated CT26 is able to do, but the lack of a sufficient anti-
CT26 response makes it difficult to assess whether this potential cross-reactive response 
would be cross-protective in vivo.  
 
Answers to these questions may yet be found in work that has run alongside mine in this 
lab, which has been able to shed additional light on this CT26 tumour model. The critical 
advance has been the elucidation of a candidate epitope for a dominant cross-protective 
response revealed by T reg depletion, the shared tumour antigen as mentioned before. 
This epitope, GSW11, which also resides in MuLV gp90, has allowed the comparison of 
the CD8 T cell responses to AH1, as the dominant epitope in the anti-CT26 response in 
the presence of T regs, with the response to GSW11, as an epitope of the cross-protective 
response in the absence of T regs. These experiments compared the AH1 and GSW11 
CD8 T cell responses with either live CT26 or live CT26GM tumours, in the absence or 
presence of T regs in both instances, and the results have led to some interesting 
conclusions:   
Firstly, the absence of T regs is absolutely essential to see a response to the GSW11 
epitope, but surprisingly this response is revealed both in response to CT26 and CT26GM 
(see figure 8.1). The AH1 response is seen with both tumours, with more CD8 T cells 
specific for AH1 in response to CT26GM compared to CT26, but in both cases the 
removal of T regs increased the number AH1-specific CD8 T cells, though the number of   129 
AH1-specific CD8 T cells remained higher with CT26GM. Another interesting 
observation was that in the absence of T regs the number of GSW11 CD8 T cells was 
equivalent to the number of AH1 CD8 T cells in the CT26 model. This is despite the fact 
that AH1 CD8 T cells are there in the presence of T regs, when GSW11 CD8 T cells are 
absent, indicating the aggressiveness of the GSW11 clone when released from T reg 
suppression.  
More recently performed in vivo experiments have also been instructive. Survival to 
CT26 depends on the depletion of T regs, whereas CT26GM is rejected in all conditions, 
a rejection that is more robust in the absence of T regs (i.e. both AH1 responses and 
GSW11 responses increase). Although AH1-specific T cells are the only means of 
tumour rejection in the CT26GM challenged mice in the presence of T regs (see figure 
8.1), both AH1 and GSW11 responses are seen in the absence of T regs with CT26 
challenge, making it more difficult to ascertain which is the most important when it 
comes to CT26 rejection. As GSW11 responses are necessary to see cross-protection it  
might be that the CT26 rejection is primarily the focus of AH1 specific T cells but that is 
not definite.  
 
Further discoveries could be made by investigating the CD4+ T cell dependence of the 
CD8+ anti-GSW11 response. Work by Golgher et al, showed that tumour rejection by 
CD4+ T cells, but not CD8+ T cells, was a specific feature of T reg depletion (Golgher, 
Jones et al. 2002); leading one to expect that CD4s will have a crucial role in the GSW11 
response. It is known that there is a helper epitope also in MuLV gp90, but it is unknown 
how much help the GSW11 CD8+ T cell response requires. If there is little requirement 
for help it would suggest that the GSW11 specific T cells are quite potent, whereas if 
there is a lot of requirement for help it would lead one to expect the response to have 
slower kinetics.    
Furthermore antigen-specific T regs, presumably activated by the gp90 helper epitope, 
are able to completely suppress the GSW11 response, suggesting that the GSW11 CD8+ 
T cell response is more sensitive to T reg suppression that the AH1 response.  
One possibility is that the avidity of GSW11 specific T cells for their antigen is low 
enough for them to be close to death by neglect when being selected in the thymus, and  Pre-treatment of 
the mice
Tumour 
challenge
CD8+ T cell 
response to AH1
CD8+ T cell 
response to GSW11
Untreated CT26 + -
Untreated  CT26GM ++ -
T reg depleted CT26 +++ +++
T reg depleted  CT26GM ++++ ++
Figure 8.1. Summary of the in-vitro CD8+ T cell responses to AH1 and GSW11. The 
relative strength of the responses are indicated by the number of + signs: (+) = weak; (++) 
= modest; (+++) = strong; (++++) = very strong; (-) = absent.  131 
as a consequence need a lot of stimulus in the periphery to form a response. Thus the 
response would take more time to build up, giving peripheral tolerance mechanisms such 
as T regs ample time to prevent the „self‟ response fully forming. More experiments 
would be needed to be certain of the requirement for CD4+ T cell help, and the 
mechanisms behind the T reg suppression, of the GSW11 response. 
 
These additional observations can be used to inform the data I have collected in this 
thesis. The observations in chapter 6 that the clonality of the response to CT26GM is 
broadened in the absence of T regs, backs up the observation that a CD8 T cell response 
is revealed to GSW11 in the CT26GM model in the absence of T regs. Furthermore, the 
observation that the response to GSW11 is only revealed in the absence of T regs in the 
CT26 model adds weight to the supposition that only in the irradiated CT26 model are 
cross-protective responses generated in the presence of T regs. It is likely that further 
experiments into the cross-protective epitope will continue to yield insights into the 
impact of T regs on induction of cross-protective tumour immunity. For example, as 
mentioned above, it will be interesting to discern the impact T regs have on the helper T 
cell response in particular, or experiments may yield answers to whether T regs are truly 
antigen-specific in suppression of tumour responses. 
 
8.2 The state of immunotherapeutic strategies to tackle cancer 
 
Despite the potential of the immune system to become a key member of the therapies we 
have to combat cancer, clinical trials employing a range of immunotherapeutic strategies 
have had somewhat limited success in inducing immune sensitisation against tumour 
antigens. However there has recently been revived interest in the possibility of combining 
radiation and immune-based therapies to achieve better local and systemic tumour 
control. It had been thought that radiation therapy would be immunosuppressive, due to 
the fact that lymphocytes are sensitive to radiation (Roses, Xu et al. 2008). It now seems 
that radiation therapy might be immunomodulatory rather than immunosuppressive, with 
a potential role for radiation in enhancing anti-tumour immunity. It seems radiation 
therapy is effective at signalling „danger‟ via the increased expression of   132 
proinflammatory cytokines, and in the activation of antigen presenting cells (McBride, 
Chiang et al. 2004). This is supported by the observations that radiation therapy enhances 
the expression of tumour-associated antigens, induces immune-mediated targeting of 
tumour stroma, and diminishes regulatory T cell activity. Radiation therapy may also 
activate effectors of innate immunity through TLR-dependent mechanisms, thereby 
augmenting the adaptive immune response to cancer (Roses, Xu et al. 2008). Radiation 
induced upregulation of Fas on tumour cells has also been shown, which would enhance 
immune recognition of antigen-expressing tumour cells (Chakraborty, Abrams et al. 
2004). 
Building upon the hypothesis that radiation can enhance anti-tumour immunity, 
investigators have begun to combine radiation therapy with immunotherapies. Generally 
the radiation is used to induce tumour cell apoptosis or necrosis, releasing tumour 
antigens for subsequent presentation by DCs. There have been promising results with 
irradiation combined with intra-tumoural or peri-tumoural DC administration (Nikitina 
and Gabrilovich 2001), or administration of Flt-3L, a growth factor that stimulates 
production of dendritic cells (Chakravarty, Guha et al. 2006). There have also been 
explorations of combining irradiation with cytokine therapy; studied cytokines include 
IL-3 (Chiang, Hong et al. 2000), IL-12 (Seetharam, Staba et al. 1999) and TNF-ʱ 
(Weichselbaum, Hallahan et al. 1994). Local radiation therapy in combination with 
CTLA-4 blockade has also been demonstrated to induce CD8 T cells in a poorly 
immunogenic murine adenocarcinoma model, whereas CTLA-4 blockade alone did not 
(Demaria, Kawashima et al. 2005). These studies overall are encouraging for the future of 
combined radiotherapy and immunotherapy.  
The work presented here involving the effect of irradiating CT26 would also back up the 
fact that radiation of tumours can enhance anti-tumour immunity. Furthermore my work 
suggests that the depletion of T regs might be an immunotherapy that would combine 
with radiotherapy to further boost the anti-tumour response.  
 
Another area of promise in the quest to induce effective anti-tumour immunity are the 
tumour cell lysate vaccines, which to date have had some success in the clinic. In one 
instance hundreds of patients with advanced stage melanoma, many with metastatic   133 
disease having failed chemotherapy, participated in a study of the vaccine Melacine. 
Melacine is composed of two allogeneic cell lines, derived from biopsies of subcutaneous 
nodules, which is administered as mechanically disrupted cell lysate in the presence of 
DETOX adjuvant (Sondak and Sosman 2003). In phase I and II trials of Melacine in 
patients with especially advanced disease (stage IV), 10-20% of patients showed clearing 
of some metastatic sites, and in another 10-20% of patients the disease was stabilised. In 
a phase III study, Melacine was compared with a four-drug chemotherapy regimen and 
the response rates and survival were the same, with the advantage that Melacine was non-
toxic compared to the chemotherapy (Mitchell 1998). A similar vaccine preparation, 
Canvaxin, was evaluated in ~1,000 stage IV melanoma patients and compared with an 
equal number of patients who were treated with surgery and chemotherapy during the 
same time period, but did not receive the vaccine. The result was a small but significant 
increase in the overall survival of the vaccinated group (Morton, Hsueh et al. 2002). In a 
more recent radomised phase III study, Jocham et al. used an autologous tumour-cell 
lysate, which had been pretreated with IFNγ, to vaccinate renal cell carcinoma patients 
after radical nephrectomy. The results indicated that the vaccine was beneficial, with 5-
year and 70-month progression-free survival rates at 77.4% and 72%, respectively, in the 
vaccine group and 67.8% and 59.3%, respectively in the control group (surgery only) 
(Jocham, Richter et al. 2004).  
Despite these small successes however, no trial of tumour-cell vaccines has been 
successful enough for routine use in the clinic. Like other immunotherapies therefore, the 
future of tumour-cell vaccines may lie in their combination with other forms of treatment. 
The data collected here adds support to that notion, with the irradiation of the tumour cell 
seemingly pushing T cell priming in favour of forming a productive response, as well as 
the removal of T regs proving to be sufficient to boost the response still further. 
 
8.3 The use of autoimmunity to investigate tumour immunity. 
 
The original hypothesis that predicted that the immune response would respond to 
tumours, thus giving us the potential of tumour vaccines, was the „tumour surveillance‟ 
hypothesis, put forward by Thomas and Burnet (Burnet 1957). The problem with the   134 
hypothesis is that if there is spontaneous and successful tumour immunity then it would 
never become apparent to observers. This makes testing the validity of this hypothesis 
very difficult. Fortunately, recent studies have offered the first direct evidence of 
naturally occurring, successful tumour immunity in humans, evident only because it is 
linked to a second phenomenon – autoimmune neurologic disease (Darnell and Posner 
2003). These diseases are the rare paraneoplastic neurologic degenerations (PNDs), in 
which the patients develop degeneration in discrete regions of the nervous system. 
Clinical examinations reveal cancers in all these patients, which can be breast or ovarian 
carcinoma or small cell lung cancer. These tumours are malignant, but show unusually 
limited spread and the patients respond well to treatment. Sometimes only microscopic 
foci of the tumours can be found, accompanied by inflammatory infiltrates, and 
occasionally spontaneous tumour regression is observed (Darnell and DeAngelis 1993).  
It is clear that this naturally occurring tumour immunity is directly linked to the 
autoimmunity, as the tumours have been shown to express neuronal proteins, and the 
PND patients harbour high titre antibodies in their blood and spinal fluid directed to 
neuronal antigens (Musunuru and Darnell 2001). This example demonstrates that 
autoimmunity and tumour immunity are both naturally occurring and spontaneous 
immune responses, which can occur simultaneously and can use the same mechanism of 
tissue destruction. This strengthens the argument that autoimmunity models can, and 
should, be used to study tumour immunity.  
Another example of a concurrent autoimmune response and anti-tumour response is in 
mice with vitiligo and melanoma. As mentioned in the introduction (section 1.8) not only 
do the responses happen concurrently but also in response to the same antigen. These 
antigens are the melanocyte differentiation factors, such as gp75 (Vijayasaradhi, 
Bouchard et al. 1990), or TYRP-2 (Bowne, Srinivasan et al. 1999). In these models B16 
mouse melanoma rejection and depigmentation of the skin were the two manifestations of 
the tumour immunity and autoimmunity respectively. The conclusions of these studies 
were that these two responses overlapped, but that they used alternative antigen-specific 
mechanisms: The tumour response was perforin independent, but required CD4+ T cells 
and NK cells; while the autoimmune response did not require CD4+ T cells or NK cells, 
but was perforin dependent. This insight means that while these two responses are to the   135 
same antigens, the responses can be uncoupled, lending further reassurance that in the 
future we will be able to induce better anti-tumour responses without autoimmunity side 
effects.  
Overall there is much knowledge to be gained from studying tumour immunity and 
autoimmunity responses together, which was the rationale behind my work with TPO+ 
tumours in the TAZ10 transgenic models. The main conclusion from this project was that 
endogenous processing of TPO is dependent on the signal peptide, and at some point in 
the intracellular transport of TPO the pathway diverges into the pathway that allows the 
processing of TPO and the association of MHC class II molecules with TPO peptides, for 
recognition by CD4+ MHC class II restricted T cells. This was shown by the fact that the 
absence of the signal peptide meant that no TAZ10 lymphocyte response was seen to 
tumour cells engineered to produce TPO protein. Exogenous processing of tumour lysate 
by dendritic cells did produce a response however, suggesting that stimulatory TPO 
epitopes are present in these engineered tumours. These interesting conclusions could be 
the first of many to come out of this study of tumour immunity in the TAZ10 
autoimmunity model, were this work to be continued further.  
 
8.4 Final comments 
 
My work has been concerned with evaluating anti-tumour responses, both in the context 
of T reg control of those responses, and in the context of how autoimmunity models may 
be used to understand them. My general conclusion is that immunotherapies that are 
designed to tackle cancer must either be multi-faceted or combined with other cancer 
treatments if we are going to see the best results in the clinic. Despite the severe potential 
side effects of manipulating regulatory T cells in humans, my work has shown that there 
still is a case for removing the influence of these cells in order to boost anti-tumour 
responses. Additionally the severest of these side-effects may be averted if we can more 
thoroughly understand the similarities and differences between anti-tumour and 
autoimmune responses, and crucially learn to uncouple those responses.   
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